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SUMMARY
This thesis is a result of the observation that plasma 
noradrenaline is increased in cirrhosis with ascites.
Three specific questions were addressed: is this increase
the result of increased spillover of noradrenaline into 
plasma (and thus increased activity of the sympathetic 
nervous system) or of reduced clearance from plasma? What 
are the implications of sympathetic activation for the 
various theories of ascites formation? Why does 
sympathetic overactivity fail to correct the reduced 
peripheral vascular resistance characteristic of cirrhosis?
The kinetics of exogenous tritiated noradrenaline were 
measured, using an HPLC separation of the radiolabelled 
noradrenaline in plasma, in 14 cirrhotics with ascites and 
13 controls. The cirrhotics had a marked increase in 
noradrenaline spillover with plasma clearance also slightly 
increased. Therefore the increased plasma noradrenaline in 
cirrhosis is due to increased sympathetic activity.
Noradrenaline, dihydroxyphenylglycol (DHPG), renin and 
atrial natriuretic peptide (ANP) were then measured in 
peripheral venous blood in 41 cirrhotic patients and 34 
control patients. Noradrenaline was increased in 
cirrhotics both with and without ascites, in contrast to 
renin which was only increased in those cirrhotics with 
ascites. Therefore sympathetic overactivity in cirrhosis 
appears to precede the development of ascites. This 
supports the "underfilling” theory of ascites, which
16
suggests that the effective central intravascular volume is 
reduced in cirrhosis. The degree of sympathetic activity 
was shown to parallel the degree of hepatic impairment, and 
plasma noradrenaline was a useful prognostic indicator in 
cirrhosis. This may prove of clinical value in assessing 
the timing of hepatic transplantation.
It has been speculated that a deficiency of ANP may 
contribute to the sodium retention of ascites. In fact 
plasma ANP was not reduced, but was marginally increased in 
the presence of ascites. This suggests that ANP is 
responding appropriately to sodium overload occurring for 
other reasons.
Despite this sympathetic overactivity, patients with 
cirrhosis demonstrate reduced peripheral vascular resistance 
and cutaneous vasodilatation. A series of experiments was 
performed to try to identify the site of this "block” to 
normal sympathetic vasoconstriction. One theoretical 
possibility would be an autonomic neuropathy, particularly 
in alcoholic liver disease. Autonomic function was 
assessed by a standard battery of parasympathetic and 
sympathetic tests in 20 cirrhotics and 20 controls. The 
parasympathetically-mediated heart rate responses to deep 
breathing, to facial immersion in water and to the Valsalva 
manoeuvre were all reduced in cirrhotics with severe hepatic 
impairment. The sympathetically-mediated blood pressure 
response to isometric exercise was also reduced. However, 
the absence of clinical evidence of neuropathy in these
17
patients suggested that the changes demonstrated might be a 
result of impaired vascular responsiveness rather than 
neuropathic damage.
To consider this question, the blood pressure responses 
to steady state intravenous infusions of noradrenaline and 
angiotensin II were measured in 20 cirrhotics and 20 
controls. Dose response curves were constructed from a 
minimum of U doses using a quadratic fit, allowing 
calculation of individual PV2O’ dose of agent required
to raise blood pressure by 20 mmHg. The rise in blood 
pressure was attenuated to both noradrenaline and 
angiotensin II in the cirrhotics with severe disease. 
Therefore the site of the ’'block" is distal to the 
sympathetic nerves. The attenuated response to both 
sympathetic and non-sympathetic vasoconstrictors could 
indicate a direct vascular abnormality. Alternatively, 
there could be parallel desensitisation to the effects of 
noradrenaline and angiotensin II, both of which are 
frequently raised in cirrhosis.
The question of sympathetic desensitisation was 
therefore considered in more detail by examining the 
cardiovascular responses to selective sympathetic agonists 
in 10 cirrhotics with severe disease and 10 controls, using 
similar methods to the previous experiment. The blood 
pressure responses to phenylephrine (an alpha-j agonist) and 
alphamethylnoradrenaline (an alpha2 agonist) were both 
impaired in the cirrhotic group, in contrast to the heart
18
rate response to isoprenaline (a beta agonist) which was 
normal. There is thus no generalised sympathetic 
desensitisation, but all responses mediated by the 
peripheral vasculature are impaired, pointing to a defect at 
this site.
Such a defect could involve the adrenergic receptors, 
by prior occupancy of the receptor site either by the 
increased circulating noradrenaline or by some 
catecholamine-like substance (c.f. the "false 
neurotransmitter" theory) or by "down-regulation" of the 
receptor number in response to sustained sympathetic 
overactivity. The alpha-) adrenoceptor on peripheral 
vessels is inaccessible to study in man, and therefore as a 
compromise the alpha2 receptors on platelets were studied in 
10 cirrhotics and 10 controls. The method involved 
incubation of the isolated platelets with tritiated 
yohimbine, measurement of free and bound radioactivity, and 
calculation of receptor affinity and number by Scatchard 
analysis. In fact both the number and affinity of the 
platelet alpha2 receptors were normal, i.e. there was no 
down-regulation nor receptor site interference. If this 
reflects the alpha-) adrenoceptor on peripheral vessels, it 
would suggest a "post-receptor" defect within the vascular 
smooth muscle cell itself. This probable localisation 
should assist in the on-going search for the vasodilator(s) 
responsible for the reduced vascular resistance.
Beta adrenoceptors were also assessed, using the beta2
19
receptor on circulating lymphocytes. The radioligand 
employed was [^1j] iodocyanopindolol. Again, normal
receptor number and affinity were demonstrated, which is in
keeping with the normal heart rate response to the beta 
agonist isoprenaline. This study therefore does not 
support the hypothesis that down-regulation of beta 
receptors contributes to reduced efficacy of the beta 
adrenergic antagonist propranolol in variceal haemorrhage in 
’’decompensated” cirrhosis.
The studies described above are in keeping with, but do
not provide proof of, the following hypothesis: that in
cirrhosis one or more vasodilatory substances accumulate, 
perhaps due to failure of hepatic inactivation, which act at 
an intracellular level on the peripheral vasculature. The 
resulting vasodilatation causes peripheral blood pooling 
with relative underfilling of the central vascular space. A 
baroreceptor-mediated increase in sympathetic activity, and 
possibly other neurohumoral mechanisms, ensues. This 
sympathetic activation could be one of the factors which 
cause sodium retention leading to ascites, and ultimately 
renal vasoconstriction leading to functional renal failure.
It appears that the sympathetic nervous system does play a 
significant role in the complications of cirrhosis of the 
liver.
20
CHAPTER 1 
BACKGROUND AND SCOPE OF THE THESIS
21
1.1. INTRODUCTION
This thesis explores aspects of the sympathetic nervous 
system in cirrhosis of the liver. Firstly, can the 
measurement of the degree of sympathetic activity shed any 
light on the continuing controversy regarding the 
pathogenesis of ascites? Secondly, does the sympathetic 
nervous system contribute to the sodium retention and renal 
vasoconstriction which are fundamental to the pathogenesis 
of ascites and functional renal failure in cirrhosis, 
respectively? Thirdly, how are the normal sympathetic 
control mechanisms altered in the presence of the still 
unexplained circulatory disturbance of cirrhosis? The 
first and last of these topics constitute the basis for the 
experiments in this thesis, in Chapters 3-U and 5-7 
respectively. The contribution of sympathetic activity to 
sodium retention and renal vasoconstriction has been 
extensively studied by others and their findings are discussed 
in this background chapter.
The principal theories of the pathogenesis of ascites 
are discussed, followed by the contribution to the debate of 
studies measuring or manipulating the plasma volume both 
directly and indirectly. The latter involves assessment of 
the renin-angiotensin-aldosterone system, the sympathetic 
nervous system and vasopressin. The mechanism of 
functional renal failure in cirrhosis, probably the extreme 
end of a spectrum which incorporates sodium retention and 
ascites, is discussed with emphasis on the role of imbalance
22
of the neurohumoral control of renal blood flow. Next, the 
circulatory disturbance of cirrhosis is described followed 
by a discussion of its possible causes, with emphasis on 
alterations in the normal sympathetic control mechanisms.
The review is prefaced by some historical background.
1.2. THE PATHOGENESIS OF ASCITES
1.2.1. History
The association of ascites with liver disease has been 
recognised for over two thousand years, the word itself 
being derived from the Greek for a fluid-filled bag. The 
first theory of its formation is attributed to Hippocrates, 
who stated that "when the liver is full of fluid and this 
overflows into the peritoneal cavity, so that the belly 
becomes full of water, death follows1 (cMOO BC). His 
choice of words reminds us that there is little new in 
medicine, since Lieberman's alternative theory of ascites 
formation, which revitalised interest in this area, has 
become known as the "overflow” theory (1).
The contributions to our knowledge from the days of the 
ancient Greeks until the mid-twentieth century were 
infrequent but noteworthy. Thus Erasistratus of Alexandria 
(c250 BC) recognised the significance of portal hypertension 
when he stated that the "narrowness of the blood vessels 
going through the liver" was the major factor leading to 
peritoneal fluid accumulation, and modern teaching echoes 
the warning of Paul of Aegina in the seventh century AD that
23
sudden or complete paracentesis (described in 20 BC by 
Celsus) would immediately kill the patient.
In 1685 a surgeon at St. Thomas1 Hospital called John 
Brown reported a patient with nodular cirrhosis who had 
ascites and oedema to the Royal Society (2). It may come as 
a surprise to modern investigators that by then an 
appropriate animal model had already been developed.
Richard Lower, an Oxford physiologist, produced ascites in 
dogs by ligating the inferior vena cava. Two centuries 
later, two famous physicians on either side of the Atlantic 
- Thomas Sydenham in England and Austin Flint in New York - 
recognised alcohol as the principal aetiological factor.
The latter also commented on the development of oliguria in 
some cases ( 3).
The spark which ignited the intense interest this 
subject has received in the past 40 years was the invention 
of the flame photometer. Sodium balance studies became 
possible and in the late 1940s and early 1950s several 
groups described avid sodium retention in ascites (4,5,6,7). 
Papper subsequently demonstrated the impaired renal 
excretory response to a saline load (8). It was apparent 
that the explanation for this sodium retention held the key 
to understanding ascites. Two apparently opposing theories 
have been developed, and, despite a vast amount of 
information, the debate has continued into the 1980s.
Indeed, the cynic might argue that the words which introduce 
a review of the situation by Atkinson in 1 956 are equally
24
applicable 30 years later "... our understanding of its 
[ascites*] pathogenesis is not in keeping with the frequency 
of its occurrence. In recent years knowledge of various 
underlying abnormalities has increased without any clear 
conception of their sequence of events in the, pathogenesis 
of ascites emerging" (9).
1 .2.2. The Traditional ("Underfilling") Theory
The Starling hypothesis states that to maintain 
equilibrium between intravascular and extravascular fluid 
volumes, the difference between the capillary and 
interstitial hydrostatic pressure must be equal to the 
difference between the capillary and interstitial colloid 
osmotic pressure (10). In cirrhosis the architectural 
disturbance within the liver impairs portal venous flow 
causing portal venous hypertension. Thus there is a rise 
in capillary hydrostatic pressure within the portal- 
splanchnic circulation. Also in cirrhosis, the reduced 
synthesis of albumin causes a reduction in capillary colloid 
osmotic pressure. These two factors disturb the Starling 
equilibrium and favour the exudation of fluid from the 
portal-splanchnic circulation into the interstitium. The
exact site of this fluid leakage is unknown, although the 
relatively high protein content of the ascitic fluid 
suggests that a major site is the liver itself, since 
hepatic sinusoids are lined by discontinuous endothelium 
allowing easier passage of plasma proteins into the hepatic
25
interstitium than elsewhere (11). Whatever the site, the 
interstitial fluid will initially be returned to the 
circulation via the lymphatic system, and indeed the flow of 
lymph in the thoracic duct is greatly increased in cirrhosis 
(12). However, once the increased formation of 
interstitial fluid exceeds the capacity of the lymphatic 
system to return it to the circulation, the fluid will 
accumulate in the peritoneal cavity and form ascites (13).
The traditional theory proposes that the consequence of 
this fluid shift is intravascular volume depletion 
("underfilling") which will activate various neurohumoral 
homeostatic mechanisms, principally the renin-angiotensin- 
aldosterone system, the sympathetic nervous system and 
vasopressin. These prompt the kidney to retain sodium and 
water, which is therefore seen as a secondary phenomenon.
1 .2.3. The "Overflow" Theory
The underfilling theory was challenged in the late 
1960s by Lieberman and his colleagues in Los Angeles. They 
demonstrated convincingly that plasma volume, far from being 
reduced in cirrhosis, was in fact increased (14). They 
also demonstrated that resolution of ascites does not cause 
a rise in plasma volume (15), that paracentesis does not 
cause a fall in plasma volume (1) and that plasma volume 
expansion by a sodium retaining hormone results in the 
formation of ascites (1). On the basis of these 
observations they proposed the "overflow" theory. This
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states that ascites formation in cirrhosis is a consequence 
of plasma volume expansion, aided by renal sodium retention, 
which is a primary rather than a secondary phenomenon (1).
There is some support for this theory both in 
experimental animals and in man. The strongest support 
comes from the observation that in dogs with experimental 
cirrhosis, urinary salt retention precedes ascites formation 
(16). In man, three groups have demonstrated that in 
contrast to the increase in plasma renin activity which 
would be expected if the circulation were underfilled, 
levels in plasma are in fact normal or even low in most 
cirrhotics with ascites (17,18,19).
1 .2.4. The measurement and manipulation of plasma volume
An important concept relevant to the debate over 
plasma volume is that of the "effective extracellular 
fluid (ECF) volume”. This refers not to the total ECF volume 
nor even to the total intravascular volume, but to that 
volume which is physiologically perceived by the afferent 
receptors, e.g. baroreceptors, which activate the 
neurohumoral mechanisms. For example, sodium excretion 
alters with change in posture - a manoeuvre which does not 
alter total intravascular volume, but presumably does alter 
the physiologically perceived "effective" volume. If the 
trigger for sodium retention in cirrhosis is a reduction in 
the effective rather than the total ECF volume, then the 
increase in total plasma volume demonstrated by Lieberman
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does not automatically disprove the underfilling theory.
Papper introduced this concept to cirrhosis in 1958
(20). He observed that intravenous infusions of the 
patient’s own ascitic fluid caused increased excretion of 
sodium (20). This confirmed that ascitic fluid is 
physiologically ineffective while it remains in the 
peritoneal cavity, and does not contribute to the effective 
ECF volume. Next, the concept of reduced effective ECF 
volume in cirrhosis was extended to the intravascular 
compartment. It was suggested that much of the increased 
plasma volume demonstrated by Lieberman was "pooled” in the 
portal-splanchnic circulation as a result of portal 
hypertension. The increased portal pressure leads to 
portasystemic shunting via new collateral vessel formation
(21) and the increase in splanchnic blood flow in cirrhotic 
rats with portal hypertension and portasystemic shunting 
approaches 50 per cent (22). However, at least in 
experimental animals, the increase in plasma volume in 
cirrhosis affects both the splanchnic and non-splanchnic 
circulation (16).
A second possible site of blood pooling is in the 
peripheral systemic circulation as a result of peripheral 
(principally cutaneous) vasodilatation. This is a 
characteristic feature of cirrhosis and as a consequence of 
the reduction in peripheral vascular resistance, patients 
with cirrhosis tend to have a low systemic blood pressure 
despite an increase in cardiac output (23,24). The cause
28
of this vasodilatation is unknown.
A third possible contribution to a discrepancy between 
effective and total ECF volume is arteriovenous 
anastomoses (25). These occur in the mesenteric, 
pulmonary and peripheral circulations of patients with 
advanced cirrhosis (26).
Effective ECF volume is a concept rather than a 
measurable entity and therefore the hypothesis that it is 
reduced in cirrhosis cannot be tested by direct measurement. 
Instead, investigators have attempted to assess the effect 
of intravascular volume expansion. It has already been 
pointed out that intravenous re-infusion of ascitic fluid 
increases renal sodium excretion (20). Other studies of 
intravenous plasma volume expansion give conflicting 
results. In the same paper (20) infusion of hypotonic 
saline increased urinary sodium excretion, and volume 
expansion may cause an increase in glomerular filtration 
rate and natriuresis, accompanied by suppression of the 
renin-angiotensin-aldosterone system (27). On the other 
hand volume expansion with dextrose increased renal blood 
flow in only 13 of 21 cirrhotics, there being no effect in 
the 8 cirrhotics who had an increased cardiac output 
(28).
Two further means of volume expansion need to be 
considered, both of which lend strong support to the 
underfilling theory. The first is the peritoneo-venous 
shunt pioneered by Le Veen (29). As its name
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suggests, this returns ascitic fluid to the systemic venous 
circulation via a one way valve. All authors agree that 
the insertion of such a shunt leads to a natriuresis 
(30,31,32). However, cirrhotic dogs continue to retain 
sodium during liberal salt intake even after ascites has 
been mobilised using a Le Veen shunt (33).
Finally, Epstein has applied the model of head-out 
water immersion to the study of ascites (3*0.
Immersion to the neck causes a prompt redistribution of 
circulating blood volume with relative central 
hypervolaemia, increasing cardiac output by 30% and 
central blood volume by 700 ml. These changes are 
similar to those induced by an intravenous saline load, 
without any change in plasma composition nor any increase in 
body weight (35). Thus this means of expanding the ECF 
will expand its ’’effective” compartment in a more 
physiological manner than those described previously.
Epstein found that in 32 cirrhotics with ascites, immersion 
resulted in marked natriuresis in the majority, with a 20- 
fold increase in the rate of sodium excretion (3*0, markedly 
in excess of the natriuresis seen in normal subjects.
Also, the manoeuvre, which does not alter glomerular 
filtration rate in normal subjects, greatly improved it in 
the cirrhotic patients (17). Epstein interpreted these 
observations as suggesting that immersion tends to 
’’normalise” the diminished ’’effective” volume of cirrhotic 
subjects and thus strongly support the "underfilling"
30
theory. However, others have argued the opposite, namely 
that an exaggerated response to volume expansion indicates 
that the ECF was already expanded (36). One of the 
drawbacks of the head-out water immersion model is that it 
decreases sytemic vascular resistance, thus increasing the 
compliance of the system. This could explain its failure 
to consistently provoke a natriuresis in the hands of the 
Denver group (37). They subsequently demonstrated similar 
results to Epstein when a noradrenaline infusion was added 
to the model to maintain vascular tone during the immersion 
period (38).
Also of relevance to this debate is the concept of 
mineralocorticoid escape in cirrhosis. This is the term 
applied to the phenomenon whereby in normal individuals, 
mineralocorticoid administration causes only temporary 
sodium retention, following which a natriuresis occurs, 
i.e. they "escape” from the sodium-retaining effects (39). 
This does not occur in the majority of cirrhotics (40,41). 
These studies were interpreted as supporting a primary 
renal defect prompting sodium retention, i.e. support for 
the overflow theory. This was based on the presumption 
that the mechanism of mineralocorticoid escape was 
expansion of ECF (41). However, an alternative 
mechanism is reduced sodium retention in the proximal 
renal tubules to compensate for the mineralocorticoid 
induced distal tubule sodium retention (42).
Therefore an alternative interpretation for the
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failure of this escape in cirrhotics could be that sodium 
retention is at least partially from the proximal rather 
than distal tubule.
It can been seen that both direct measurement and 
manipulation of the plasma volume in cirrhosis have failed 
to conclusively answer the debate regarding the pathogenesis 
of ascites. What light can studies of the indirect 
determinants of plasma volume shed on the problem?
1 .2.5 . The Renin-Aneiotensin-Aldosterone System
Traditionally, the renin-angiotensin-aldosterone system 
(RAAS) has been seen as the principal mediator of sodium 
retention in ascites. Early studies found increased plasma 
concentrations of renin (43), angiotensin (44) and 
aldosterone (45) in cirrhosis with ascites, and these 
findings were confirmed by many others. The stimulus to 
the system was presumed to be vascular underfilling.
However, subsequently studies which excluded dietary salt 
restriction, diuretic therapy and paracentesis as causes of 
a high renin state found the RAAS to be activated in only a 
minority of cirrhotics with ascites (17,18,19). On the 
afferent side, this is indirect evidence against a reduced 
effective ECF as this would be expected to stimulate the 
RAAS. On the efferent side, it might appear at first 
glance as evidence that aldosterone is not the principal 
mediator of sodium retention in these patients. Certainly 
Epstein found a dissociation between suppression of plasma
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aldosterone and the absence of a natriuresis (17).
However, spironolactone - an aldosterone antagonist - 
effectively induces a diuresis in most cirrhotics, even 
without activated RAAS. Wilkinson proposed that this might 
be explained by an increase in the renal tubular sensitivity 
to aldosterone (46).
All authors agree that when RAAS activation does occur 
in cirrhosis, it is usually in the more advanced cases, and 
by the time renal failure intervenes, it is universal.
Indeed Arroyo and his associates have shown the poor 
prognosis associated with RAAS activation in cirrhosis, with 
a six month survival of only 50% (47).
In conclusion there is evidence that the RAAS is 
activated in some but not all cirrhotics. Aldosterone may 
play a central role in sodium retention even in those 
cirrhotics without raised levels via raised renal tubular 
sensitivity, but the conflicting evidence on this point has 
justified the search for other possible mediators of sodium 
retention.
1 .2.6. The sympathetic nervous system
Since the degree of activation of the sympathetic 
nervous system depends on baroreceptors an index of 
sympathetic activity would be an attractive indirect measure 
of effective ECF volume. The first such index to be 
considered was plasma noradrenaline concentration.
Initial attempts at noradrenaline estimation in liver
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disease yielded conflicting results (48,49,50,51). This 
was probably the result of problems with the bioassay and 
fluorimetric techniques of measurement. Subsequently more 
sensitive assays using radioenzymatic methods have been 
developed (52). The first report of the use of such an 
assay in liver disease showed decreased catecholamine levels 
(53) but since then several investigators have found 
elevation of noradrenaline levels in cirrhosis (54,55,56).
The Danish group demonstrated a mean plasma noradrenaline 
level of 2.7 nmol.l"*^ in 8 cirrhotics with severe liver 
disease, half of whom had ascites, as compared to 0.3 
nmol.l”  ^ in healthy controls (54). Bichet and colleagues 
studied 26 patients with alcoholic cirrhosis and ascites, 
and found plasma noradrenaline concentrations of
4.1 nmol.l"^ compared with a control value of 1.5 nmol.l"^
(55). Arroyo studied a sufficiently large group of 
cirrhotics (65 patients) to allow subdivision into groups 
according to presence of ascites and renal failure. He 
demonstrated not only elevated noradrenaline levels in 
cirrhotics vs controls, but within the cirrhotic group 
demonstrated the highest noradrenaline values in those 
cirrhotics with both ascites and renal failure (6.8 nmol.l” )^, 
followed by those with ascites but without renal failure 
(3.0 nmol.l*^), who in turn had higher values than in 
cirrhosis without ascites (2.0 nmol.l” )^ (56). Does this 
increase in noradrenaline concentration represent increased 
sympathetic activity in cirrhosis? Plasma noradrenaline
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concentration depends on both its release from sympathetic 
nerve endings and its rate of clearance from plasma. 
Therefore the increased plasma noradrenaline in cirrhosis 
might result from impaired clearance due to hepatic 
dysfunction. This problem is addressed in this thesis by 
studying the kinetics of radiolabelled noradrenaline 
(Chapter 3).
If there were an increase in sympathetic 
activity in cirrhosis, as most workers have assumed, this 
raises two questions with regard to the pathogenesis of 
ascites. Firstly, is sympathetic overactivity only present 
in established, severe ascites as with the renin- 
angiotensin-aldosterone system, or does it precede the 
development of ascites? The former situation is compatible 
with the overflow theory, whereas the latter would suggest 
vascular underfilling. This question may be answered by 
studying sympathetic activity in a large number of 
cirrhotics with a spectrum of disease severity (Chapter 4) .
Secondly, does the increased sympathetic activity play 
a part in the development of ascites itself? There is now 
strong evidence to suggest it does, by both direct and 
indirect means. Both proximal and distal renal tubules are 
richly innervated by sympathetic nerves in a variety of 
mammals (57,58). The work of Bello-Reuss using initially 
micropuncture studies of rat kidneys (59) and subsequently 
an isolated rabbit proximal convoluted tubule preparation 
(60) provides strong evidence for sympathetically-mediated
sodium reabsorption at the proximal tubule. This effect is 
not mediated by the renin-angiotensin-aldosterone system or 
by renal prostaglandins (61). In addition sympathetic 
stimulation will have indirect effects on sodium retention. 
Beta-adrenoceptor mediated sympathetic neural activity 
promotes renin release from the juxtaglomerular apparatus 
which will stimulate angiotensin and aldosterone secretion, 
resulting in sodium reabsorption from the distal tubule. 
Renal sodium retention could also result from a reduction in 
renal blood flow and/or glomerular filtration rate, both of 
which may result from alpha-adrenoceptor mediated 
sympathetic activation (42). Glomerular filtration rate is 
only rarely sufficiently reduced to be a major cause of 
sodium retention in ascites and such a situation implies the 
development of functional renal failure (62). However 
renal blood flow is reduced in cirrhosis even in the absence 
of overt functional renal failure (63). The relationship 
between renal blood flow and sympathetic activity is 
discussed in more detail in the section on functional renal 
failure (Section 1.3.).
Thus the increased sympathetic activity in cirrhosis is 
associated with renal sympathetic activation which can cause 
renal sodium retention directly via an effect on the 
proximal tubule and indirectly by renin-angiotensin- 
aldosterone stimulation and possibly by altering renal blood 
flow.
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1.2.7. Vasopressin
Despite avid sodium retention, hyponatraemia is common 
in cirrhosis - in one study H0% of all cirrhotics had a 
serum sodium concentration below 130 mmol.l”* (64).
Therefore these patients must retain water in greater 
excess, i.e. they have impaired free water excretion. Free 
water reabsorption takes place in the distal convoluted 
tubules and collecting ducts of the kidney under the control 
of the antidiuretic hormone arginine vasopressin (65).
Much of the work on the role of vasopressin in abnormal 
water excretion in cirrhosis comes from Robert Schrier and 
his co-workers in Denver over the past decade, following the 
development of a sensitive radioimmunoassay. They found 
that in experimental cirrhosis in rats (66) and in cirrhotic 
man (67) impaired free water clearance was associated with 
increased plasma vasopressin concentrations, suggesting a 
principal role for this hormone in mediating the water 
retention of cirrhosis. They had previously demonstrated 
that vasopressin may be released not only in response to 
osmotic stimuli via hypothalamic osmoreceptors but also to 
non-osmotic stimuli such as low and high pressure 
baroreceptors, acting on parasympathetic pathways (68).
Thus vasopressin can be viewed as another indirect hormonal 
indicator of the state of filling of the vasculature, with 
increased levels supporting the underfilling theory of 
ascites (69).
Vasopressin may not, however, be the sole mediator of
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water retention in cirrhosis. The decreased delivery of 
filtrate to the distal nephron which results from reduction 
in glomerular filtration rate and avid proximal tubular 
reabsorption may itself impair free water clearance 
(70). Increased water excretion induced by head-out water 
immersion may (37) or may not (71) be accompanied by 
suppression of plasma vasopressin. The insertion 
of a peritoneovenous shunt for ascites corrects the 
hyponatraemia and increases free water clearance before any 
fall in the elevated vasopressin concentration occurs 
(72) supporting the theory that increased delivery of 
filtrate to the distal nephron is more important than a 
reduction in vasopressin levels in promoting free water 
excretion in cirrhosis.
1 .2.8. Therapy
The debate regarding the pathogenesis of ascites has 
direct bearing on its therapy. There is no doubt about the 
avid sodium retention in these patients and strict dietary 
sodium restriction to ^0 mmol per day or less is required. 
The avoidance of medications which either contain large 
amounts of sodium (e.g. certain antacids and antibiotics) or 
themselves promote sodium retention, whether by aldosterone­
like actions (carbenoxolone) or prostaglandin antagonism 
(non steroidal anti-inflammatory drugs), is important. Bed 
rest combined with dietary sodium restriction alone will 
result in natriuresis and diuresis in a significant
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proportion of patients (73). It has traditionally been 
taught that further treatment involved diuretics, 
principally with the aldosterone antagonist spironolactone. 
Opinion is divided as to the efficacy of this agent. 
Wilkinson (36) cited the response seen in the great majority 
of patients as evidence for a fundamental role for 
aldosterone in the development of sodium retention. On the 
contrary, Epstein (74) found that spironolactone only 
elicited a modest natriuretic response, greatly augmented by 
water immersion, which suggests that the contribution of the 
distal nephron to sodium retention is small. Clinical 
experience favours the former situation with several 
controlled trials showing ninety per cent response to 
spironolactone (75,76) especially in high doses of up to 
1g/day (77). The principal alternative is the loop 
diuretic, frusemide. Although more potent than 
spironolactone in other conditions, it only provokes a 
diuresis in 50% of ascitic patients (76). Spironolactone 
is therefore the diuretic of choice. Frusemide may however 
be successful when added to spironolactone in patients 
unresponsive to the latter alone (78,79), although this 
increases the risk of complications (80).
Other therapeutic options have been considered. Other 
diuretics have been assessed, singly or in combination, 
namely metolazone, either alone (81) or in combination with 
spironolactone (82) or frusemide (83); amiloride (84); 
ethacrynic acid (85) and muzolinine (86). None has been
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superior to high or moderate doses of spironolactone, with 
or without the addition of frusemide (25).
The introduction of angiotensin-converting enzyme 
(ACE) inhibitors has proved valuable in the treatment of 
cardiac failure and hypertension. These agents therefore 
had some appeal in the therapy of resistant ascites where 
the renin-angiotensin-aldosterone system is invariably 
activated. Initial case reports of a favourable effect of 
captopril (87,88) were countered by worries about systemic 
hypotension and impaired renal function (89,90) and 
confusion (91). Captopril appears to cause an average 20$ 
fall in mean arterial pressure and glomerular filtration 
rate (92). This effect could be predicted by earlier work 
using the experimental angiotensin II antagonist, saralasin, 
which provoked severe hypotension in cirrhotic patients, 
indicating that in these cases, maintenance of systemic 
blood pressure is dependent on circulating angiotensin II 
(93). Several groups subsequently confirmed this finding 
(94,95,96). Thus it is unlikely that the ACE inhibitors 
will have a therapeutic role in resistant ascites.
All authors emphasise the importance of a gradual 
rather than a sudden diuresis, recommending weight loss 
of only 0.5 kg per day (1kg/day where peripheral oedema is 
present). This is because the maximum rate of mobilisation 
of ascites is 900 ml per day (97,98). The dangers of 
overdiuresis are electrolyte disturbance, especially 
hypokalaemia, and intravascular volume depletion which may
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precipitate encephalopathy (80), and functional renal 
failure respectively. Functional renal failure is 
considered in more detail below (Section 1.3.).
For similar reasons, paracentesis of large volumes has 
long been considered contra-indicated in these patients - 
rapid reaccumulation of ascites precipitating hypovolaemia, 
renal failure, encephalopathy and death. This cautious 
view has recently been challenged by the Spanish group under 
Professor Rodes. In their hands paracentesis of up to 3 
litres daily was not associated with any more risk of renal 
insufficiency or electrolyte disturbance than traditional 
therapy with diuretics, provided plasma volume was replaced 
by albumin infusions (99). Two other groups have recently 
confirmed the safety of paracentesis (100,101).
An extension of the paracentesis/albumin infusion 
concept is that of the intravenous reinfusion of ascitic fluid 
itself. This was employed as a research tool as long ago 
as 1958 (20). It can be achieved on a temporary basis by 
an external pump arrangement employing ultrafiltration 
(Rhodiascit) which has very limited clinical applications 
(102). A more permanent solution is the peritoneovenous 
shunt (29) which returns ascitic fluid to the superior vena 
cava via a tunnelled catheter with a one-way valve, and is 
effective in initiating a natriuresis (30). However, it is 
plagued by complications including shunt blockage, 
septicaemia and disseminated intravascular coagulation. Its 
use is therefore limited to the rare patient with truly
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resistant ascites and preserved hepatic function (79).
What are the implications of these treatments for the 
theories of ascites described above? The efficacy of the 
paracentesis/albumin infusion regime supports the 
underfilling theory, while the success of judicious diuretic 
therapy supports the overflow theory. The greater efficacy 
of spironolactone than other diuretics favours the distal 
tubule as the principal site of sodium reabsorption. It 
has been argued that the frequent precipitation of renal 
failure by diuretics favours an already underfilled 
intravascular compartment (69), but this would 
not apply if such complications only occurred where too 
rapid a diuresis (exceeding the mobilisation capacity of the 
ascites) had occurred. The natriuresis which follows the 
insertion of the peritoneovenous shunt is accompanied by 
depression of all markers of intravascular volume depletion, 
i.e. renin, noradrenaline and vasopressin (103) which 
provides strong support for the underfilling theory.
1 .2.9. Conclusion
It seems likely that the two theories of ascites 
formation are in fact complimentary rather than conflicting. 
Most of the studies whose results favour vascular 
underfilling have been carried out on patients with fully 
established ascites. Most of the studies supporting the 
"overflow" theory have concentrated on the sodium retention 
occurring at the commencement of, or even preceding, the
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formation of ascites. Although in the past five years the 
weight of evidence has moved against the overflow theory, 
largely as a result of studies on the sympathetic nervous 
system and on the head-out water immersion model, it is 
inconceivable that all the diverse evidence for the overflow 
theory is ’'wrong”. The basic flaw in the original 
underfilling theory was that the intravascular volume 
depletion was said to result from loss of fluid into the 
peritoneal cavity. Ascites cannot be caused by ascites 
alone! There requires to be some initiating mechanism.
The modified underfilling theory, which cites peripheral 
vasodilatation as the cause for underfilling despite 
increased cardiac output and blood volume is more credible. 
The two basic flaws in the overflow theory as the sole 
explanation for events have until now been the lack of the 
precipitating factor which initiates sodium retention de 
novo, and the obvious underfilling present later in the 
natural history of the disease process. Interestingly, the 
proponents of the overflow theory have pointed out that the 
sympathetic nervous system could be stimulated by the 
increase in hepatic venous pressure in cirrhosis, via 
hepatic baroreceptors (104). Thus sympathetic 
activation could precede vascular underfilling and could 
conceivably be the missing trigger for sodium retention. 
Better and Schrier in an attempt to formulate a 
unifying hypothesis incorporating both theories, suggest a 
central role for activation of the sympathetic nervous
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system (105).
1.3. FUNCTIONAL RENAL FAILURE
Some patients with advanced liver disease develop 
"unexplained renal failure in the absence of any clinical or 
anatomical evidence of other known causes of renal failure"
(106). This is variously known as functional renal failure
(107), the hepatorenal syndrome (106,108) and hepatic 
nephropathy (109). I will use the first of these terms and 
confine the discussion to the development of renal 
impairment complicating cirrhosis, i.e. excluding renal 
problems in fulminant hepatic failure and obstructive 
jaundice. In the context of cirrhosis, functional renal 
failure represents the extreme end of the spectrum which 
incorporates sodium retention and ascites (105).
The absence of pathological damage to the kidney in 
this condition is fundamental, as confirmed by the 
successful transplantation of such kidneys, where they 
function normally in recipients (110). This suggests that 
the primary abnormality is a circulatory one, either 
disturbed intrarenal or extrarenal haemodynamics. In 1970, 
Epstein demonstrated reduced renal blood flow, particularly 
to the renal cortex in fifteen cirrhotics with functional 
renal impairment (111). The following year Kew showed that 
blood flow to the renal cortex was reduced in thirty 
three cirrhotics without biochemical renal impairment (63). 
Ring-Larsen found progressive reduction in renal blood flow
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in cirrhotics without ascites, those with ascites, and those 
with renal impairment (64). Therefore functional renal 
failure appears to be closely linked to reduced renal blood 
flow.
The control of renal blood flow is extremely 
complex. Of particular interest in the context of this 
thesis is the role of renal sympathetic activity. Although 
the renal vasculature is richly innervated by sympathetic 
nerves (58), it has not been conclusively proven that these 
sympathetic nerves directly regulate renal blood flow (113). 
Nevertheless, sympathetic stimulation in animal models, e.g. 
chronic bile duct-ligated dogs, causes renal 
vasoconstriction via alpha adrenoceptor activation (114), 
and renal sympathetic activity certainly modulates renal 
blood flow indirectly, via beta-adrenoceptor mediated 
stimulation of the renin-angiotensin system.
Peripheral plasma noradrenaline concentration is 
significantly higher in functional renal failure than in 
cirrhotics with ascites but without renal impairment (56). 
Regional studies are divided as to whether this sympathetic 
activity is (115) or is not (116) primarily of renal origin. 
Alpha adrenergic blockade by infusion of phentolamine 
directly into the renal artery in four patients failed to 
significantly improve renal perfusion (111). However, the 
study was clouded by significant arterial hypotension 
following phentolamine. Baldus therefore repeated the 
experiment with the inclusion of plasma expansion to prevent
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arterial hypotension, but with the same results (117). 
However, dihydroergocristine, an alternative alpha 
adrenergic antagonist, did improve renal blood flow (118). 
The question of the contribution of increased renal 
sympathetic activity to renal vasoconstriction in cirrhosis 
therefore remains open.
There are other hormonal factors involved in the 
control of renal blood flow. Although angiotensin II, a 
renal vasoconstrictor, is probably increased in functional 
renal failure (19), its inhibition both directly, using the 
antagonist saralasin (36,95) and indirectly, by beta 
adrenergic blockade (119) fails to improve renal blood 
flow. However, the oral angiotensin converting enzyme 
inhibitor, captopril, has a renal vasodilating effect both 
in normal and cirrhotic subjects (92). Unfortunately this 
is of little practical value as it selectively dilates the 
efferent glomerular arteriole which may lower the glomerular 
filtration rate, and can cause marked systemic hypotension 
when used in cirrhosis. In fact activation of the renin 
angiotensin system may result from decreased renal blood 
flow. The suppression of plasma renin activity by 
dopamine-induced renal vasodilatation supports this theory 
(120) .
Renal prostaglandins play an important role in 
maintaining normal renal blood flow. In an elegant 
clinical study, Arroyo demonstrated that in cirrhotics with 
ascites, urinary PGE2 (a vasodilatory renal prostaglandin)
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and plasma noradrenaline are both increased, but when 
functional renal failure ensues, urinary PGE2 falls while 
plasma noradrenaline increases further (56). Others 
(121,122) have confirmed these findings which suggests that 
in ascites without functional renal failure, the tendency to 
renal vasoconstriction from sympathetic activation is 
prevented by a compensatory increase in vasodilating 
prostaglandins, while in functional renal failure this 
mechanism fails, renal prostaglandin secretion falls and 
vasoconstriction ensues (123).
The practical implication of these findings for the 
cirrhotic patient is that drugs which inhibit prostaglandin 
synthesis - principally non steroidal anti-inflammatory 
drugs - have a deleterious effect. They cause both sodium 
and water retention and reduced renal blood flow (124,125).
A new non steroidal anti-inflammatory drug, sulindac, appears 
to spare the renal prostaglandins in normal subjects but 
there is controversy as to whether it does (126) or does not 
(127) impair renal blood flow in cirrhosis.
Another hormone system with renal vasodilatory 
properties is the kallikrein-kinin system/ Plasma 
bradykinin (128), and urinary kallikrein (129,130,131) are 
reduced in cirrhotics, particularly with functional renal 
failure. One group found urinary kallikrein to be 
increased in cirrhosis with ascites alone, but decreased in 
patients with ascites and renal failure (121) analogous to 
the pattern with renal prostaglandins. The significance of
47
these observations, and the inter-relationships between the 
kinin system and the other hormones controlling renal blood 
flow, remain to be determined.
An alternative explanation for the renal 
vasoconstriction of functional renal failure, other than 
imbalance between the normal neurohumoral control 
mechanisms, would be the presence in cirrhosis of a 
pathological renal vasoconstrictor. One such agent is 
endotoxin. This degradation product of intestinal 
bacteria normally inactivated by hepatic Kuppfer cells may 
reach the systemic circulation in cirrhosis. Wilkinson 
found that endotoxaemia was associated with the development 
of renal failure in both fulminant hepatic failure (132) and 
cirrhosis (133) and showed a possible benefit from polymixin 
B, which has an anti-endotoxin effect (13*0. Unfortunately 
this agent is too nephrotoxic for general clinical use. 
However, endotoxin is only present in a minority of cases of 
functional renal failure and cannot be its sole explanation.
Gastrointestinal peptides have potentially harmful 
vasoactive effects if released into the systemic circulation 
because of impaired hepatic metabolism or portasystemic 
anastomoses. Vasoactive intestinal peptide (VIP) is an 
attractive candidate in this regard, as it may cause 
systemic vasodilatation and renal vasoconstriction, i.e. the 
haemodynamic profile of advanced cirrhosis. There are 
conflicting reports regarding the plasma concentration of 
VIP in cirrhosis. An initial report showed an increase
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(135) but a much larger study failed to confirm this (136). 
However, this latter group did identify a subgroup 
of patients with high levels in fulminant hepatic failure, 
which corresponded to those patients with a lower systemic 
blood pressure (137), results supported by more recent work 
in cirrhosis (138). VIP levels do not correlate with renal 
blood flow and it is unlikely to play a significant role in 
most causes of functional renal failure. The possibility 
remains that some of the other GI hormones elevated in 
fulminant hepatic failure - which include insulin, glucagon, 
pancreatic polypeptide and enteroglucagon (137)'- or indeed 
other, as yet unidentified, agents which the failing liver 
fails to inactivate, may have a deleterious effect on renal 
blood flow.
What are the implications for the management of 
functional renal failure in cirrhosis?
The cirrhotic patient who develops renal impairment 
should have known causes of renal damage identified and 
treated, diuretic therapy discontinued and any pre-renal uraemia 
corrected, which will often require a trial of intravenous 
fluid loading. If these measures fail, the patient has 
established functional renal failure. Haemodialysis should 
be considered if spontaneous improvement in hepatic function 
is anticipated or if the patient is awaiting hepatic 
transplantation. Otherwise it should be avoided as it 
holds no longterm prospects of improvement. Pharmacological 
intervention remains of no proven benefit. In particular
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sympathetic blockade, both of alpha (111,117) and beta (119) 
adrenoceptors, angiotensin blockade (92) and octapressin, a 
synthetic vasopressin analogue with renal vasodilatory 
properties (139) have not improved renal blood flow. 
Dopamine (120) and aminophylline (1*40) have improved renal 
blood flow but have yet to be shown to have clinical value. 
The prognosis reflects the underlying severity of the liver 
disease in most cases and although the mortality approaches 
100$, few die of uraemia in isolation.
1.4. CIRCULATORY CHANGES IN CIRRHOSIS
The remainder of this background chapter considers the 
abnormal circulation of cirrhosis, whose disturbed 
sympathetic control is currently poorly understood.
The patient with cirrhosis typically has a 
’’hyperdynamic” circulation comprising increased plasma 
volume, increased cardiac output, tachycardia, cutaneous 
vasodilatation, reduced peripheral vascular resistance and 
systemic hypotension (23,141). These features account for 
the florid complexion, bounding pulse, flow murmurs and 
possibly cutaneous vascular manifestations such as palmar 
erythema and spider naevi (142).
Although this circulatory disturbance has been 
recognised for over thirty years, it has received only 
sporadic attempts to identify its cause. Nevertheless, it 
may be of primary importance in triggering the formation of 
ascites, via stimulation of neurohumoral homeostatic
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mechanisms such as the sympathetic nervous system which 
promote sodium retention.
The studies which approach this problem fall into four 
categories. Firstly, there are those which simply measure 
the haemodynamic disturbance. Secondly there are those 
which seek to measure the effect of altering the circulation 
by physiological means such as changes in posture or reflex 
autonomic stimulation. Thirdly, some studies consider the 
cardiovascular responses to exogenous vasoactive substances 
such as noradrenaline and angiotensin II. Finally there 
are studies which seek to alter the circulation by blockade 
of the normal vasomotor control systems.
In the first category there is general agreement. The 
initial observation of increased cardiac output, reduced 
peripheral vascular resistance and reduced systemic blood 
pressure was made by Kowalski in 1953 (1 Ml) and confirmed by 
Murray in 1958 (23). The suggestion that the same abnormalities 
persisted or were even more marked in terminal liver failure 
(143) were also confirmed (144). Kontos identified 
the site of the reduced vascular resistance as being 
principally within the skin and/or skeletal muscle (24).
Stimulation of sympathetic activity by exercise caused 
an appropriate increase in cardiac output in cirrhosis, the 
greatest increase being in those individuals with 
supranormal resting values (145). This is supported by 
more recent work indicating normal increases in plasma 
noradrenaline and heart rate during exercise in cirrhosis
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C146). Sympathetic activity can also be stimulated by 
changes in posture. Ring-Larsen found similar changes in 
heart rate, blood pressure, renal blood flow and plasma 
noradrenaline concentrations in cirrhotic patients as in 
controls during tilting, suggesting normal neurovascular 
reactivity (147)• However, other studies do not support 
this contention. The haemodynamic response to sympathetic 
stimulation by head-up tilting was abnormal in cirrhosis in 
that the heart rate and blood pressure rose only transiently 
and subsequently fell, in contrast to a sustained rise in 
control subjects (148,149). Also, head-up tilting caused 
significantly less peripheral vasoconstriction and 
tachycardia in cirrhosis as measured by changes in forearm 
blood flow (150). This group also used changes in forearm 
blood flow to measure cardiovascular responsiveness to a 
number of other autonomic stimuli, including application of 
ice, stressful mental arithmetic and lower body negative 
pressure (151). They found that in each case the response 
was reduced in the cirrhotic patients.
Parasympathetic cardiovascular responses have also been 
considered in a number of studies. Their interpretation 
requires consideration of the role of alcohol, since vagal 
neuropathy is described in chronic alcoholics (152). 
Autonomic neuropathy is said to be more common in alcoholics 
with than without chronic liver disease (153) but the groups 
were not matched for duration and severity of their 
alcoholism. Vagal function was impaired in cirrhosis only
52
if of alcoholic origin (154). However, an earlier study 
found the heart rate response to the Valsalva manoeuvre - a 
parasympathetic effect - to be impaired in non-alcoholic 
cirrhosis (151).
The third category of experimental evidence to be 
considered concerns the cardiovascular response to the 
infusion of vasoactive agents, both in experimental animals 
and in man. In both situations the evidence to date is 
conflicting. In carbon tetrachloride-induced cirrhosis in 
rats some workers have found decreased pressor responses to 
angiotensin II but not to noradrenaline (155). Others 
using the same model have found decreased pressor responses 
to both agents (156,157). In dogs with chronic bile duct 
ligation, a model with a similar haemodynamic disturbance to 
cirrhotic man, the cardiovascular response to angiotensin 
was markedly reduced, but to noradrenaline only slightly so
(158). The pressor response to vasopressin, another non- 
sympathetic vasoconstrictor was impaired in cirrhotic rats
(159) .
In human studies of cirrhosis the cardiovascular 
response to the administration of exogenous noradrenaline is 
variously reported as markedly reduced (151), minimally 
reduced (160), normal (144,161) or even enhanced (162). 
Angiotensin II administration has yielded equally confusing 
results with reports that responsiveness in cirrhosis is 
decreased (160,161,163), normal (151) or increased (162).
The injection of tyramine, which promotes release of
53
endogenous noradrenaline caused a less marked rise in blood 
pressure in cirrhotics than controls (144). The rise in 
heart rate in response to isoprenaline, a sympathetic 
stimulant which acts selectively on beta adrenergic 
receptors, is reported to be reduced in cirrhosis (162,164). 
There are no studies reporting the effect of selective alpha 
adrenoceptor stimulation.
The final group of studies to consider are those which 
examine the effect of blockade of the normal vasoactive 
systems. Parasympathetic blockade by atropine causes a 
less marked rise in heart rate in cirrhosis than controls 
(162) but this effect is limited to alcohol-induced 
cirrhosis (154). Blockade of both sympathetic alpha 
adrenoceptor action by phentolamine (111) and angiotensin- 
mediated responses by captopril, an angiotensin converting 
enzyme inhibitor (92) or saralasin, an angiotensin II 
antagonist (93) can cause profound hypotension. This 
suggests that the increased activity of these two vasomotor 
control systems is an attempt to maintain a normal blood 
pressure. Sympathetic beta adrenoceptor blockade has been 
widely studied in cirrhosis since the observation that 
propranolol lowers portal pressure (165) and may reduce the 
risk of rebleeding from oesophageal varices (166). As 
regards the effect on the systemic circulation, the 
reduction in cardiac output and blood pressure in cirrhosis 
has not been specifically compared to normal values, but 
appears to be of the expected order of magnitude. Finally
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reduction in sympathetic activity by clonidine (a centrally- 
acting alpha2 adrenoceptor agonist) reduces plasma 
noradrenaline, cardiac output and mean arterial pressure in 
cirrhosis (167,168).
Although these studies define the nature of the 
haemodynamic disturbance, and hint at abnormal autonomic 
circulatory control, no clear picture of the nature of the 
autonomic disturbance emerges. In some instances, the 
autonomic tests are too imprecise to define the site of the
abnormal response. The conflicting results of the studies
administering vasoactive substances reflect widely diverging 
and often poorly validated techniques. Autonomic 
neuropathy can best be assessed by a battery of
cardiovascular function tests, which are applied to
cirrhosis in Chapter 5. Pharmacological studies have now 
provided valid, reproducible techniques of measuring the 
cardiovascular responses to infusions of vasoactive 
substances, and these are applied to cirrhosis in Chapter 6. 
The question of whether abnormal autonomic circulatory 
control reflects changes in the number or function of 
adrenergic receptors, which had not previously been 
studied, is addressed in Chapter 7.
It is appropriate to consider the mechanisms, other 
than disturbed autonomic function, which have been proposed 
to explain the circulatory changes in cirrhosis. One 
possibility is failed hepatic inactivation of vasoactive 
gastrointestinal peptides. VIP is a systemic vasodilator,
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but as already explained when discussing renal 
vasoconstriction (Section 1.3.), is only elevated in a 
minority of cirrhotics (138). An alternative 
vasodilatory gut peptide is substance P, which has recently 
been reported as markedly elevated in the plasma of cirrhotics 
(169). Other potential vasodilators are the enkephalins, 
which are elevated in cirrhosis due to reduced hepatic 
metabolism (170).
Atrial natriuretic peptide (ANP) is a potent systemic 
vasodilator. It has variously been reported in cirrhosis 
as being increased (171,172,173,174), normal (175,176,177) 
or reduced (178). If it is reduced, this might contribute 
to the sodium retention of ascites. Alternatively the 
sodium retention occurring for other reasons might be 
expected to stimulate its release, hence causing an increase 
in plasma levels. The conflicting results to date 
probably largely reflect initial methodological problems 
with sampling and assay techniques. These have now been 
resolved and ANP measurements in cirrhosis are reported in 
Chapter 4.
Another group of vasodilating agents increased in 
cirrhosis are the prostaglandins. Renal prostaglandins 
with a vasodilator effect, e.g. prostaglandin E2 , are 
increased in cirrhotics without functional renal failure
(56). Increased systemic production of prostacyclin, a 
powerful vasodilator, has been demonstrated in 
cirrhosis (179). Also, prostaglandin E has been
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shown to contribute to the pressor resistance to 
angiotensin, since this could be partially reversed by 
pretreatment with indomethacin, a prostaglandin inhibitor 
(180) .
An alternative hypothesis for the abnormal 
vasodilatation of cirrhosis is the so called "false 
neurotransmitter” theory. This proposes that the 
neurotransmitters which maintain vascular tone, e.g. 
noradrenaline, are displaced from their receptors by 
chemically similar agents. One such agent is octopamine 
(181), though this was only elevated in two out of ten 
cirrhotics (182). The studies in Chapter 7 of adrenoceptor 
number and affinity consider the possibility of interference 
at the receptor binding site.
In summary, the abnormal systemic circulation in 
cirrhosis is unexplained. It seems possible that the 
primary defect is that which causes a reduction in 
peripheral vascular resistance. This in turn allows 
underfilling of the intravascular space despite an increase 
in cardiac output. This stimulates sympathetic activation, 
the renin-angiotensin-aldosterone system and non osmotic 
vasopressin release. For reasons yet to be determined 
these fail to correct the vascular abnormalities, although 
striving to maintain them, such that pharmacological 
blockade precipitates severe hypotension. The continual 
overactivity of these neurohumoral homeostatic mechanisms 
causes sodium and water retention and hence ascites.
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CHAPTER 2
GENERAL METHODOLOGY
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2.1 . PATIENTS
2.1.1. Liver Disease
The 41 subjects with liver disease used in these studies 
were drawn from patients attending Stobhill General 
Hospital, Glasgow. In the majority of cases, they had 
histologically proven cirrhosis. In addition, a number of 
cases have been included with presumed cirrhosis. These 
are patients in whom liver biopsy was contraindicated by 
either coagulopathy or lack of patient consent. To be 
included in any of the studies, such cases required to have 
clinical evidence of chronic liver disease, with abnormal 
biochemical liver function tests plus portal hypertension 
indicated by either oesophageal varices (endoscopically 
proven) or splenomegaly (palpable spleen on abdominal 
examination confirmed on isotope scanning), with these 
findings persisting for longer than six months.
Cirrhosis of any aetiology was included, although the 
majority were of alcoholic origin. The effects of alcohol 
on autonomic function have been taken into account 
in the interpretation of each study.
The severity of the liver disease has been graded 
according to the method of Child (183) as modified by Pugh 
(184). This utilises the three laboratory tests v/hich give 
an indication of hepatocellular function, i.e. serum 
albumin, serum bilirubin and prothrombin time, and two 
readily assessible clinical features, i.e. ascites and 
encephalopathy (see Table 2.1.).
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TABLE 2.1.
PUGH'S GRADING OF LIVER DISEASE SEVERITY (184)
1 2 3
Encephalopathy (grade) 0 1 and 2 3 and 4
Ascites None Slight Moderate 
or severe
Bilirubin (umol.l” )^ < 34 34-51 > 51
Prothrombin time 
(seconds prolonged)
« 3 4-6 > 6
Albumin (g.l“ )^ > 35 28-35 < 28
Bilirubin in PBC (umol.l“ )^ < 68 68-170 > 170
Cumulative Score 5-6: Grade A (mild)
7-9: Grade B (moderate)
10 -15: Grade C (severe)
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The cirrhotic patients studied represent most of those 
presenting to the two physicians with an interest in 
gastroenterology in Stobhill Hospital. There were no 
secondary referrals from outwith the hospital's catchment 
area.
2.1.2. Control Sub iects
Choice of control groups is particularly critical to 
studies on the sympathetic nervous system. Plasma 
catecholamine concentrations rise with age (185,186), and 
are lower in hospital or laboratory staff familiar with 
study techniques than in "naive” subjects (187). Also, 
certain disease states are associated with raised 
catecholamine levels, including hypertension, cardiac 
failure, thyroid disease and chronic obstructive airways 
disease. For the studies of autonomic function, diabetes 
mellitus and neoplasia must also be excluded. To satisfy 
these criteria the control subjects used were drawn from 
patients attending the gastroenterology clinic with non- 
hepatic disorders (principally peptic ulcer disease and 
irritable bowel syndrome/diverticular disease) and from 
patients awaiting minor elective surgery (principally hernia 
repair or varicose vein ligation). The latter group were 
studied as in-patients prior to their surgery, allowing for 
matching of dietary sodium intake.
Patients with peptic ulcer disease were included as 
controls despite the reported increase in plasma
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catecholamines in this condition (188). Plasma 
noradrenaline levels in our peptic ulcer patients (2.7 ± 1.9 
nmol.l” , n=8) were no different from our control patients 
with other non-hepatic disorders (2.5 ± 1.2, n=26; p =
0.75) .
2.2. LABORATORY CONDITIONS
All studies were carried out in the Clinical 
Investigation Unit of the University Department of Materia 
Medica. The studies were performed by one investigator 
(the author) on all occasions, with a research nurse in 
attendance. The environmental conditions were constant, 
with the ambient temperature maintained at 21°C. In each 
study the timing of the procedure was constant (usually 9
a.m. commencement). Wherever possible subjects were 
studied in tandem, one cirrhotic plus one control patient on 
each study day. On all study days, the subjects abstained 
from caffeine-containing beverages, alcohol, tobacco and all 
medication. The details of fasting or non-fasting state, 
and of duration of abstinence from alcohol and medication 
prior to the study day, varied between studies and is 
described in the appropriate chapters.
2.3. HANDLING AND PREPARATION OF BLOOD SAMPLES
2.3.1. Catecholamines
The same procedure for catecholamine measurement was 
adhered to in all studies. The subjects had an indwelling
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cannula inserted into an antecubital vein, and patency 
maintained with heparinised saline (1 ml containing 20 units 
heparin). After a minimum of 30 minutes rest in a supine 
position and after verification of a stable blood pressure 
and heart rate, blood was drawn from the cannula and 
immediately placed in cooled lithium heparin tubes on ice. 
This was centrifuged immediately at i4°C at 1000 rpm for 10 
minutes. The plasma was separated and stored in plastic 
tubes at -70°C.
2.3.2. Plasma Renin Activity
As above, with the exception that 5 ml of blood only 
were required, placed in an E.D.T.A. tube and the plasma 
stored at -20°C.
2.3.3. Atrial Natriuretic Peptide
As above, with the exception that to the lithium 
heparin tubes prior to the insertion of the blood, had been 
added aprotinin, 20 KIU for a 10 ml blood sample.
2.3.4. Adrenoceptor Studies
120 ml blood (cirrhotic patients) or 60 ml (control 
patients) were drawn from an intravenous cannula after 30 
minutes supine rest and placed in universal containers 
containing 5% sodium citrate (18 ml blood to 2 ml citrate). 
The samples were removed for immediate analysis (see Chapter 
7) .
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2.4. ANALYTICAL METHODS
2.4.1 . Plasma noradrenaline and plasma dihvdroxv- 
phenvlethvlene glvcol (DHPG)
Noradrenaline and its dihydroxymetabolite DHPG 
were measured simultaneously using high performance liquid 
chromatography with electrochemical detection (189).
Plasma collected and stored as outlined in 2.3.1. was 
mixed with 4 mg of alpha-methylnoradrenaline (as an internal 
standard) and the pH adjusted to 8.6 using 500 ul of 1.5 M 
Tris. The sample was mixed with acid-washed alumina (50 
mg) for 30 minutes. After the alumina had settled the 
plasma was aspirated and the alumina washed twice with 10 ml 
distilled water. The catecholamines were then eluted by 
vigorously mixing the alumina with 250 ul of 0.2 M 
perchloric acid. A 200 ul aliquot of the eluate was 
injected into the liquid chromatograph.
The chromatographic system consisted of a Pye-Unicam LC-XPS 
pump, a precolumn (40 x 1 mm) packed with Li Chroprep 
(Merck) and a 25 cm x 4.0 mm I.D. reversed-phase column.
The column was packed with Spherisorb 5u silica (Phase 
Separating). The mobile phase was 70 mM NaH2P04 (pH 3.0) 
(Fisons) with 1.85 mM octanesulphonic acid (Fisons) and 13.4 mM 
EDTA (BDH, Anala R). The flow rate was 1 ml.min-1 and the 
column effluent was passed through a TL3 cell (Bioanalytical 
Systems) with a glassy carbon electrode where the 
catecholamines were detected using an LC4 amperometric 
detector (Bioanalytical Systems). The applied potential
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was set at +0.66 V relative to the Ag/AgCl reference 
electrode. The sensitivity of the detector was set 
at 1.10 nA/V and the background current was 1.2 nA.
The sensitivity of the system (twice background level) 
was 30 pg for noradrenaline and DHPG. The within-day 
coefficients of variation were 3.4$ for noradrenaline 
and 4.1$ for DHPG, and between day coefficients of 
variation were 4.6$ for noradrenaline and 8.9$ for 
DHPG.
A typical chromatogram is illustrated in Figure 2.1.
The plasma concentration of the catecholamine is calculated 
by the ”peak height ratio” method:
plasma noradrenaline (nmol.l- )^ =
height of noradrenaline X
---------------------------------   x ----------------------
height of internal standard peak volume of plasma (ml)
where X = amount of internal standard (ng) added, divided by 
the ratio of peak height of noradrenaline internal standard 
on a chromatogram of an extracted standard, divided by 
molecular weight of noradrenaline x 10“3.
2.4.2. Plasma Renin Activity
Plasma renin activity was determined by a specific 
radioimmunoassay of angiotensin I formed upon cleavage by 
renin of its substrate angiotensinogen (190). The limit of
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Figure ZA-
Chromatogram from plasma following HPLC with electrochemical detection 
for simultaneous determination of noradrenaline and DHPG.
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detection of the assay was 0.1 ng AI ml“^hr"^ and the inter 
and intra assay variations were 7.0% and 5.5% respectively.
2.4.3. Atrial Natriuretic Peptide 
Extraction
Atrial natriuretic peptide (ANP) was extracted from 
plasma, using Water's Sep Pac C18 cartridges. The adsorbed 
ANP was eluted in an ethanol solvent. Eluates were dried 
down in oxygen free nitrogen at 40°C and residues were 
reconstituted in assay buffer.
Radioimmunoassay
ANP antibody was raised in New Zealand white rabbits 
against synthetic human 1-28 ANP. To evoke a greater 
immunogenic response the ANP immunoglobulin was conjugated 
using carbon di-inide as a coupling agent (191). The 
resulting antisera were used at 1-11,000 dilution to give 50% 
binding in the assay system. ANP label was purchased
from Amersham International and used in the assay at a 
concentration of 4pg/tube. The diluent used throughout the 
assay was sodium hydrogen phosphate buffer 0.1M, pH 7.4, 
containing 0.25% egg albumin.
The non equilibrium assay system was used along with 
dextran coated charcoal to separate the free from the 
antibody "bound” radioactivity. The sensitivity of the 
assay was 10 pg/100 ul. Intra and interassay coefficients 
of variation was 4.9% and 8.2% respectively. The extraction
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recovered was 90-953.
2.4.4. Biochemical and Haematological Analysis
Urea and electrolytes and biochemical liver function 
tests were measured in the Department of Biochemistry at 
Stobhill Hospital by standard autoanalyser techniques 
(TECHNICON). Full blood count including platelets was 
measured by the Haematology Department using a Coulter 
counter. Prothrombin time was compared to a standard 
control sample, and the result expressed as the number of 
seconds by which the study sample exceeded the control 
sample (normal < 3 secs).
2.5. r3HlHORADREMALIME METHODOLOGY
2.5.1. Introduction
The spillover of noradrenaline into plasma and its 
clearance from plasma were calculated using a method 
developed in the Department of Materia Medica (192). The 
rationale behind this development and the methodology 
employed will be discussed in some detail.
Plasma noradrenaline concentration depends not only on 
the spillover into plasma from sympathetic nerve endings but 
also on its clearance from plasma by uptake into sympathetic 
nerves, uptake into other tissues or by metabolism 
principally by the catechol-O-methyltransferase (COMT) 
system. The spillover rate is therefore a better guide to 
sympathetic activity than simply plasma noradrenaline.
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Spillover and clearance can be calculated using steady state 
kinetics of 1-[^H] noradrenaline (193). This method 
involves the intravenous infusion of [^H] noradrenaline to 
steady state in a resting individual, and calculation of 
amount of radioactivity in plasma extracted on alumina. 
Although it has previously been assumed that all such 
radioactivity is due to [^H] noradrenaline, there are 
theoretical grounds to suspect that [^H] metabolites of 
noradrenaline may also form. For example, DHPG is an 
important metabolite of noradrenaline cleared from plasma by 
uptake into sympathetic nerves (19*0, and a substantial 
proportion of [^H] noradrenaline infused intravenously is 
cleared in this manner (195). A method was therefore 
developed which introduced a high performance liquid 
chromatographic (HPLC) separation of plasma [^H] 
noradrenaline.
2.5.2. Composition of plasma radioactivity during [^H] 
noradrenaline infusion
Methods
L-[7,8-3h ] noradrenaline (1.1-1.85 TBq mmol"**) 
(Amersham) was prepared for human use by ultrafiltration. 
Radiochemical purity was checked by thin layer 
chromatography and found to be greater than 95%. 4MBq of 
[^H] noradrenaline, diluted to 55 ml in normal saline with 
500 mg of ascorbic acid was infused at a rate of 3.6 x 10^
Bq min“"' (0.458 ml m i n ” ^ ) using a Braun perfusor Mark 4 pump
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into a peripheral vein of six healthy male volunteers who 
had been resting supine for at least 30 minutes. Ten mis 
of blood were collected from the opposite arm into chilled 
lithium heparin tubes at regular intervals during the two 
hour infusion. An additional 12 ml of blood were taken at 
30 min for comparisons between the amount of radioactivity 
in plasma, the amount recovered on alumina and the amount 
recovered from the HPLC column.
The blood was centrifuged at 1000 g for 10 min (4°C) 
and the plasma separated. Five ml of plasma from each 
sample was added to 50 mg of alumina, 4 ml of 1 mol I”* Tris 
EDTA (pH 8.7) and 235 pmol of dihydroxybenzylamine (DHBA) 
which was used as a cold internal standard. The samples 
were mixed on a rotary mixer for 15 min then washed twice 
with distilled water. Catechols were eluted from the 
alumina by the addition of 230 ul of 0.2 mol 1“  ^ perchloric 
acid. 20 ul of this was assayed by HPLC with 
electrochemical detection to determine the recovery of 
internal standard in each sample, and the remainder was 
injected onto the HPLC to separate out [^H] noradrenaline. 
The alumina eluate from the additional 30 min sample was 
counted by liquid scintillation spectrometry without 
separation on the HPLC column. This allowed a comparison 
of the total amount of radioactivity recovered from the 
column with the amount recovered on alumina. A 1 ml plasma 
sample was also counted from the 30 min time point without 
preparation on alumina, to determine the total plasma
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radioactivity.
Alumina eluates from the 30 and 90 min time points of 6 
subjects were separated by HPLC to allow simultaneous 
isolation of [^H] noradrenaline, [^H] DHPG and [^H] 
dihydroxymandelic acid ([^H] DOHA) another hydroxymetabolite 
of noradrenaline. The mobile phase was 70 mmol 1“  ^ KH2 POU 
(Fisons, HPLC grade) with 13.4 mmol 1“"* EDTA (Analar, BDH) 
and 1.85 mmol.l“  ^ octane sulphonic acid (Fisons, HPLC 
grade). The column was 25 cm x 4 mm internal diameter 
packed within the laboratory with spherisorb 5u ODS. The 
flow rate was 1 ml min“ .^ Under these conditions, the 
retention times of DHPG, noradrenaline and DOMA determined 
by electrochemical detection (ED) were 5.6, 10.5 and 24.0
min respectively. The sensitivity of this system for the 
assay of plasma noradrenaline and DHPG was 20 pg, and the 
between assay coefficients of variation were 4.6% and 8.9% 
respectively. DOMA was much less electrochemically active 
than noradrenaline and DHPG and therefore not normally 
detectable in plasma. For the separation of plasma 
radioactivity fractions, the outflow tube from the column 
was disconnected from the electrochemical detector and 
connected to a Gilson Fraction collector. Fractions were 
collected at 1 min intervals for 30 min (the usual run time 
of the system) to allow comparative plots of the 
radioactivity that eluted from the column at 30 and 90 min 
in the 6 selected subjects. At all other time points, only 
[^H] noradrenaline radioactivity was collected. This was
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performed on a slightly different system using a 10 cm x 4 
mm internal diameter column packed with 3u ODS spherisorb 
(Waters Movapak C-jg) allowing a shorter run time (15 min).
In this system, [^H] DHPG eluted in the solvent front, [^H] 
noradrenaline had a retention time of 6.4 min and [ ^  H ] DOMA 
a retention time of 11.0 min. The column eluate was 
collected for 2.5 min from the time corresponding with the 
start of a cold noradrenaline standard peak. Injections of 
standard solutions of [^H] noradrenaline followed by 1- 
minute fraction collections were performed on this system to 
ensure that the [^H] noradrenaline eluated over a similar 
time to cold noradrenaline. Standard injections of 15 pmol 
of cold noradrenaline were made each day to check its 
retention time. HPLC eluate fractions were collected into 
glass vials and 20 ml of scintillant (Optiphase, Fisons) 
added. The vials were counted on a liquid scintillation 
counter at an efficiency of 20-30$. HPLC eluate fractions 
taken prior to and after each run were counted to determine 
the level of background radiation, typically 30-35 c.p.m. 
[^H] noradrenaline radioactivity per ml of plasma was 
calculated after the subtraction of background radioactivity 
and correction for the recovery of the cold internal 
standard (DHBA) from alumina, which averaged 53.9 ± 5.5$ 
(n=85).
In two subjects, an additional 16 ml of plasma was 
collected at the 90 min time point and the plasma from the 
two subjects pooled and divided into six 5 ml aliquots.
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Each of these aliquots was then processed as described above 
to determine plasma [^H] noradrenaline levels. This 
allowed the calculation of the within-day coefficient of 
variation of the procedure.
Results
Injections of [^H] noradrenaline were eluted from the 
column over a similar time course to injections of cold 
noradrenaline standards, with the exception that the peak 
was followed by a small tail of radioactivity lasting 5 min.
The recovery of [^H] noradrenaline injected onto the 
column was 75.7 ± 3.1/5 (n=6) when using a 2.5 ml collection 
fraction. After 30 min of [^H] noradrenaline infusion the 
percentage of total plasma radioactivity recovered on 
alumina was 50.1 + 10.6% (n=7) and that eluted from the 
column was 80.3 ± 4.8% (n = 6). This value is slightly 
higher than the calculated recovery of [^H] noradrenaline 
from the column because the "tails" of the major peaks of 
radioactivity in the plasma samples were included.
Figure 2.2. shows a representative plot of the 1 
minute fraction that eluted from the column following the 
injection of a 30 minute sample, compared to a corresponding 
electrochemically detected chromatogram of plasma from the 
same subject. Three major peaks of radioactivity were 
found, having the same retention times as DHPG, 
noradrenaline and DOMA. At 30 min, the proportions due to 
these three peaks were 32.3 ± 11.5%, 57.2 + 13.2% and 4.9 ±
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Comparison of the radioactivity (collected in 1 min fractions) eluted 
after injection of plasma extracted in alumina (top) with an 
electrochemically detected chromatogram from the same patient using 
the same system (bottom).
6.0% respectively (n=6). After 90 mins of [3H] 
noradrenaline infusion the proportion due to DHPG rose to 
.4 5.9 ± 9.5% (p < 0.05, StudentTs paired t test) while the 
proportion due to [ ^ H] noradrenaline fell to 4*1.4 + 10.4% (p 
< 0.005). The proportion due to [^H] DOMA remained 
unchanged (5.1 ± 4.8%).
Figure 2.3. shows the mean accumulation of plasma [^H] 
noradrenaline radioactivity during the 110 min constant 
infusion. This reached a plateau after 20-30 min, although 
in some subjects it fluctuated substantially during the 
infusion. The within-day coefficient of variation for the 
determination of [^H] noradrenaline radioactivity 
concentration was 3.9% (n=6).
Discussion
These experiments suggested that a substantial 
proportion of the radioactivity recovered from alumina 
following [^H] noradrenaline infusion was not [^H] 
noradrenaline itself. The lack of any detectable 
impurities in the stock [^H] noradrenaline on thin layer 
chromatography and the fact that the principal second peak 
of the chromatogram had the same retention time as [^H]
DHPG, prompted speculation that [^H] DHPG was present in 
plasma during the [^H] noradrenaline infusion. The 
increase in the proportion of radioactivity from this second 
peak as the infusion progressed could reflect the slower 
elimination of DHPG compared with noradrenaline (192).
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However, other workers have been unable to confirm 
these findings (196,197). Eisenhofer (196) adopted a 
similar HPLC technique but could only detect small amounts 
of O ’H] DHPG (3.9^ of plasma radioactivity). McCance (197) 
also found that [ ^ H] DHPG could be detected in plasma and 
accumulated as the infusion progressed but with values much 
lower than those found by ourselves. Although Eisenhofer 
and McCance showed similar percentages of [ ]  metabolites 
in plasma McCance concluded that HPLC separation was 
unnecessary, while Eisenhofer recommended that it improved 
the accuracy of the technique. The principal difference in 
our study was the nature and source of the [^H] 
noradrenaline stock. Our group used 7,8 labelled 
noradrenaline from Amersham pic while other investigators 
have used ring labelled noradrenaline from New England 
Nuclear (MEN). My colleagues have since undertaken further 
studies to determine whether there was any impurity in the 
Amersham preparation (198). A sample of the infusion 
solution was extracted on alumina and injected into the HPLC 
system. A peak corresponding to the retention time of DHPG 
was found in the infusion solution and also in the stock 
[^H] noradrenaline (1M.57 and 157 of total radioactivity 
respectively). Thin layer chromatography was again 
performed on the stock [^H] noradrenaline (Amersham) and the 
radioactivity from the region of the plate subjected to HPLC 
separation, after the radioactivity had been eluted from the 
silica by washing with 1 mg ml sodium meta-bisulphide in
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100% ethanol and extracted on alumina. Again, two peaks of 
radioactivity with retention times the same as noradrenaline 
and DHPG were demonstrated.
Thus the stock from Amersham appears to contain an 
impurity which was not resolved from [^H] noradrenaline 
using the thin layer chromatography technique recommended by 
the manufacturers and which co-chromatogaraphed with DHPG in 
our HPLC system.
Nevertheless, Eisenhofer and our own group were in 
agreement that, due to their slower elimination, even small 
concentrations of [^H] dihydroxy metabolites could 
accumulate during a prolonged infusion. Therefore 
separation of [^H] noradrenaline from its [^H] 
metabolites by HPLC after alumina extraction offers a more 
accurate assessment of [^H] noradrenaline kinetics than 
previous methods which measured total tritium content of the 
alumina extract without further purification (196).
This problem of contamination did not come to light 
until after the experiments on [^H] noradrenaline kinetics 
in cirrhosis, described in Chapter 3, had been completed. 
These were carried out using the same batch of [^H] 
noradrenaline from Amersham as the experiments described 
above. Since the amount of contamination appears to be 
approximately 15% of the total radioactivity, the values of 
spillover and clearance obtained have been reduced by this 
figure (see equations below).
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2.5.3. C^H] Noradrenaline kinetics
Having developed the method outlined above, the 
values for noradrenaline spillover and clearance using this 
technique were determined.
Methods
Eight normal male subjects aged 25-41 years were 
studied at least 1 hour following a light breakfast.
Cannulae were inserted into antecubital veins of both arms 
and they then rested supine in a quiet room for at least 30 
mins. Two MBq of [^H] noradrenaline, diluted to 55 ml in 
sodium chloride solution with 500 mg ascorbic acid, were 
infused at a rate of 3.6 x 10^ Bq/min (0.916 ml min"^) using 
the same Braun pump. Blood for plasma [^H] noradrenaline 
assay was removed at 40, 47.5 and 55 minutes. Additional 
10 ml blood samples were taken at 40 and 55 mins for the 
assay of unlabelled plasma noradrenaline levels by HPLC with 
electrochemical detection (see Section 2.4.1.). Plasma 
[^H] noradrenaline radioactivity was determined as outlined 
in 2.5.2.1. using the second HPLC column.
[^H] noradrenaline plasma concentration was calculated 
from [^H] noradrenaline radioactivity as follows. The 
efficiency of the scintillation counter was checked for each 
sample (from the Quench factor supplied and a previously 
determined Quench curve), allowing determination of [^H] 
noradrenaline disintegrations per minute (dpm) from the 
counts per minute, from which the background count was
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subtracted. Corrections were then made for:
i) Recovery from alumina (ratio of peak height of internal 
standard to unextracted standard on HPLC chromatogram)
ii) Recovery from HPLC column (i.e. 75.7% - see 2.5.2.).
iii) Adjustment for volume of plasma removed for internal 
standard recovery experiment. Using the shorter column, the 
volume of perchlorate added to the alumina was 130 ul, 120 
ul of which were recovered and 20 ul were used for recovery 
experiment. Therefore this adjustment is 100/130 = 0.77
iv) Volume of plasma used (typically 4-5 ml).
This represents the plasma [^H] noradrenaline concentration 
in dpm.ml”**. Finally the [^H] noradrenaline infusion rate 
was calculated from an aliquot of the infusion solution 
adjusted to the pump rate.
Noradrenaline spillover and clearance can then be 
calculated from the following formulae (193)
3
/ j \ . plasma [ Hi NA concentration
(1; specific radioactivity;' ____ _________ __________________
of plasma endogenous plasma NA concentration
[%] NA infusion rate
(2) NA spillover rate = — ------------------------------
specific radioactivity of plasma NA
3
[ H] NA infusion rate
(3) NA plasma clearance =  ■*----------------------
plasma [ ii] NA concentration
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Traditionally, the results of spillover and clearance 
are expressed corrected for body surface area. This was 
calculated from an individual’s height and weight using a 
nomogram (Geigy scientific tables).
Results
In the eight normal subjects the resting endogenous 
plasma noradrenaline level was 0.70 ± 0.23 nmol.l”  ^ (mean + 
SD), noradrenaline spillover was 2.48 ± 1.40 nmol min”**m“2 
and noradrenaline plasma clearance was 3.69 ± 1.82 1 min“^m” .^
Discussion
The values obtained for noradrenaline spillover and 
plasma clearance by this method are higher than those 
reported by Esler (193) whose method did not include 
separation of plasma radioactivity. This suggests that 
some [^H] dihydroxy metabolites may be formed during the 
infusion, since an overestimate of plasma [^H] noradrenaline 
radioactivity will result in an underestimate of both 
clearance and spillover. However the impurities in the 
Amersham [^H] noradrenaline render valid comparisons between 
the methods difficult. Certainly the NEN product, whose 
purity is checked by HPLC at source is likely to contain 
less impurities than the Amersham product. In addition, 
there is reason to believe that in the rabbit model the 
amount of [^H] DHPG formed during [^H] noradrenaline
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infusion using ring-labelled product (as in the NEN product) 
is 40$ less than if using the chain-labelled variety (as in 
the Amersham product). (199).
In conclusion, although the ideal method for the 
determination of noradrenaline spillover into plasma remains 
a matter of debate, the method developed in our laboratory, 
namely the introduction of HPLC to separate [^H] 
noradrenaline in plasma from [^H] dihydroxy metabolites or 
contaminants appears to be both valid and worthwhile.
2.6. STATISTICAL ANALYSIS
The details of the statistical analyses are indicated 
in the individual chapters. In general, the normality or 
otherwise of the distribution of the data was determined by 
correlation with the normal scores calculated using MINITAB 
(200). If the distribution was not normal, a logarithmic 
transformation was undertaken. If this also failed to 
satisfy the criteria for normal distribution, a non- 
parametric test was employed. For comparison between 2 
groups, the Student's t-test was used for parametric and the 
Mann Whitney U test for non-parametric analysis (for 
unpaired data in all cases). Where more than 2 groups 
were being compared, a one-way analysis of variance was 
undertaken, or in the case of non-parametric data, a 
Kruskall-Wallis analysis of variance. Where appropriate, 
both the p values obtained and the 95$ confidence intervals 
are quoted (201).
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Correlations were determined by linear regression and, 
in the case of multiple comparisons, stepwise regression 
analysis or general linear modelling was employed, using 
MINITAB (200) or RUMMAGE (202).
2.7. ETHICAL CONSIDERATIONS
All the studies described in this thesis were approved 
by the Research and Ethical Committee of the Greater Glasgow 
Health Board, Units North 1, 2 and 3. All participants 
received written and oral explanations of the studies to be 
undertaken and gave written consent. The studies involving 
the administration of radioisotopes were approved by the 
appropriate committee of the Department of Health and Social 
Security.
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CHAPTER 1 
NORADRENALINE KINETICS IN CIRRHOSIS
84
3.1. INTRODUCTION
The reported increase in plasma noradrenaline 
concentration in cirrhosis (54,55,56) has been interpreted 
as evidence that sympathetic activity is increased in 
cirrhosis thus supporting the traditional "underfilling” 
theory of ascites formation (69,203). However, before such 
a conclusion can be drawn, the kinetics of noradrenaline in 
plasma deserve closer scrutiny.
V/hen a sympathetic nerve fires, some noradrenaline is 
released from storage granules in the nerve ending into the 
synaptic cleft. Most of this is taken back up into the 
nerve ending, but a small proportion escapes into the 
circulation. This constitutes the majority of 
noradrenaline found in plasma, with a small contribution 
from the adrenal medulla. Noradrenaline in plasma has 
three possible fates. It may be taken back into neuronal 
tissue (uptake 1) or other tissues (uptake 2) by specific 
transport mechanisms, or undergo metabolism. The 
principal method of metabolism is via the catechol-0- 
methyl transferase system of which the liver is a rich 
source. It is therefore possible that the increased 
noradrenaline in plasma in cirrhosis results not from 
increased release, or "spillover" into plasma, and by 
implication, increased sympathetic activity, but from 
reduced clearance from plasma due to impaired hepatic enzyme 
activity.
Plasma noradrenaline spillover and clearance can be
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estimated by the intravenous infusion to steady state of a 
sub-pressor dose of 1-noradrenaline labelled with the 
radioisotope tritium [^H] (193). A modification of this 
method which includes high performance liquid chromatography 
(HPLC) to separate plasma [^H] noradrenaline from other 
contaminants or metabolites is described in the previous 
chapter. The present study utilised this method to measure 
noradrenaline spillover into plasma and its clearance from 
plasma in cirrhosis with ascites.
3.2. METHODS
3.2.1. Sub iects
Fourteen patients with cirrhosis and clinically 
obvious ascites were studied. The diagnosis of cirrhosis 
was histological in nine cases and clinical in four (see 
Chapter 2 for clinical criteria for cirrhosis). The 
ascites was confirmed to be a transudate (protein content < 
30 gl“ )^ in all cases by diagnostic paracentesis. Hepatoma 
was excluded by serum alphafetoprotein < 4ul“ . The 
cirrhosis was alcohol-induced in all but two cases which 
resulted from chronic active hepatitis. There were 10 
males and 4 females with a mean age of 56 years (range 39 to 
77). None had bled from oesophageal varices or other 
source in the previous three months. Two patients had 
clinically evident hepatic encephalopathy. Thirteen 
control subjects were studied. They were otherwise healthy 
patients awaiting hospital admission to undergo minor
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elective surgery, principally hernia repairs or varicose 
vein surgery. None had any clinical or biochemical 
evidence of liver disease. There were 9 males and 4 
females with a mean age of 51 years (range 39 to 59). No 
subject (control or cirrhotic) had systemic hypertension (BP 
> 160/90), cardiac failure, obstructive airways disease or 
diabetes mellitus.
3.2.2. Study Outline
All subjects were studied as in-patients. Daily 
sodium intake was restricted to 50 mmol for three days in 
both groups. Those cirrhotics previously on diuretic 
therapy (usually spironolactone, amiloride and/or frusemide) 
had these drugs stopped at least 72 hours prior to study.
No alcohol was permitted for one week prior to study.
Urine was collected for 24 hours on two occasions for 
measurement of creatinine clearance and urinary sodium and 
potassium excretion. Serum was collected on the study day 
for serum sodium, potassium, chloride, bicarbonate, urea, 
creatinine, albumin, bilirubin and prothrombin time.
On the study day the subjects fasted and avoided 
caffeine-containing beverages from 2400 hours the previous 
evening. In-dwelling cannulae were inserted in an 
antecubital vein in both forearms and subjects then rested 
supine in a quiet room for the remainder of the study.
After a minimum of 30 minutes, blood pressure and heart rate 
were measured using a semiautomatic sphygmomanometer
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(Sentron, Bard). Recordings were taken at 1 min intervals 
until 5 consecutive readings varied by less than 5 mmHg.
The mean of these readings was then recorded.
2 MBq of l-C^H] noradrenaline (Amersham International) 
was added to 55 ml sodium chloride solution (0.9%) and 500 
mg ascorbic acid. This was then infused via one 
intravenous cannula over one hour using a Braun perfuser 
pump at a rate of 3.6 x 10^ Bq min”  ^ (0.916 ml.min” )^. At 
40, 47.5 and 55 min blood was drawn from the opposite arm 
for the determination of [^H] noradrenaline radioactivity in 
plasma. A further 10 ml blood was removed at 40 and 55 min 
for estimation of cold (endogenous) plasma noradrenaline and 
dihydroxyphenylglycol (DHPG) concentration. The laboratory 
methods employed in these analyses are described in detail 
in Chapter 2 (Sections 2.4.1. and 2.5.3.).
3.2.3. Statistical Analysis
The majority of the data, including liver function 
tests, plasma noradrenaline and the spillover and clearance 
values were not normally distributed, but became so 
following logarithmic transformation. All these results 
are therefore quoted as the medians (with ranges in 
parentheses) and comparisons between groups are carried out 
by an unpaired Student’s t test on a logarithmic 
transformation of the data. The haemodynamic data did 
satisfy a normal distribution and are therefore quoted as 
means and standard deviations, with comparison by unpaired t
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test on untransformed data. Correlations were calculated by 
linear regression and stepwise linear modelling using the 
MINITAB computer programme (200).
3.3. RESULTS
The biochemical and haemodynamic results are summarised 
in Tables 3.1. and 3.2. respectively. The noradrenaline 
kinetic results are detailed in Table 3.3. and summarised in 
Table 3.4. Figures 3.1. to 3.3. illustrate plasma 
noradrenaline, noradrenaline spillover and plasma 
noradrenaline clearance respectively.
The cirrhotic patients had biochemical evidence 
of severe liver disease with ten of the fourteen being 
Pugh's Grade C (184). They demonstrated reduced renal 
excretion of sodium, potassium and free water (the latter 
indicated by their significant hyponatraemia), impaired 
renal function with elevation of serum creatinine, reduced 
creatinine clearance and low urine volumes compared to 
controls. Although they had increased heart rates compared 
to controls, blood pressure was similar in both groups.
These cirrhotics demonstrated a highly significant 
increase in plasma noradrenaline spillover which closely 
followed the expected increase in endogenous plasma 
noradrenaline concentration. The clearance of 
noradrenaline in plasma was slightly but significantly 
increased in the cirrhotic group.
Both noradrenaline and DHPG are strongly correlated
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TABLE 3.1 BIOCHEMICAL MEASUREMENTS IN SERUM AND URINE
Values quoted are medians, with ranges in parenthesis. 
Comparisons are by unpaired Student’s t-test following a 
logarithmic transformation in all cases except serum sodium 
and prothrombin time, where log transformation was unhelpful 
and Mann Whitney U test employed, and serum albumin and 
urinary volume, where normal distribution of the data 
permitted a t-test on untransformed data.
Cirrhosis + Ascites Controls
(n=14) (n=13)
Serum
Sodium (mmol.l- )^ 134(11 <1-1 *10) 140(136-145)
Urea (mmol.l” )^ 6.2(1.7-19.6) 5.2(3.3-6.5)
Creatinine (umol.l"^) 101(60-429) 92(60-115)
Bilirubin (umol.l” )^ 71(8-505) 9(7-17)
Albumin (g.l~^) 27(21-40) 43(39-46)
Prothrombin time 
(seconds prolonged)
6(0-25) 0(0-1)
Urine
Volume (ml24hr“ )^ 552(400-1337) 1990(1288-3334)
Sodium ( m m o ^ h r - )^ 20(3-64) 45(23-105)
Potassium (mmol24hr“b 21(8-56) 47(19-73)
Creatinine clearance
( m l  ' 1
46(7-104) 93(73-233)
(ml.min-1)
P
< 0.001 
NS
< 0.05
< 0.001 
< 0.001 
< 0.001
< 0.001 
< 0.001 
< 0.01 
< 0.001
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TABLE 3.2. BLOOD PRESSURE AND HEART RATE
Values quoted are mean + SD and comparisons are by Student's t-test for 
unpaired data.
Cirrhosis+Ascites Controls P
(n=14) (n=13)
Heart rate (min"') 84 + 12 64 + 7 < 0.005
Systolic BP (mmHg) 115 ± 16 117 ± 11 NS (p=0.57)
Diastolic BP (mmHg)
CO+1
vO 71 ± 7 NS (p=0.l6)
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TABLE 3.4. NORADRENALINE KINETICS SUMMARY
Values are median (range) and comparison is by unpaired Student’s t-test 
on a logarithmic transformation.
Cirrhotics Controls
(n=14) (n=13)
Plasma noradrenaline 4.9 1.9 < 0.0005
(nmol.l"') (2.0-17.1) (1.0-3.7)
< 0.0001Noradrenaline spillover 14.5 3.9
(nmol.min“ 'm“2) (5.7-61.6) (1.6-8.5)
Plasma noradrenaline 3.5 2.1 <0.01
Clearance (l.min^m”2) (0.8-6.0) (1.1-3.8)
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2 0 i
Plasma 
noradrenaline 
(nmol. I'1)
10 -
□ □
-B-D-
□ □
p<0.0005
B
□
□ o n
■b 4 b-
B
cirrhosis + ascites 
n=14
controls
n=13
Figure U . .
Plasma noradrenaline concentrations in 14 cirrhotics with ascites and 
13 controls (horizontal bar represents the median value).
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Noradrenaline 
spillover 
(nmol, m in1. m'2)
40-
20-
p<0.0001
cirrhosis + ascites controls
n=14 n=13
Noradrenaline spillover in cirrhotics with ascites and 13 controls 
(horizontal bar represents the median value).
Noradrenaline 
clearance 
(I. min’1 .m'2) p<0.01
cirrhosis + ascites controls
n=14 n=13
Figure U .
Noradrenaline plasma clearance in 14 cirrhotics with ascites and 13 
controls (horizontal bar represents the median value).
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with spillover (r = 0.83 and 0.64 respectively, both p < 
0.01) but not at all with clearance (Figures 3.4. 
and 3.5.). Within the cirrhotic group, there was no 
correlation between noradrenaline spillover and the severity 
of liver disease as judged by serum bilirubin, albumin, 
prothrombin time or numerical Pughfs score nor was there any 
link with the degree of haemodynamic disturbance, indicated 
by heart rate and systemic blood pressure. There was, 
however, a weak negative correlation between noradrenaline 
spillover and glomerular filtration rate indicated by both 
serum creatinine (r = 0.42, p < 0.05) and creatinine 
clearance (r = -0.53, P < 0.05).
Plasma noradrenaline clearance in this study was 
negatively correlated with numerical Pugh’s score (r =
-0.72, p < 0.01) and also with serum bilirubin (r = -0.54, p 
< 0.05), although not with other markers of hepatic 
impairment. As with spillover, there was no relationship 
with the systemic haemodynamic state. Clearance was also 
higher in these cirrhotics with less marked reductions in 
serum sodium (r = 0.69, P < 0.01) and sodium and potassium 
excretion (r = 0.4, p < 0.05 and r = 0.66, p < 0.01 
respectively). There was no correlation, however, with the 
various indices of glomerular filtration.
3.4. DISCUSSION
This study demonstrates that the spillover of 
noradrenaline into plasma is increased in cirrhosis with
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ascites. This is in agreement with two other studies 
measuring plasma noradrenaline kinetics in cirrhosis, both 
of which were published after this work was undertaken 
(116,204). There is therefore compelling evidence that 
global sympathetic activity is increased in cirrhosis with 
ascites. This is likely to be a vascular baroreceptor- 
mediated response to a reduction in the effective 
extracellular fluid volume and therefore supports the 
traditional "underfilling” theory of ascites. However, 
sympathetic overactivity could also be an hepatic 
baroreceptor-mediated response to the increased 
intrasinusoidal pressure which occurs in cirrhosis (104). 
Also, these patients all had advanced disease with well- 
established fluid retention and do not necessarily reflect 
the situation earlier in the evolution of ascites.
The lack of any correlation between noradrenaline 
spillover and the indices of hepatic impairment is likely to 
reflect the latter's poor ability to discriminate between 
degrees of disease severity, particularly in a group of 
cirrhotics all as severely ill as in this study. The weak 
correlation between increased sympathetic activity, as 
indicated by noradrenaline spillover and impaired renal 
function is in keeping with the work of Arroyo (56) 
who found that the highest plasma noradrenaline 
concentrations were in those cirrhotics who had developed 
functional renal failure. Such increased sympathetic 
activity could contribute to the renal vasoconstriction
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which is thought to be important in the development of 
functional renal failure (63,111).
The increase in noradrenaline plasma clearance is a 
little surprising. Noradrenaline is largely metabolised 
but not released by the liver (205) which has a high content 
of the catecholamine degrading enzyme catechol-O-methyl- 
transferase (206). Also, the high splanchnic extraction of 
noradrenaline (68$) (207) mneans that splanchnic clearance - 
which accounts for 30$ of the total body turnover of 
noradrenaline (207) - is dependent on liver blood flow, 
which is usual]y reduced in cirrhosis (208). Therefore one 
might predict a reduction in plasma noradrenaline clearance 
in cirrhosis. However, an uncontrolled regional study 
which suggested no major reduction in hepatic noradrenaline 
clearance in cirrhosis (147) has since been confirmed in two 
controlled studies (115,207) both of which demonstrated only 
a slight reduction in hepatic noradrenaline clearance.
An increase in noradrenaline plasma clearance in 
cirrhosis was also reported by one (116) but not the other 
(204) of the two previous studies measuring [^H] 
noradrenaline kinetics. It is likely that any slight 
reduction in hepatic clearance is more than compensated by 
increased regional clearance elsewhere. Willett (116) 
proposed that the site might be the pulmonary circulation, 
since pulmonary blood flow is increased along with the 
increase in cardiac output in cirrhosis (23) and pulmonary 
clearance accounts for 41$ of the total clearance of
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noradrenaline (209). However, this assumes that the 
extraction of noradrenaline across the pulmonary bed remains 
constant, which seems unlikely in view of the extensive 
pulmonary arteriovenous shunting in advanced cirrhosis 
(210). The renal clearance of noradrenaline is not 
increased in cirrhosis (116,147). The site of increased 
noradrenaline clearance therefore remains a matter of 
speculation.
The negative correlation between noradrenaline plasma 
clearance and the indices of liver disease severity, 
principally Pugh's score, is in contrast to the work of 
Willett (116) who found that the increased clearance was 
only apparent in the most ill cirrhotics. The present 
study suggests that the increase in clearance is not simply 
a reflection of deteriorating hepatic function.
The increased plasma clearance of noradrenaline means 
that measurements of plasma noradrenaline alone will 
slightly underestimate the degree of sympathetic activity. 
Nevertheless, the increase in plasma noradrenaline 
concentration in cirrhosis (54,55,56) is seen to be due to 
an increase in spillover into plasma rather than any 
reduction in clearance. As such, plasma noradrenaline is 
still a useful guide to sympathetic activity in cirrhosis, 
as indicated by the close correlation between plasma 
noradrenaline and spillover in this study.
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CHAPTER 4
SYMPATHETIC ACTIVITY AND ATRIAL NATRIURETIC PEPTIDE
IN CIRRHOSIS
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4.1 . INTRODUCTION
In the previous chapter sympathetic activity was found 
to be increased in patients with cirrhosis and ascites. The 
increased concentration of noradrenaline in plasma in these 
patients was the result of increased spillover of 
noradrenaline into the circulation from sympathetic nerve 
endings. As noradrenaline plasma clearance was in fact 
increased in these cirrhotic patients, plasma noradrenaline 
is likely to underestimate the degree of sympathetic 
activation. Nevertheless it remains a valid approximation 
of sympathetic activity, and could be used as such in a 
large scale study, where detailed kinetic studies are 
impractical.
Another catecholamine detectable in plasma is 
dihydroxy-phenylethylene glycol (DHPG), the major dihydroxy- 
metabolite of noradrenaline in mammals (211) formed by 
oxidative deamination of noradrenaline within noradrenergic 
neurones. Plasma free DHPG is dependent upon noradrenergic 
impulse flow (212,213) and is thus a useful index of 
sympathetic activity. Indeed its prolonged half-life makes 
it less prone than noradrenaline to rapid fluctuation, and 
may make it a better index of sympathetic activity over a 
prolonged time, although it has no advantages over 
noradrenaline as an acute sympathetic index (214).
This study describes the measurement of these two 
catecholamines in a wide range of cirrhotic patients of 
varying aetiologies, duration and severity, with and without
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ascites, to further assess the contribution of the 
sympathetic nervous system in cirrhosis. In addition, 
plasma renin activity has been measured as an appropriate 
guide to the state of the renin-angiotensin-aldosterone 
system. Finally, most cases have also measured the 
plasma concentrations of immunoreactive atrial natriuretic 
peptide (AMP), which may be of relevance both to the sodium 
retention and vasodilatation of severe cirrhosis. Previous 
workers have found conflicting results with one report of a 
reduced level of plasma AMP in cirrhosis (178) three reports 
of no change (17^—177) and four reports of increased plasma 
levels (171-17*0. There is clearly scope for further 
study of plasma ANP levels in cirrhotic man.
*1.2. METHODS 
4.2.1 . Sub iects
Fortyone patients with cirrhosis were studied on 62 
occasions over a 20 month period from March 1985 until 
October 1986. Every patient with chronic liver disease 
attending the 2 gastroenterologists in the hospital was 
considered for study. To be included they had to have 
cirrhosis, either confirmed histologically (30 cases) or 
diagnosed on clinical grounds (11 cases) - see Chapter 2 for 
the criteria for a clinical diagnosis of cirrhosis.
Fifteen patients were studied on more than one occasion, 9 
twice and 6 three times. Patients were eligible to be re­
studied if either more than 6 months had elapsed since the
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previous study, or the severity of the patient's liver 
disease had changed significantly. This latter criteria 
was defined as a shift from one to another of the 3 grades 
of disease severity (A, B and C) as defined by Pugh (184). 
Eleven of the repeat studies were performed after a gap of 6 
months or more and 10 following a change in the patient's 
condition (2 deteriorations, 8 improvements).
There were 29 males and 12 females. Their ages ranged 
from 33-78 years (mean). The duration of the liver disease 
(from diagnosis) ranged from 1 month to 12 years (median 24 
months). The diagnosis was alcoholic cirrhosis in the
majority, with a handful of other aetiologies (Table 4.1.).
All but one of the 41 cirrhotic patients had established 
portal hypertension indicated either by the endoscopic 
demonstration of oesophageal varices, or clinically evident 
splenomegaly, confirmed by isotope scanning. Alcohol 
consumption was assessed in an approximate manner, on each 
visit. Thirtysix of the subjects were teetotal at the time 
of study. Twentyseven of these had formerly drunk alcohol 
to excess, but not within the preceding 3 months. Twentysix 
of the subjects were still drinking regularly, 23 of these 
consuming more than one drink per day. No subject was
suffering from acute alcohol withdrawal. Nineteen subjects
were smokers, 21 non-smokers and in one case the smoking 
habit was not recorded.
Twentyseven of the studies were performed when the 
subjects were in-patients, the remaining 35 on an outpatient
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TABLE 4.1. DIAGNOSES IN THE CIRRHOTIC PATIENTS
DIAGNOSIS NUMBER {%)
Male Female Total
Alcoholic Liver Disease 22 (76) 6 (50) 28 (68)
Chronic Active Hepatitis 4 (14) 2 (17) 6 (15)
Primary Biliary Cirrhosis 1 (3) 1 (8) 2 (5)
Haemochromatosis 1 (3) 0 1 (2)
Alpha-1-antitrypsin 0 1 (8) 1 (2)
Deficiency
Cryptogenic Cirrhosis 1 (3) 2 (17) 3 (7)
29 (100) 12 (100) 41 (100)
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basis. On 26 of the study days the patients had recently 
been receiving diuretic therapy, mainly spironolactone or 
amiloride, with a few subjects receiving frusemide. On the 
remaining 36 study days they were not on diuretics. In 
addition 26 of the 62 subjects studied were receiving other 
medication, either H2 receptor antagonists, corticosteroids, 
lactulose and/or neomycin.
None of the cirrhotic patients had any clinically 
evident cause for haemodynamic disturbance other than their 
liver disease. In particular none had bled from 
oesophageal varices (or other source) within the previous 10 
days and none was receiving intravenous fluid replacement.
Thirtyfour control subjects were studied. As outlined in 
Chapter 2, these consisted either of patients attending the 
gastroenterology clinic with non-hepatic disorders 
(principally peptic ulcer disease, gastro-oesophageal 
reflux, diverticular disease and the irritable bowel 
syndrome) or patients being admitted for minor surgical 
procedures, principally hernia repair and varicose vein 
ligation. There were 21 males and 13 females. Their ages 
ranged from 39 to 75 years (mean 55). Seventeen were 
teetotal, none of whom were reformed alcoholics. Of the 17 
who drank alcohol, 15 took less than one drink per day.
There were 9 smokers and 23 non-smokers, the smoking habit 
having not been recorded in 2 cases. Sixteen subjects were 
in-patients when studied and 18 outpatients. Ten subjects 
had received medication in the recent past, principally H2
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receptor antagonists. None of the control subjects had 
been receiving diuretic therapy.
Conditions known to alter sympathetic activity or 
plasma catecholamine levels, i.e. systemic hypertension, 
cardiac failure, thyroid disease and overt diabetes mellitus 
were excluded from both the cirrhotic and the control group. 
(Some of the cirrhotic patients had impaired glucose 
tolerance, but required no therapy).
4.2.2. Study Design
The cirrhotic subjects studied as in-patients received 
a strictly controlled salt intake of 50 mmol per day, and 
any diuretic therapy was discontinued 72 hours prior to the 
study day. Those studied as outpatients were either 
receiving an unrestricted salt intake, or a "no added salt" 
diet (approximately 80-100 mmol Na+ per day). If these 
patients required diuretic therapy, this was omitted on the 
study day only. The in-patients were studied fasted. The 
outpatients took a light breakfast least 1 hour prior to the 
study. All subjects abstained from tea, coffee, alcohol, 
tobacco and all medication on the study day. In the 
cirrhotic patients, the presence or absence of ascites and 
hepatic encephalopathy were noted. Ascites was graded as 
absent, mild or severe. Encephalopathy was graded from 0 
(absent) to 4 (unconscious) according to Trey (215). An 
intravenous cannula was inserted into an antecubital vein. 
After a minimum of 30 mins heart rate and blood pressure
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were recorded. When the systolic pressure varied by less 
than 5 mmMg on 5 consecutive readings, the subjects were 
judged to be at steady state and the mean of the 5 readings 
recorded. Blood was then drawn from the indwelling cannula 
for measurement of bilirubin, albumin, prothrombin time, 
sodium, potassium, urea, creatinine, noradrenaline, DHPG, 
plasma renin activity and atrial natriuretic peptide. The
precise method of collection and the laboratory assay 
methods are described in Chapter 2 (sections 2.3. and 2.4.). 
This study was of course often undertaken in conjunction 
with some of the experiments described in other chapters.
4.2.3. Statistical analysis
The statistical analysis was carried out using the 
MINITAB 85 computer programme (200). The distribution of 
each variable was assessed by correlation with a derived set 
of normal scores. Comparison between cirrhotic and control 
groups were made using Student's unpaired t test, with or 
without a logarithmic transformation, depending on the 
distribution of the variable being assessed. Where a 
logarithmic transformation failed to render the data 
suitable for parametric analysis, the Mann Whitney U test 
was employed. Where the cirrhotic group were subdivided 
one way analysis of variance was used. Correlations were 
calculated by simple linear regression and by stepwise 
regression analysis.
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4.3. RESULTS
The liver function tests, heart rate and blood 
pressure, plasma noradrenaline and DHPG, plasma renin 
activity and ANP in the cirrhotic and control groups are 
summarised in Table 4.2, Noradrenaline, DHPG and renin were 
all significantly raised in the cirrhotic patients who also 
demonstrate impaired hepatic function by their raised 
bilirubin, decreased albumin and prolonged prothrombin time, 
slightly impaired glomerular filtration by their raised 
serum creatinine and impaired free water clearance by their 
reduced serum sodium concentration. The group as a whole 
showed little haemodynamic disturbance, with increased heart 
rate and lowered diastolic BP but no alteration in systolic 
pressure.
The increase in plasma noradrenaline concentration was 
unrelated to the duration of liver disease (r = -0.17) or to 
its aetiology (analysis of variance (AOV) on the diagnostic 
categories F = 1.42). Plasma noradrenaline concentrations 
were similar whether or not the cirrhotic patients had 
recently been taking diuretics or other medication 
(diuretics 4.7 + 2.5 v no diuretics 4.5 ± 2.8 nmol.l""' , NS) 
or alcohol (AOV on 4 grades of consumption, F = 1.45). 
Noradrenaline tended to be higher in those cirrhotics on 
sodium restriction (5.9 ± 3.2 nmol.l"^) than those with 
unrestricted sodium intake (4.3 ± 2.3 nmol.l"^) although 
this was not significant (p = 0.15). Consideration of 
these potential confounding variables with respect to the
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TABLE UtZj, LIVER AND RENAL FUNCTIONf HEART RATE AND BLOOD PRESSURE.
PLASMA CATECHOLAMINES. RENIN AND ANP IN CIRRHOTIC AND 
CONTROL PATIENTS
DHPG = dihydroxyphenylglycol, PRA = plasma renin activity and 
ANP = atrial natriuretic peptide. Values quoted are median (range) 
or mean ± SD with comparison by unpaired t-test with (t-log) or 
without (t) logarithmic transformation, or by Mann Whitney U test 
(MWU), according to distribution.
CIRRHOSIS
n=62
CONTROLS
n=34
Bilirubin (umol.l”b 36.5 (4-600) 8.0 (5-17) p < 0.001
(t-log)
Albumin (g.l” >^ 32.1 ± 6.2 40.8 + 2.9 p < 0.001 
(t)
Prothrombin time 
(secs prolonged)
4 (0-30) 0 (0-3) p < 0.001 
(MWU)
Serum sodium 
(mmol.1”')
139 (114-144) 141 (136-145) p < 0.001
(MWU)
Serum creatinine 
(umol.l"')
91 (46-429) 85 (53-120) p < 0.05 
(t-log)
Heart rate (min“ )^ 78 + 13 67 + 11 p < 0.001
(t)
Systolic BP (mmHg) 120 ± 16 127 ± 16 NS p = 0.07 
(t)
Diastolic BP (mmHg) 67 ± 11 73 ± 9 p < 0.01
(t)
Plasma noradrenaline 
(nmol.I”')
4.3 (0.9-17.4) 1.9 (0.7-5.3) p < 0.001
(t-log)
Plasma DHPG (nmol.l-^ 14.6 + 5.8 
n=50
9.0 ± 3.3 
n=30
p < 0.001 
(t)
PRA (ngAIml”^hr"^) 11.5 (0.9-419) 
n=50
3.0(0.7-17.1)
n-22
p < 0.001 
(t-log)
ANP (pg.ml"1) 37.7(8.1-238)
n=13
33.3(5.6-81.2)
n=25
ns p=0.12 
(t-log)
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raised DHPG concentrations yielded similar results with the 
exception that the increase in the sodium-restricted group 
(16.2 + 6.5 v 12.5 ± 4.0 nmol.l*^) was significant, p <
0 .02.
Subdivision of the cirrhotic group according to the 
presence or absence of ascites reveals that although the 
increase in noradrenaline and DHPH levels is greatest in 
those patients with ascites, they are also significantly 
increased in cirrhotic patients who have never had ascites 
(Table 4.3., Figure 4.1.). In contrast plasma renin 
activity is only significantly increased in those patients 
with ascites (currently or formerly), values in the non- 
ascitic patients being similar to control subjects (Table 
4,4., Figure 4.2.).
Plasma noradrenaline and DHPG are both positively 
correlated to liver disease severity as indicated by Pugh's 
score and in the case of DHPG also to serum albumin and 
prothrombin time (Table 4.5.). The progressive increase in 
noradrenaline in relation to Pugh's grades is illustrated in 
Figure 4.3. This trend is supported by the limited 
information available on plasma catecholamine concentrations 
as disease severity alters in a few patients studied on 
several occasions. In the one patient who deteriorated, 
both noradrenaline and DHPG rose. In ten patients who 
improved, plasma noradrenaline fell in five cases, remained 
the same in one and rose (minimally) in four, while DHPG 
results in seven of these patients showed a fall on five
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TABLE. H.11* PLASMA CATECHOLAMINESf RENIN AND ANP IN RELATION TO ASCITES
Subdivided into those who have never had ascites (Group I), those now 
free of ascites on diuretics (Group II) and those currently with 
ascites (Group III).'
Values are median (range) and comparison between groups is by one way 
analysis of variance.
CONTROLS CIRRHOSIS
I II III
Plasma 1.9 3.8 4.2 4.7
noradrenaline
(nmol.l
(0.7 - 5.3) (0.9 - 10.4) (1.8 - 9.5) (1.4 - 17.4)
n=34 n=17 n=22 n=23
Plasma DHPG 
(nmol.l*"1)
8.8 12.0 13.7 14.7
(3.2 -17.1) (4.4 - 20.2) (8.3 -31.5) (7.2 - 28.6)
n=30 n=14 n=19 n=17
PRA
(ngAImVhr”1)
3.0 4.5 20.1 32.0
(0.7 -17.1) (0.9 - 52.0) (1.2 - 118.0) (3.2 - 419.0)
n=32 n=14 n=19 n=17
ANP (pg.ml-^ 33 3 
(5.6 -81.2) 
n=25
29.2 
(8.1 -67.2) 
n=10
37.6 
(16.1 - 163.0) 
n=12
50.0 
(20.0 - 238.0) 
n=11
In the case of plasma noradrenaline and DHPG all three groups of 
cirrhotic patients including those who have never had ascites, have 
significantly higher values than controls. In contrast PRA is only 
significantly raised in those cirrhotics with ascites (currently or 
formerly) whereas cirrhotics who have never had ascites have values 
similar to control subjects. The differences in ANP concentrations 
among the groups just fails to achieve significance (F=2.5, p = 
0.064).
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Plasma noradrenaline 
( n m o l f 1)
10 -
CONTROLS II
CIRRHOSIS
Eigurg iL l.
Plasma noradrenaline concentrations in control subjects and 
cirrhotic patients who have never had ascites (Group I), 
those now free of ascites on diuretics (Group II) and those 
currently with ascites (Group III). Horizontal lines 
represent median values.
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TABLE M,. CORRELATION COEFFICIENTS FOR PLASMA CATECHOLAMINES
Related to liver function tests, heart rate and blood pressure, 
plasma renin activity (PRA) and atrial natriuretic peptide (ANP).
r
Noradrenaline DHPG
Bilirubin 0.25 0.29
Albumin -0.34 P < 0.01 -0.56* P < 0.001
Prothrombin time 0.26 0.42* P < 0.001
Pugh’s score 0.52* P < 0.001 0.43* P < 0.001
Heart rate 0.34 P < 0.01 0.20
Systolic BP -0.15 -0.07
Diastolic BP -0.16 -0.22
Serum sodium -0.23 -0.21
Creatinine 0.38* P < 0.005 0.16
PRA 0.34 P < 0.01 0.27
ANP 0.60* P < 0.001 0.23
11 variables, therefore significance level is 0.05 -f- 11 = 0.005 
approximately; corresponding r value for 62 subjects is 0.35.
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PRA(ngAIml hr
200-
100-
— — x „
CONTROLS II III
CIRRHOSIS
Ei£U££. iL£.
Plasma renin activity in control subjects and cirrhotic patients 
who have never had ascites (Group I), those now free of ascites 
on diuretics (Group II) and those currently with ascites (Group 
III). Horizontal lines represent median values.
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occasions. One patient with cirrhosis and ascites studied 
on three occasions persistently had noradrenaline values in 
excess of DHPG values, a pattern usually only seen in 
phaeochromocytoma.
Other correlations are indicated in Table 4.5. Plasma 
noradrenaline (but not DHPG) was related to impaired renal 
function, although this result is artifically weighted by 
two patients with functional renal failure who had very high 
noradrenaline concentrations. Interestingly, the third 
patient studied with functional renal failure had low values 
of both noradrenaline and DHPG. There was no correlation 
whatsoever between plasma noradrenaline or DHPG and serum 
sodium, heart rate or blood pressure. Multiple regression 
analysis failed to identify any independent factors among 
these correlations.
The significance of plasma noradrenaline as a 
prognostic indicator is illustrated in Figure 4.4. The 41 
patients studied have been followed up for 12 to 27 months. 
The noradrenaline concentration in the 26 survivors (median
3.5, range 0.9-9.5) is significantly lower than in the 15 
patients who have died (median 6.4, range 2.8 - 17.4).
None of the four patients with noradrenaline concentrations 
greater than 10 mmol.I"1 on first measurement survived six 
months. Of the ten patients with noradrenaline between 5 
and 10 mmol.I'1, 50$ were still alive at one year, while 
the corresponding figure for the 26 patients with
4
noradrenaline below 5 mmol.l- is 88$.
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Plasma ANP concentrations were not significantly 
different in the cirrhotic group as a whole compared to 
controls (Table 4.1.). There is a tendency towards higher 
concentrations in the patients with ascites than in those 
who have never had ascites, although the majority of both 
groups still fall within the range of the normal controls, 
and analysis of variance just fails to detect a significant 
difference between the groups (Table 4.3., Figure 4.5.). 
Similarly there is a non-significant trend towards 
progressively increasing concentrations of ANP with 
increasing disease severity as indicated by Pughfs grade 
(Figure 4.6.) .
DISCUSSION
Before discussing the significance of the results of 
this study, three technical matters require consideration. 
Firstly, what is the optimum sampling site for noradrenaline, 
arterial or venous, central or peripheral? In theory, 
arterial or central venous levels should give a better 
indication of total sympathetic activity. Sympathetic 
activity is organ specific and varies widely from one site to 
another. Antecubital venous noradrenaline is largely 
derived from skeletal muscle (216). However, noradrenaline 
levels in antecubital veins are similar to those in the right 
atrium in normal subjects (195) and to the femoral vein in 
both normal and cirrhotic subjects (217). In the latter 
paper, both antecubital and femoral venous noradrenaline
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concentrations correlated closely with arterial values. It 
therefore appears that antecubital venous noradrenaline 
levels may be suitable for comparison between cirrhotic and 
control groups, obviating the need to expose those patients 
with coagulation defects to arterial or central venous 
sampling.
Secondly, should adrenaline as well as noradrenaline 
concentrations be measured? Plasma adrenaline, derived 
from the adrenal medulla which responds to similar stimuli 
which activate sympathetic nerves, might be expected to give 
useful additional information. However, two studies which 
demonstrated increased plasma noradrnaline in cirrhosis 
found no such increase in venous adrenaline unless 
functional renal failure had supervened (55,56). Increased 
levels of adrenaline in venous blood (54) could not 
subsequently be confirmed on arterial samples (217), the 
optimum site for adrenaline measurement (218). More 
recently two groups have found elevated adrenaline levels in 
cirrhosis in venous (146) and arterial (207) blood. In all 
these studies the differences in plasma noradrenaline were 
more striking and there seems little to be gained from the 
addition of adrenaline measurements.
Thirdly, should urinary as well as plasma 
catecholamines be measured? Mo, since the complexity of 
renal handling of catecholamines renders the interpretation 
of urinary catecholamines difficult (219) and the 
concentrations of catecholamines in plasma are more
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reproducible than those in urine providing the many 
variables which influence plasma levels are taken into 
consideration (220).
This study confirms the increase in plasma 
noradrenaline concentration in cirrhosis noted in the 
previous chapter and by numerous others 
(54,55,56,116,203,207). Since the clearance of 
noradrenaline from plasma is not reduced in cirrhosis, as 
indicated in the previous chapter and supported by others 
(116,203), there must be an increase in overall sympathetic 
activity in cirrhosis. The parallel increase in plasma 
DHPG is further evidence of this increased sympathetic 
activity, which does not appear to be due to such 
confounding variables as alcohol and diuretic intake. The 
degree of sympathetic activation seems to depend on the 
severity of the disease process rather than its duration or 
a particular aetiology. The progressive rise in 
noradrenaline as the severity of the hepatic impairment 
increases is a feature common to all studies in this field 
(54,55,56) .
However, the situation in the "compensated" patient who 
has not developed ascites is more controversial. Henriksen 
found normal plasma noradrenaline concentrations in this 
group (115) but Arroyo showed plasma noradrenaline in 
cirrhotic patients without ascites to be increased by fifty 
per cent over control values (56). The Denver group did 
not address this question specifically, but did note that
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their cirrhotic subject? with unimpaired free water 
clearance (probably equivalent to a "compensated” state) had 
noradrenaline values no greater than control subjects (55). 
The current study is in agreement with that of Arroyo with 
increased sympathetic activity in cirrhotic patients who 
have never had ascites. This is despite the fact that 
plasma renin activity in this group was not increased, again 
in keeping with Arroyo's work (56) and several others 
(17,18,19) often cited in support of the overflow theory.
If the increased sympathetic activity in the pre-ascitic 
cirrhotic group is in response to baroreceptor stimulation, 
this represents strong evidence in favour of a reduced 
effective circulating volume in these patients.
This study was unable to confirm any relationship 
between the haemodynamic status - as indicated by heart rate 
and blood pressure - and the degree of sympathetic activity. 
Although this could be argued as evidence against the 
sympathetic activation being in response to systemic 
haemodynamic disturbance, heart rate and blood pressure are 
relatively crude measures. In fact, Henriksen was able to 
demonstrate significant correlations between noradrenaline 
and more direct indices of central haemodynanics such as 
stroke volume and cardiac output, when no such correlations 
were evident with either heart rate or blood pressure (221). 
However, one potential mechanism of sympathetic activation 
independent of the state of systemic vascular filling would 
be direct stimulation of the sympathetic nervous system in
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response to increased hepatic sinusoidal pressure. Such 
hepatic baroreceptors have been demonstrated in non­
cirrhotic dogs (104) but not in man, either healthy or 
cirrhotic.
Further evaluation of the stimulus to sympathetic 
activity depends on invasive studies, which will yield 
information on regional sympathetic activity. Such 
invasive procedures were outwith the scope of the current 
study, and indeed published data on this subject are sparse. 
Plasma noradrenaline correlated closely to wedged hepatic 
venous pressure (r = 0.86) in one study (54), supported by a 
similar correlation with wedged minus free hepatic venous 
pressure (r = 0.75), a better index of portal pressure, in a 
subsequent study from the same investigators (115).
However, such correlations between either systemic or 
portosplanchnic haemodynamics do not prove a causal link, 
since both might be indicators of some other factor in 
deteriorating liver function, e.g. accumulation of 
vasodilator substances.
Regional sympathetic studies have been undertaken by 
two centres, with conflicting results. The Danish group, 
measuring renal arterial-venous differences in catecholamine 
concentrations, found a net renal release and suggested that 
renal sympathetic drive was a major contribution to total 
sympathetic activity (115). In contrast Willett and co­
workers studying net renal release by [^H] noradrenaline 
kinetics concluded that renal sympathetic activity merely
126
reflected overall sympathetic activation (116). The 
agreement that renal sympathetic activity is increased has 
important implications for the clinical effects of 
sympathetic stimulation, irrespective of its cause. Renal 
sympathetic activation will result in sodium retention from 
the proximal tubule, probably by a direct effect (60,61), 
which might explain the failure of cirrhotic patients to 
"escape" from the sodium-retaining effects of 
mineralocorticoid administration (41). Renal sympathetic 
activation will also cause sodium retention from the distal 
tubule, indirectly, by stimulation of the renin-angiotensin- 
aldosterone system. Thirdly, renal sympathetic stimulation 
will cause renal vascular constriction, particularly to the 
renal cortex, which might contribute to the functional renal 
failure which can complicate cirrhosis with ascites 
(56,111,222).
The theoretical link between sympathetic overactivity 
and development of ascites and renal failure in cirrhosis 
may be relevant to the apparent value of plasma 
noradrenaline as a prognostic indicator which this study has 
demonstrated. A significantly increased plasma 
noradrenaline concentration indicates a very poor prognosis 
in these patients. Other studies have demonstrated an 
equally poor survival with increased plasma renin (47) and 
decreased serum sodium (64). Interestingly, a recent study 
of 141 cirrhotic patients over a six year period found that 
plasma noradrenaline was one of only six variables out of a
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possible M2 measured which were independent predictors of 
survival. The other were mean arterial pressure, urinary 
sodium excretion, ascitic protein concentration, serum urea 
and serum albumin (223). The advent of hepatic 
transplantation means that such prognostic indicators are of 
vital importance in assessing the correct timing of 
transplantation, which is perhaps the most taxing problem 
facing hepatologists today.
This study also considers the significance of ANP in 
cirrhosis. ANP is a natriuretic peptide (or group of 
peptides) derived from the right atrium (22M). This 
discovery rejuvenated an older theory that the sodium 
retention of ascites might result from the lack of some 
undefined natriuretic factor (225). However, the current 
study demonstrated no reduction in plasma ANP levels, even 
when ascites was present. Indeed, although the differences 
are just outwith statistical significance, there is a clear 
trend towards higher levels of ANP in the cirrhotics with 
ascites and more severe hepatic dysfunction. These 
findings are in keeping with reports in the literature that 
ANP levels are either normal (176,177) or high (171-17^,226) 
in patients with cirrhosis. Only one group have found 
reduced plasma levels of ANP in cirrhosis (178), although 
this has been reported in dogs with experimental cirrhosis 
(227). The cardiac content of ANP is reduced in cirrhotic 
rats (228), but this could represent either decreased 
synthesis of ANP, or depletion of ANP stores as a result of
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increased release! It is possible that methodological 
problems with sample collection and assay have contributed 
to these variable results, since reliable radioimmunoassays 
have only become available in the past three years 
(229*230). The consensus view would appear to be.that a 
deficiency of ANP is not responsible for the sodium 
retention of cirrhosis, and the current study supports this 
conclusion. Further evidence against lack of ANP being 
significant in ascites is the response to infusion of 
exogenous ANP in these patients. Numbers studied so far 
have been small, but the natriuretic response seems to be 
modest and incomplete (231,232). It remains possible that 
in cirrhosis the kidney has in some way developed resistance 
to the natriuretic action of ANP.
ANP in supraphysiological concentrations is also a 
vasodilator (233). Although the majority of cirrhotic 
patients have ANP- levels in plasma which are only slightly 
elevated, there were a few patients in this study with high 
enough concentrations for AMP to be a contributory factor to 
the systemic vasodilatation which occurs and whose 
significance is considered in more detail in subsequent 
chapters.
What are the implications of normal or raised plasma 
ANP levels for the theories of ascites formation? A 
regional study has suggested that any increase in plasma ANP 
in cirrhosis is due to increased cardiac release rather than 
impaired hepatic clearance (173). The only proven stimulus
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to AMP release is atrial stretch, and therefore normal or 
raised plasma levels would seem to favour an increase 
rather than a reduction in the effective circulating volume. 
Attempts to expand the effective circulating volume in 
cirrhosis, e.g. by head-out water immersion, or by insertion 
of peritoneovenous shunts, result in marked rises in plasma 
AMP, both in dogs (227) and in man (176,234), which does 
suggest initial volume depletion. However, this effect is 
also seen in normal subjects, albeit to a lesser degree 
(235,236). It has also been suggested that factors other 
than atrial stretch might stimulate AMP release, for example 
the sympathetic nervous system (237), which could explain the 
increased ANP in cirrhosis with ascites even with central 
volume depletion (171). However, recent work in normal 
subjects does not support a direct sympathetic role in ANP 
release (23?) and Wernze has argued that his failure to show 
any correlation between plasma noradrenaline and plasma ANP 
is evidence against a direct relationship in cirrhosis (176). 
The present study, examining many more subjects, did 
demonstrate a correlation between plasma noradrenaline and 
ANP in cirrhosis (r = 0.60, p < 0.001). Dietary sodium 
intake also influences ANP levels, and this study could be 
criticised as the dietary sodium varied amongst the cirrhotic 
patients. In fact, although in normal subjects increased 
sodium intake promotes ANP release, the cirrhotics on sodium 
restriction exhibited higher levels (median 40.0 v 
33.2 pgml"1, p = 0.08), presumably since these were the
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patients with ascites. Plasma ANP concentration cannot be 
used as a categorical indication of the state of vascular 
filling in cirrhosis until more is known about the 
interaction with the other neurohumoral disturbances.
In summary, this chapter shows increased sympathetic 
activity in cirrhosis both when ascites is present and in 
the pre-ascitic stage, which tends to support the 
underfilling theory of ascites formation. The degree of 
sympathetic activity is related to the extent of liver 
damage and significantly raised plasma noradrenaline is a 
useful indication of poor prognosis. Plasma levels of ANP 
are not reduced in cirrhosis, with or without ascites, 
therefore deficiency of ANP is not a factor in the sodium 
retention in these patients.
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CHAPTER £
AUTONOMIC FUNCTION IN CIRRHOSIS
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5.1. INTRODUCTION
There is a well documented haemodynamic disturbance in 
cirrhosis characterised by a reduced blood pressure despite 
increased heart rate and increased cardiac output, 
indicating a fall in peripheral systemic vascular resistance 
(23»24). The question has been raised as to whether 
autonomic dysfunction may contribute to this (239).
Autonomic damage might be expected in some cirrhotics, as 
the majority in the UK are alcohol-induced, and autonomic 
neuropathy, especially of vagal origin, is seen in chronic 
alcoholics (152). At the time this study was undertaken, 
there was no published work examining the effect of 
cirrhosis on autonomic function. It has been suggested 
that the best way of assessing autonomic function clinically 
is by performing a battery of both sympathetic and 
parasympathetic tests in each individual (240). We 
therefore examined autonomic function in this way in a 
heterogeneous group of 20 cirrhotics, subdivided into those 
with mild and those with moderate to severe liver damage, 
and 20 patient controls.
5.2. METHODS
5.2.1 . Sub iects
Twenty patients with hepatic cirrhosis were studied.
The cirrhosis was confirmed histologically in 15 cases and 
in the remainder a clinical diagnosis of cirrhosis was made 
(see Chapter 2, Section 2.1.1. for the criteria for
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clinically-defined cirrhosis). These patients were divided 
into two groups according to their degree of liver 
impairment. Group 1 consisted of 10 patients with Pugh’s 
Grade A disease and group 2 consisted of 10 patients with 
Pugh’s Grade B or C. The cirrhosis was due to alcohol in 
12 cases (5 group 1, 7 group 2), primary biliary cirrhosis 
in 2 (1 in each group) and one each of haemochromatosis 
(Group 1) alpha-1-antitrypsin (Group 1) and cryptogenic 
(Group 2). The duration of liver disease ranged from 2 to 
98 months in Group 1 (median 34 months) and from 1 to 133 
months in Group 2 (median 20.5 months).
These were compared to tv/enty control patients (Group 3) 
with non hepatic disorders who had no clinical or 
biochemical evidence of liver disease. No subject in 
either group had hypertension, cardiac failure, diabetes 
mellitus, thyroid disease or malignancy.
The mean age in Group 1 was 55.6 years (range 33-65), in 
Group 2, 56.4 years (41-73) and in controls 55.3 years (39- 
75). The sex ratio (male: female) was 8:2 in Group 1, 5:5 
in Group 2 and 13:7 in controls.
Although medication was kept to a minimum, several 
patients had received diuretic therapy within 3 months of 
the study. One cirrhotic patient in Group 1 had taken 
frusemide and spironolactone. In Group 2, 7 patients in 
total had taken diuretics (1 frusemide alone, 4 
spironolactone or amiloride, and 2 both classes of 
diuretics). Two cirrhotics (both Group 1) were taking
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azathioprine with or without prednisolonej 1 cirrhotic 
(Group 1) and 5 control patients were taking a variety of 
ulcer healing agents and 4 cirrhotics (1 in Group 1 and 3 in 
Group 2) were taking lactulose and/or neomycin.
Despite the prevalence of alcoholic liver disease, only 
7 cirrhotic patients (3 in Group 1, 4 in Group 2) had been 
drinking alcohol in excess of 10 g per day during the 3 
months prior to study, with 5 of the 20 control patients 
consuming this quantity also. Three cirrhotics in Group 1, 
4 in Group 2 and 8 control patients smoked.
5.2.2. Study Design
Mo alcohol was taken during the 7 days preceding the 
study, and all diuretic therapy was stopped for at least 3 
days. On the study day the patients fasted and abstained 
from caffeine-containing beverages and tobacco. An 
indwelling cannula was inserted into an antecubital vein, 
and the subject rested supine for a minimum of 30 minutes. 
Heart rate and blood pressure (BP) were recorded using a 
semi-automatic sphygmomanometer (Sentron, Bard Biomedical) 
and blood drawn from the cannula for measurement of urea and 
electrolytes, albumin, bilirubin, prothrombin time, 
noradrenaline and plasma renin activity. After a light 
breakfast they rested for a further hour then the following 
tests of autonomic function were performed. BP was again 
recorded by semi-automatic sphygmomanometer. Heart rate 
and/or RR intervals were recorded using 3 praecordial
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electrocardiograph electrodes linked to a multichannel 
recorder (Grass Polygraph model 7B1B; Quiney, Mass. USA).
This in turn was connected to a Nodecrest computer terminal 
programmed to directly analyse the RR interval data.
5.2.3. Parasympathetic tests 
Standing to lying test (241)
The patient stood erect for 5 minutes, then lay supine 
while the heart rate was recorded continuously. The 
standing to lying ratio (SLR) which was calculated as the 
mean of the 10 RR intervals immediately preceding lying down 
divided by the shortest RR interval during the 30 seconds 
after lying down was performed in duplicate. The transient 
increase in heart rate on lying down is a measure of vagal 
withdrawal, and the normal SLR is > 1,07 (241).
Valsalva manoeuvre (242)
The patient, after becoming familiar with the 
instrument, maintained forced expiration to hold a column of 
mercury in a modified sphygmomanometer at 50 mmHg for 15 
seconds. The heart rate was recorded during and for 1 minute 
after the manoeuvre. The test was performed in duplicate.
The longest RR interval following the manoeuvre divided by 
the shortest RR interval during the manoeuvre is known as 
the Valsalva Ratio (VR) which reflects parasympathetic 
function (243). The normal VR is > 1 .20 (244).
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"Diving" test (245)
The heart rate was recoroed for 30 seconds with the 
patient seated with face held 4 cm above a basin of cold 
water (temperature 18-20°C). On instruction he lowered his 
face into the water, taking care to avoid a large 
inspiration or Valsalva manoeuvre. The patient then held 
this position for 30 seconds, or as long as he/she was able, 
while the heart rate was recorded continuously. The test 
was performed in duplicate. The profound bradycardia which 
ensues is parasympathetically mediated (246). The maximum 
reduction in heart rate is calculated from the longest RR 
interval during immersion compared to the mean of the 5 RR 
intervals preceding immersion.
Heart rate variation with deep breathing (247)
After 10 minutes supine rest the patient took maximum 
inspiration and expiration at a rate of 6 respiratory cycles 
per minute. The heart rate was recorded continuously for 1 
minute and the maximum variation in heart rate during the 
last respiratory cycle was noted, calculated from the 
longest and shortest RR intervals during that cycle. The 
normal response, indicating parasympathetic tone, is a 
variation of 15 or more beats per minute (240).
5.2.4. Sympathetic tests 
Forearm isometric exercise (2481
After 10 minutes rest in a sitting position, the heart
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rate and BP were recorded and blood drawn for plasma 
noradrenaline assay. The patient then squeezed a modified 
sphygmomanometer inflated at 60 mmHg to record his maximum 
handgrip. He then maintained the column of mercury at 30$ 
of his maximum for 2 minutes. Heart rate and BP were 
recorded from the opposite arm at 1 and 2 minutes, and blood 
for noradrenaline assay drawn immediately after the 
procedure. The sympathetically mediated rise in diastolic 
blood pressure normally exceeds 15 mmHg (240).
Cold pressor test (240)
After 10 minutes seated rest, heart rate and BP were 
recorded and blood drawn for plasma noradrenaline assay.
The patient then inserted his right hand in a bucket of iced 
water (0°C) and maintained this position for 2 minutes. HR 
and BP were recorded from the opposite arm at 1 and 2 
minutes, and blood for noradrenaline assay drawn immediately 
after the procedure.
Dynamic exercise tests
A modification of the Balke-Ware exercise test was 
employed (250). The patient was familiarised with a 
bicycle ergometer (Tuntura, Pugh). Commencing with a 
workload of 25 watts, the patient cycled upright 
continuously against a progressively increasing workload, at 
increments of 25 watts every minute. The test was stopped 
when the patient achieved a heart rate of 210 minus age in
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years, or when symptoms required the patient to stop. Both 
of these end points were regarded as representing maximal 
exercise capacity. BP and plasma noradrenaline were 
measured before and immediately after the exercise and heart 
rate recorded by ECO at the end of each minute. After a 15 
minute rest, the test was repeated, on this occasion the 
patient cycling for 5 minutes at a workload equal to 507, of 
the maximum workload achieved (referred to as "timed 
exercise") .
The order of the tests was standing to lying, forearm 
isometric exercise, Valsalva manoeuvre, diving test, cold 
pressor test, heart rate variation with deep breathing and 
finally the 2 dynamic exercise tests. All the tests with 
the exception of those of dynamic exercise had been 
previously validated within the Department of Materia Medica 
(251), and shown capable of detecting subtle differences 
between groups (252). The graded bicycle exercise test was 
chosen because of the frailty of some of the cirrhotic 
patients.
5.2.5. Statistical methods
The results of the tests of parasympathetic function, 
with the exception of the standing to lying test, v/ere not 
normally distributed even after a logarithmic transformation 
and therefore non parametric statistical methods were 
employed. Comparison between the 3 groups was made using 
the Kruskall-Wallis one way analysis of variance. The
139
sympathetic data, which were normally distributed were 
analysed by repeated measures analysis of variance where 
more than 2 time points were recorded. Comparison between 
the 3 groups was by one way analysis of variance. 
Correlations were obtained by linear regression and general 
linear modelling using Minitab (200) and Rummage (202) 
computer programs.
5.3. RESULTS
5.3.1 • Liver function tests. plasma noradrenaline and 
systemic haemodvnamics 
The liver function tests, blood pressure, heart rate 
and plasma noradrenaline are recorded in Table 5.1. The 
bilirubin, albumin and prothrombin time were of course 
markedly abnormal in the cirrhotics with severe liver 
damage. The severe cirrhotics had higher plasma 
noradrenaline concentrations, faster heart rate and lower 
systolic BP than controls.
5.3.2. Parasympathetic tests
The parasympathetic results are summarised in 
Table 5.2. and illustrated in Figures 5.1.-5.4. As 
can be seen from the numbers, not all patients 
completed all tests. In the standing to lying test, 
electrical interference with the ECG tracing prevented 
accurate measurement of the RR intervals in 4 cases, one 
each in Groups 1 and 2 and 2 in group 3. Eight patients
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and controls (A)« Horizontal bars represent median values.
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were unable to carry out the diving test (3 in Group 1, 2 in 
Group 2 and 3 in Group 3). In each case, they were unable 
to maintain facial immersion for sufficient time to analyse 
the HR response. There was no difference in the standing 
to lying ratio in the 3 groups, significant reduction in the 
Valsalva ratio, the facial immersion-induced bradycardia and 
the heart rate variation on deep breathing in the severe 
cirrhotic group compared to the control group, with no 
significant differences in the severe v mild cirrhotics, nor 
in mild cirrhotics v controls. Linear regression analysis 
and linear modelling revealed no significant correlations 
between the results of the various parasympathetic tests and 
recent alcohol consumption, nature or duration of liver 
disease, diuretic therapy or plasma noradrenaline. The 
only test affected by baseline haemodynamics was the diving 
test which was most abnormal in those patients with the 
lowest systolic BP (r = 0.54, p < 0.01), but this effect was 
not independent of liver disease severity. There was a 
weak correlation between the diving and deep breathing tests 
and severity of liver disease as indicated by prothrombin 
time (r = -0.49, p < 0.05) and serum albumin (r = 0.54, p < 
0.01) respectively.
5.3.3. Sympathetic tests
The results of isometric exercise and the cold pressor 
tests are given in Tables 5.3. and 5.4. respectively. The
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Maximal and timed dynamic exercise results are given in 
Tables 5.5. and 5.6. respectively. 4 of the cirrhotics and 
4 control subjects were unable to satisfactorily complete 
the dynamic exercise tests.
The blood pressure rise in response to forearm 
isometric exercise was markedly reduced in the severe 
cirrhotics (14/8 mmHg) compared to controls (30/20 mmHg). 
Although isometric exercise increased the heart rate and 
marginally raised plasma noradrenaline in all 3 groups, the 
differences between the groups were not significant.
During the cold pressor test the blood pressure, heart rate 
and plasma noradrenaline increased in all 3 groups, but 
there were no significant differences between the groups.
The pattern of blood pressure response to isometric exercise 
and the cold pressor test is illustrated in Figure 5.5.
All three groups demonstrated a marked rise in plasma 
noradrenaline during dynamic exercise. When exercised to 
their maximum, the control subjects1 systolic pressure rose 
markedly while the diastolic pressure fell slightly. The 
severe cirrhotics demonstrated a smaller rise in systolic 
pressure, without any fall in diastolic pressure. Although 
these differences were not significant, the increase in the 
pulse pressure reflecting both systolic and diastolic 
changes was significantly smaller in the severe cirrhotics 
(15 ± 17 v 37 + 21 mmHg, p < 0.05). This was not apparent 
in the mild cirrhotic group. The blood pressure response 
to a period of timed, sub-maximal exercise was similar in
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ISOMETRIC
EXERCISE
COLD
PRESSOR
Blood 
pressure 120 . 
(mmHg')
60
20 120 1
TIME (mins)
Elfiurs 5*5.
Blood pressure changes during isometric exercise and the cold pressor 
test in mild cirrhosis (^^), severe cirrhosis and controls
(A). Upper lines represent systolic BP and lower lines diastolic BP.
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all 3 croups with a marked rise in systolic pressure and no 
significant change in diastolic pressure. These blood 
pressure changes are illustrated in Figure 5.6.
The increase in heart rate was less pronounced in the 
cirrhotics than the controls, significantly so during the 
submaximal exercise. This is illustrated in Figure 5.7.
The cirrhotics with severe liver disease tolerated the 
bicycle exercise less well than the other 2 groups. Thus 
the maximal workload achieved in the severe cirrhotic group 
was limited by symptoms in all cases (usually fatigue) 
whereas 2 of the mild cirrhotic group and 6 of the control 
group achieved their target heart rate. The maximal 
workload achieved by the severe cirrhotics (92 + 30 watts) 
was less than mild cirrhotics (136 ±33 watts) or controls 
(130 + 36 watts) and thus the maximal exercise test was of 
shorter duration in the severe cirrhotic group. These 
differences mean that the total energy expended during 
maximal exercise was less in the cirrhotics with severe 
disease (11.3 ± 6.6 joules) than those with mild liver 
disease (26.8 ± 11.5 joules) or controls (28.9 ± 18.6 
joules), although this difference was not significant.
There was a similar, although less marked, trend during the 
timed exercise.
5.4. DISCUSSION
The cirrhotics with the most severe liver damage 
consistently show impaired parasympathetic responses. This
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Figure
Changes in systolic and diastolic blood pressure in response to 
maximal and timed dynamic exercise. The bars represent mean values 
with standard deviations indicated by error bars.
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Heart rate increase in response to maximal and timed dynamic exercise. 
The bars represent mean values with standard deviations indicated by 
error bars.
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appears to be independent of the duration of liver disease 
and of the underlying aetiology. In particular the 
responses in alcoholic liver disease were no different from 
cirrhosis of other origins. In addition, the analysis did 
not suggest alcohol consumption was a confounding variable, 
although the alcohol history must be interpreted with 
caution. Although more of the severe cirrhotic group had 
taken diuretics within three months, linear regression 
analysis showed no correlation between the parasympathetic 
responses and diuretic ingestion. There is no published 
evidence of a direct effect of diuretic therapy on 
parasympathetic function. The severe cirrhotics have, as 
expected, lower systolic blood pressure and faster heart 
rates than controls. However, there was no evidence that 
these differences had a confounding effect on the 
parasympathetic results. Despite the significant 
differences demonstrated between the groups, the cirrhotic 
patients did not have marked parasymapthetic failure, the 
great majority of the results falling within the established 
"normal range” (240). This is in keeping with the absence 
of any symptoms of autonomic failure in the cirrhotic group.
There is little published evidence concerning 
parasympathetic function in cirrhosis. Barter found that 
autonomic neuropathy was more common in alcoholics with than 
without liver disease (153). However, it was not clear 
whether this was simply a reflection of heavier and more 
prolonged alcohol consumption in the liver disease group,
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who were very different from the patients in the present 
study in that over 90% had clinical evidence of peripheral 
neuropathy. Vagal autonomic neuropathy is well recognised 
in chronic alcoholics (152). The present study does 
however seem to confirm that liver damage is an important 
contributing factor to the development of abnormal 
parasympathetic responses. Other evidence of vagal 
neuropathy comes from Decaux (154) who found that 16 of 25 
alcoholic cirrhotics had vagal impairment in contrast to 
nine patients with non-alcoholic cirrhosis, of whom none 
had evidence of vagal damage. They demonstrated a 
correlation between vagal neuropathy and hyponatraemia and 
proposed that autonomic impairment could explain the 
impaired free water excretion in ascites by stimulating 
hypothalamic release of vasopressin (154). Lenz also found 
an impaired heart rate response to atropine in cirrhotics 
with hepatic encephalopathy, suggesting a reduced 
parasympathetic tone (162). These studies in conjunction 
with the present work, support a minor role for impaired 
parasympathetic function as a contributory factor to the 
haernodynamic disturbances of severe cirrhosis.
In respect of the sympathetic tests, there is a 
striking reduction in the pressor response to isometric 
exercise in the severe cirrhotic group. Although this 
could represent a sympathetic autonomic neuropathy, the 
result is best explained by a reduction in the vascular 
response to the sympathetic stimulus. The degree of
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sympathetic activation was similar in all three groups as 
indicated by the rise in plasma noradrenaline 
concentrations. Also, by analogy to the autonomic 
neuropathy of diabetes, where vagal damage invariably 
precedes sympathetic damage (240), it seems improbable that 
a sympathetic neuropathy would develop in the absence of 
marked parasympathetic failure.
The response to cold pressor stimulation was similar in 
all 3 groups. This could indicate efferent sympathetic 
activity (249). Alternatively, the lack of any rise in 
plasma noradrenaline during the test in any of the groups 
may indicate that it is an insufficient stimulus of
sympathetic activity to detect minor differences between
groups. Interestingly, in the severe cirrhotic group, 
although the initial rise in blood pressure is similar to 
the other groups, they are less well able to sustain this 
increase (Figure 5.5.). This effect is similar to that
reported by Bernardi (148) who found that in response to
head-up tilting, cirrhotics initially showed a normal rise 
in blood pressure, but that this was not sustained despite 
maintaining an increased plasma noradrenaline. They 
interpreted this result as supporting some interference with 
vascular receptors, a possibility considered further in 
Chapter 7.
There is some agreement between the findings of the 
present study and the few published studies which consider 
sympathetic responses. The response of cirrhotics to
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sustained head-up tilt is impaired in terms of both 
vasoconstriction (150) and blood pressure (148) although 
Ring-Larsen could not confirm the latter observation (147). 
Cardiovascular responses to such sympathetic stimuli as 
application of ice, stressful mental arithmetic and lower 
body negative pressure are impaired in cirrhosis (151).
What conclusions can be drawn from the bicycle exercise 
experiments? Firstly, the ability of the sympathetic 
nervous system to respond to a marked stimulus such as 
dynamic exercise is unimpaired even in severe cirrhosis 
where sympathetic activity is already increased. This was 
apparent even in those cirrhotics too ill to exercise to any 
great extent. Secondly, the blood pressure response to 
exercise is largely intact. The only difference 
demonstrated in cirrhosis is a less marked increase in pulse 
pressure during maximal exercise. This could reflect the 
peripheral vasodilatation of the ill cirrhotics, with 
limited ability to increase this further during exercise.
The published evidence is divided as to whether the 
vasodilatation of cirrhosis does (24) or does not (150) 
affect skeletal muscle as well as skin. The apparent 
failure of the cirrhotic group to increase their heart rate 
during exercise to the same extent as the control group 
could indicate some impairment of beta-adrenoceptor- 
mediated sympathetic responses, a possibility considered 
further in Chapters 6 and 7.
Two previous studies have explored the response to
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dynamic exercise in cirrhosis. Bayley found normal or 
supranormal increases in cardiac output during exercise 
(145). Ratge exercised 30 patients with alcoholic liver 
disease using a bicycle ergorneter (146). He found that the 
increases in plasma noradrenaline and heart rate were 
similar to control values. This contrasts with the 
possible impairment of heart rate response demonstrated in 
the present study. These studies suggest a relatively 
normal response to dynamic exercise. The extent of the 
sympathetic stimulation during dynamic exercise may be 
sufficient to overcome any competitive interference with the 
sympathetic response, e.g. by vasoactive amines.
In summary, parasympathetic responses are mildly 
impaired in severe cirrhosis, independently of the nature 
of the liver damage, alcohol consumption and diuretic 
intake. Evidence from other studies suggests a possible, 
although minor, role for this reduced parasympathetic 
activity in the haemodynamic disturbance of cirrhosis, and 
also a possible role in permitting excessive antidiuretic 
hormone secretion in ascites. Sympathetic responses to 
dynamic exercise are largely intact, but to isometric 
exercise are clearly impaired. This may reflect abnormal 
vascular responsiveness rather than neuropathy itself.
This question is explored in the next chapter.
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CHAPTER 6
CARDIOVASCULAR REACTIVITY IN CIRRHOSIS
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6.1. INTRODUCTION
The preceding chapters have demonstrated that there is 
a global increase in sympathetic activity in cirrhosis. 
Despite this, most patients with cirrhosis have reduced 
peripheral vascular resistance (141) as indicated by low 
systemic blood pressure despite increased cardiac output 
(23). This is in keeping with the clinical appearance of 
these patients whose palmar erythema, warm extremities, 
capillary pulsations and cutaneous spider naevi suggest 
cutaneous vasodilatation (24). The fact that the 
increased sympathetic activity, whatever its explanation, 
fails to correct the apparent reduction in peripheral 
vascular resistance suggests some interference with the 
normal adrenoceptor-mediated control of vascular tone.
The reduced pressor response to such sympathetic stimuli as 
forearm isometric exercise demonstrated in the previous 
chapter is in keeping with this proposal.
Previous attempts to address this problem by assessing 
neurovascular reactivity in response to various pressor 
agents have yielded conflicting results
(144,151,160,162,163) probably because of variability of the 
methods employed. A method to assess the cardiovascular 
response to vasoactive agents has been developed and 
validated within the Department of Materia Medica at 
Glasgow University (253) which employs construction of dose- 
response curves by infusing a range of doses of the agents. 
This chapter describes the first application of this
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technique, which has been widely used in clinical 
pharmacology, to patients with cirrhosis. The aim of both 
studies was to localise the defect responsible for the 
impaired sympathetic control of vascular tone.
6.2. VASCULAR REACTIVITY TO NORADRENALINE AND ANGIOTENSIN II
(STUDY AI 
6.2.1 . Methods 
Patients
Twenty patients with cirrhosis (histological proof in 
14, clinical diagnosis in 6 - see Chapter 2 for clinical 
definition of cirrhosis) were subdivided into "compensated1 
(Pugh's Grade A; Group 1, n = 10) and "decompensated" (Pugh's 
Grade B or C, Group 2, nr10). The demographic details 
including diuretic, smoking and alcohol ingestion are listed 
in Table 6.1. and the nature and duration of liver disease 
in Table 6.2. Two patients had ascites and four 
encephalopathy (all Grade 1-2). No patient had 
gastrointestinal bleeding within 1 month of study.
These were compared to an equal number of control subjects 
with non hepatic disorders (see Chapter 2), whose 
demographic details are also listed in Table 6.1. Each
cirrhotic patient was matched with a control subject of the 
same sex and age (within 5 years) and wherever possible also 
matched for alcohol and tobacco consumption.
164
TABLE 6.1.
STUDY Ai DEMOGRAPHIC DETAILS
CIRRHOSIS CONTROLS
GROUP 1 GROUP 2 GROUP 3
(Pugh's A) (Pugh's B/C)
Number 10 10 20
Mean age (years) 55.7 58.3 56.0
(Range) (33-65) (43-77) (41-75)
Sex (M:F) 8:2 6:4 14:6
Smokers 1 4 8
Recent alcohol 
ingestion#
2 4 9
Recent diuretic 1 7 0
therapy+
* refers to preceding 3 months, details of daily consumption 
as follows: Group 1: 0-10g (1), 20 g (1);
Group 2: 0-10 g (1), 30 g (1), 200 g (2, both of whom 
had had no alcohol for 4 weeks); Group 3: 0-10 g (7),
20 g (1), 50 g (1).
+ during preceding 3 months, no subject received diuretics 
within 72 hours of study.
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TABLE 6lm2±
Study A: NATURE AND DURATION OF LIVER DISEASE
CIRRHOSIS 
GROUP 1 GROUP 2 Total
(Pugh’s A) (Pugh’s B/C)
Diagnosis
Alcoholic liver disease 5 7 12
Chronic active hepatitis 2 1 3
Primary biliary cirrhosis 1 1 2
Haemochromatosis 1 0 1
Cryptogenic cirrhosis 1 1 2
10 10 20
Duration
Mean duration (months) 31 0^
(range) (6-96) (1-120)
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Study Design
The subjects abstained from alcohol for 24 hours and 
from caffeine-containing beverages and smoking for 10 hours 
preceding the study. All medication was omitted on the 
study day, diuretics having been stopped 72 hours 
previously. Thirty minutes following a light breakfast an 
intravenous cannula was inserted into an antecubital vein 
and flushed with 1 ml heparinised saline. After 30 minutes 
supine rest, blood was taken from the cannula for plasma 
catecholamines, plasma renin activity, liver function tests 
and prothrombin time. Blood pressure and heart rate were 
then measured by semi-automatic sphygmomanometer (Sentron, 
Bard) every 2 minutes for 20 minutes. The subject was 
regarded as being at steady state when the systolic blood 
pressure varied by less than 5 mmHg on 5 consecutive 
readings. The values were then averaged to obtain baseline 
heart rate and blood pressure.
The blood pressure responses to progressively 
increasing infusion rates of noradrenaline were then 
determined. 1:1000 noradrenaline tartrate solution 
containing 2 mg.ml”  ^ sodium metabisulphide (Levophed, 
Winthrop) was diluted in 0.9$ sodium chloride solution to a 
final concentration of 0.1 ug kg*"^  subject’s weight ml”**, 
immediately prior to infusion. This solution was then
— 1infused at increasing rates ranging from 0.1 to 3 ml min 
(0.01 to 0.3 ug noradrenaline kg“1min”1) using a Braun 
Perfusor 4 infusion pump. The total volume of solution
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infused did not exceed 30 ml per subject. At least four 
dose levels were investigated in each subject. Blood 
pressure and heart rate were recorded at 1 minute intervals 
for 10 minutes at each infusion rate. The average blood 
pressure for the last 5 minutes of the infusion by which 
time steady state had been reached (254), were calculated. 
The infusion was stopped if the blood pressure rose by more 
than 45 mmHg systolic or 30 mmHg diastolic above pre­
infusion values or if the subject experienced unpleasant 
symptoms, e.g. headache.
After a 1 hour drug-free period, the above procedure 
was repeated substituting angiotensin II for noradrenaline. 
Angiotensin II (Hypertensin, Ciba-Geigy) was diluted in 0.9% 
sodium chloride solution to a final concentration of 10 ng 
kg~^ subjects weight ml."^. This solution was infused at 
increasing rates (a minimum of 4) varying from 0.025 to 6 ml 
min“1 (2.5 to 60 ng.kg^min'*1). The total volume of 
solution infused did not exceed 60 ml. The same procedure 
for recording blood pressure and heart rate was followed.
A trained nurse and a doctor (the author) were in attendance 
throughout the study period.
The average rise in systolic, diastolic and mean 
arterial blood presure was calculated for each dose of 
noradrenaline and angiotensin II, and the rise in pressure 
plotted against the log of the dose (noradrenaline: loge of 
dose in ng kg“  ^ min"^, angiotensin II: loge of dose in ng 
kg“1min“1 x 10). A dose response curve for each subject
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was constructed using a quadratic fit. This was based on 
the assumption that in man one is likely to be exploring the 
lower end of a sigmoid dose response curve, whose shape 
resembles one limb of a parabola, which is the shape of 
curve constructed using a quadratic fit (see Figure 5.1.) 
(253). Other mathematical models to construct dose 
response curves to pressor agents in man have been proposed, 
including a linear fit of the dose of agent against the 
blood pressure and a linear fit of the log of the dose 
against the log of the blood pressure (255). It was found 
that in the case of noradrenaline in all subjects the 
quadratic fit was mathematically more closely correlated to 
the values than either of these options (by comparing 
correlation coefficients derived from least squares 
regression analysis). In the case of angiotensin II, the 
quadratic fit gave a correlation at least as good as the 
alternatives in the majority of cases and therefore this fit 
was adopted for analysis.
From these curves the doses of noradrenaline and 
angiotensin II (and their logarithmic transformations) 
required to raise blood pressure by 10 and 20 mmHg were 
calculated in each individual (referred to as PD^q and p^20 
respectively). The log PD10 and PD20 values were compared 
between the 3 groups, by one way analysis of variance and 
correlations were derived from linear regression analysis.
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complete dose response curve
part of dose response curve 
assessed in human studies
quadratic fit
iM
Figure 6_tl.
Rationale for a quadratic fit for human dose response curves.
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6.2.2. Results
The results of the biochemical tests of liver function, 
plasma catecholamine levels and plasma renin activity are 
summarised in Table 6.3. and the baseline haemodynamic data 
similarly in Table 6,4. Plasma noradrenaline and plasma 
dihydroxyphenylethylene glycol (DHPG), were significantly 
elevated in the severe cirrhotic group, reflecting enhanced 
sympathetic activity (see Chapter 3). Heart rate was 
significantly higher in the cirrhotics with severe disease 
and there was a reduction in systolic pressure in the severe 
cirrhotics, significant at the 5% level in comparison to 
mild cirrhosis and showing a clear trend (as indicated by 
the confidence intervals) in comparison to controls. 
Diastolic pressure did not differ significantly between the 
3 groups.
The systolic blood pressure responses to noradrenaline 
are listed in Table 6.5. and the mean arterial pressure 
responses to angiotensin in Table 6.6. (Noradrenaline raises 
systolic but not diastolic pressure, whereas angiotensin 
raises both systolic and diastolic pressures, hence the 
decision to examine mean pressure responses to angiotensin).
The severe cirrhotic group demonstrate impaired pressor 
responses to infused noradrenaline, as demonstrated by the 
significant increase in log PD-jq and log P^O* values
in the cirrhotics with mild disease are similar to those of 
controls, indicating no impairment of pressor response in 
this group.
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There was an impaired pressor response to the infusion 
of angiotensin II in the severe cirrhotic group. The log 
PD<| q and log PD2q values were significantly higher in this 
group compared to controls. The magnitude of the change 
was rather greater than that seen in the noradrenaline 
infusions. It should also be noted that, although not 
statistically significant, the PD20 and particularly PD10 
values in the cirrhotics with mild disease were higher than 
the control values. Two of the mild cirrhotics had 
obviously impaired pressor responses, despite being 
indistinguishable from the rest of their group in terms of 
baseline haemodynamic data or catecholamine values.
The dose response curves of a representative subject 
from the cirrhotic group with severe disease and those of 
her paired control subject are illustrated in Figures 6.2. 
(noradrenaline) and 6.3. (angiotensin II). For both agents 
the response curve for the cirrhotic lies to the right of 
that of the control, indicating decreased vascular 
reactivity in the cirrhotic subject. The mean responses in 
the 3 groups are illustrated in Figure 6.4. (noradrenaline) 
and Figure 6.5. (angiotensin II). The standard deviation 
bars are omitted for clarity. Again the shift to the right 
in the severe cirrhotics, indicating decreased vascular 
reactivity in this group, is demonstrated for both 
noradrenaline and angiotensin.
There was a weak but significant correlation between 
the degree of hepatic impairment, as judged by the
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negative correlation between baseline systolic blood 
pressure and PD2q for noradrenaline (r = - 0.50, p < 0.025) 
and between baseline diastolic blood pressure and PD2q for 
angiotensin (r = -0.46; p < 0.05). Thus the lower the 
starting blood pressure, the greater the impairment of 
adrenergic reactivity. The pressor responses to the 2 
agents were themselves significantly correlated (r = 0.56. p 
< 0.02). Stepwise linear regression of these various 
factors failed to identify any one as being independently 
related to the pressor responses. Interestingly, there was 
no correlation between the pressor responses to 
noradrenaline and resting plasma noradrenaline concentration 
(r = 0.14).
6.2.3. Discussion
This study has demonstrated that there is reduced 
peripheral vascular reactivity to both noradrenaline, an 
adrenoceptor mediated vasoconstrictor, and to angiotensin 
II, a non-adrenergic vasoconstrictor, in patients with 
cirrhosis. In the case of noradrenaline, this is only 
apparent in those individuals with severe hepatic 
impairment, but in the case of angiotensin, reduced vascular 
responsiveness has also been demonstrated in some patients 
with apparently mild disease. This is the first study in 
man to find reduced reactivity to both agents.
The few previous studies which have examined the 
effects of these agents on the systemic vasculature have
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yielded conflicting results. Mashford gave bolus 
injections of noradrenaline to cirrhotics, some of whom were 
stable, and some in liver failure (144). The resulting 
increase in blood pressure was greater in the more ill 
patients, in contrast to the present study. However, the 
numbers studied were few, there were no control data and the 
authors themselves drew no conclusions. Laragh and his co­
workers (1 6 0 ,1 6 3 ) gave prolonged infusions (up to 6 days) of 
both noradrenaline and angiotensin to a group of cirrhotics. 
The doses employed were variable but in general higher than 
in the present study. They found pressor sensitivity to 
angiotensin to be diminished in their cirrhotic patients. 
There was a suggestion of reduced pressor sensitivity to 
noradrenaline, but this was not significant. In a 
controlled study of 21 cirrhotic patients, Lunzer 
demonstrated convincing evidence of a reduction in 
peripheral vascular responsiveness to noradrenaline, when 
intravenous noradrenaline (10 ug min” )^ reduced forearm 
blood flow in controls but not in cirrhotics (151).
However, angiotensin II (2 ug min"^) failed to alter limb 
blood flow in either controls or cirrhotics. More recently 
Lenz reported that infusions of noradrenaline (0.4 ug kg“ 
1min“1) and angiotensin (20 ng kg“1min"1) yielded similar 
rises in blood pressure in patients with cirrhosis and 
hepatic encephalopathy and in control subjects (162).
The present study has the advantage of employing a 
range of doses of both agents to allow construction of a
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dose response curve, rather than relying on a single bolus 
response. With this exception, it is difficult to explain 
the conflicting results between the present study and that 
of Lenz. The lack of effect of angiotensin on forearm 
blood flow in the study of Lunzer (151) may reflect 
insufficient sensitivy of the technique, since no effect was 
seen in either control or cirrhotic patients. The earlier 
studies described differ too greatly in methodology to allow 
direct comparison with the present study.
Data from 2 other sources should be considered, namely 
the results of exogenous infusions of such agents in 
experimental animals, and attempts to measure the effect of 
modulating endogenous catecholamines. Animal studies have 
yielded uniform results with respect to angiotensin. 
Resistance to the pressor effect of exogenous angiotensin II 
has been observed in the bile duct ligated dog (1 5 8 ) and in 
rats with carbon tetrachloride-induced cirrhosis (155-157). 
Regarding noradrenaline infusions, Finberg found only 
alishgly reduced pressor response in the bile-duct ligated 
dog (158) and Murray found no such reduction in the rat 
model (155). However two other groups have recently 
reported reduced pressor responses to noradrenaline using 
the same rat model (156,157). Assessing adrenergic
responses by stimulating the sympathetic nervous system is a 
more physiological, though less readily controlled approach 
than exogenous infusions. The blood pressure response to 
isometric exercise was clearly blunted in severe cirrhosis
(Chapter 5). The suggestion of decreased peripheral 
adrenergic responsiveness is supported by the work of Lunzer 
on forearm blood flow. He demonstrated less peripheral 
vasoconstriction in cirrhotics than controls in response to 
head-up tilting (150) and to sympathetic stimulation by 
application of ice and lower body negative pressure (151). 
Two other groups have examined the effect of posture on 
blood pressure in cirrhosis, with conflicting results.
Eight cirrhotics were unable to sustain the normal rise in 
blood pressure on prolonged standing, despite raising their 
plasma noradrenaline levels by a similar amount as control 
subjects, suggesting an inadequate vascular response to 
adrenergic stimulation (148). The same group subsequently 
confirmed these findings in a larger series (149). However, 
Ring-Larsen, measuring intra-arterial pressure in response 
to 6 0 ° head-up tilt, found no postural change either in 
controls or cirrhotics (147). They interpreted the lack of 
any fall in blood pressure as evidence of normal 
neurovascular reactivity.
Potential confounding variables in the present study 
include diuretic therapy, alcohol and smoking. Although 
the 7 2 hour diuretic-free period will have allowed washout 
of the drug itself, the effects of certain diuretics (e.g. 
thiazides) on the vascular tree may persist for months (2 5 6 ) 
and spironolactone, the principal diuretic employed in these 
patients, is reported to reduce vascular reactivity to 
noradrenaline (257,258). This is a difficult problem to
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resolve, since it was deemed ethically unacceptable to stop 
diuretic therapy for longer than 7 2 hours in these ill 
patients. It is worth noting, however, that within the 
group of severe cirrhotics (in whom the diuretic question 
arises) the vascular reactivity is similar in the 7 who had 
taken diuretics (log PD2 0 ^ « 7 9 ± 0.4) and the 3 who had not 
(log PD2q 4.75 ± 0.3). Ingestion of alcohol for 4 days is 
known to reduce vascular reactivity to noradrenaline, but 
not angiotensin (259). The long term effects are unknown. 
However, only 2 of the cirrhotics in this study had been 
drinking heavily within 3 months, and in both instances had 
abstained for 1 month prior to study, having been 
hospitalised during this period. Smoking, also known to 
reduce vascular reactivity was taken into account during the 
matching of cirrhotic-control pairs.
In view of the above, it seems likely that vascular 
reactivity to both noradrenaline and angiotensin II is 
indeed impaired in cirrhosis with severe liver impairment. 
This suggests an abnormality of vascular smooth muscle 
causing a generalised decrease in vascular reactivity. 
However "desensitisation” of the vasculature to the 
increased sympathetic activity would be an alternative 
explanation, if in addition there was a parallel but 
separate angiotensin desensitisation. To further 
complicate the issue it has recently been suggested that the 
two systems are not entirely independent in man (260) and 
therefore the possibility that overactivity of one system
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influences sensitivity to the other ("heterologous 
desensitisation") must be borne in mind.
The next section explores the question of 
sympathetic desensitisation in more detail by examining 
cardiovascular responsiveness to selective adrenoceptor 
agonists.
6.3. CARDIOVASCULAR RESPONSIVENESS TO SELECTIVE ADRENOCEPTOR 
AGONISIS CSTUPY b i
6.3.1. Introduction
Having demonstrated in the previous study (6.2.) that 
cirrhotic patients with severe, but not mild, impairment of 
hepatic function have decreased vascular reactivity to both 
sympathetic and non sympathetic stimulation, the next experiment 
was designed to assess whether the decreased response was 
limited to the peripheral vasculature, or was a reflection 
of generalised sympathetic desensitisation. To achieve 
this we selected 10 cirrhotic patients with severe liver 
disease and infused a series of adrenoceptor agonists with 
different affinities for the alpha and beta subtypes - 
phenylephrine (selective alpha-) agonist),
alphamethylnoradrenaline (preferential alpha2 agonist) and 
isoprenaline (beta.) and beta2 agonist).
6.3.2. Methods 
Patients
Ten "decompensated11 cirrhotic patients (Pugh’s grade B
184
TABLE 6.7. STUDY B: DEMOGRAPHIC DETAILS
CIRRHOSIS 
(PughTs B/C)
CONTROLS
Number 10 10
Mean age (years) 56.5 57.7
Sex (M:F) 7:3 7:3
Smokers 5
Recent alcohol 
ingestion*
2 6
Recent diuretic 6 0
therapy+
* refers to preceding 3 months, details of daily consumption 
as follows: cirrhotics: 50 g (1), 150 g (1 , who had had no
alcohol for 8 weeks prior to study); controls: < 10 g (3), 
10-15 g (3).
+ during preceding 3 months, no subject received diuretics 
within 72 hours of study.
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or C) and ten control patients from similar sources to those 
outlined in 6.2., were studied. The cirrhosis was 
confirmed histologically in 4 cases and diagnosed on 
clinical grounds in the remaining 6 . The aetiology of the 
cirrhosis was alcoholic liver disease in 7 cases, chronic 
active hepatitis in 2 and cryptogenic in 1. The mean 
duration of liver disease was 3 0 . 5 months with a range of 2 
to 145 months. No patient had bled from oesophageal varices 
or elsewhere in the preceding month. Two patients had 
encephalopathy (grade 1) but none had ascites. The 
diagnoses in the control patients were as follows: peptic
ulcer disease (6 ) and 1 each of hiatus hernia, inguinal 
hernia, varicose veins and diverticular disease (all of 
these inactive, on no therapy). Demographic details, 
including alcohol and smoking history and diuretic therapy 
are listed in Table 6.7.
The cirrhotic patients were matched with a control of 
the same sex and age (within 5 years) and in 9 of the 10 
pairs, they were studied on the same day.
Study Designs
An identical format to that outlined in the previous 
study was adopted. For this study the sequence 
of agonist administration was randomly allocated and the 
drug-free period between infusions was 45 minutes. 
Phenylephrine hydrochloride was diluted in 0.9/6 sodium 
chloride solution to a final concentration of 2 ug kg“ 1
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subject's weight ml" 1 and infused at a minimum of 4 rates 
ranging from 0.25 to 3.0 ml.min" 1 (0.5 - 6.0 ug kg"1min"1). 
Alphamethylnoradrenaline was similarly diluted, to 2 
concentrations: a) 0.1 ug kg" 1 ml" 1 and b) 0.5 ug kg" 1 ml"1. 
Solution (a) was infused at rates varying from 0.2 to 2.0 ml
min"1, and solution (b) from 0.5 to 1.0 ml min"1. This
allowed doses ranging from 0.02 to 0.5 ug kg“ 1 min“1. 
Isoprenaline was similarly diluted to a concentration of 50 
ng kg“ 1 ml” 1 and infused at rates varying from 0.2 to 1.0 ml
min” 1 (10 to 50 ng kg” 1 min"1). Each infusion dose step
lasted 10 min and the heart rate and blood pressure recorded 
during the last 5 minutes, when steady state was reached 
(254). As in the previous study, the infusion was 
discontinued if the systolic blood pressure rose by > 45 
mmHg or the diastolic by > 30 mmHg. In the case of
isoprenaline the maximum rise in heart rate permitted was 45
• - 1m m  ' .
As in the case of noradrenaline and angiotensin II, 
dose response curves were constructed from the loge dose of 
agent v blood pressure for phenylephrine and 
alphamethylnoradrenaline, and v heart rate for isoprenaline. 
In all three agonist infusions, the quadratically fitted 
curve was best suited to the individual data points and this 
curve used to calculate dose of agonist required to raise 
blood pressure by 10 and 20 mmHg (PD-jq and PD2 0  
respectively) or heart rate by 10 and 2 0 min” 1 (CD^q and 
CD2 0 respectively). The logarithmic transformations of
187
PDi o* P^2 0 > C D 10 anc* ^ ^ 2 0  were compared between the 2 groups 
by Studentfs unpaired t test. Correlations were calculated 
by linear regression.
6.3.3. Results
The results of the biochemical tests of liver function, 
plasma catecholamine levels and plasma renin activity are 
summarised in Table 6 .8 . and the baseline haemodynamic data 
similarly in Table 6.9. There is significant elevation of 
plasma noradrenaline and DHPG indicating enhanced 
sympathetic activity. The resting heart rate is increased 
in the cirrhotics. In this particular group the systolic 
blood pressure shows no reduction, while the 7 mmHg 
reduction in diastolic pressure, is just outwith the 5% 
significance level, but with a clear trend illustrated in 
the confidence intervals.
The mean arterial pressure responses to phenylephrine 
are listed in Table 6.10. The systolic pressure 
responses to alphamethylnoradrenaline are listed in Table 
6.11 and the heart rate responses to isoprenaline in 
Table 6.12.
The PDiq and PD2 0 values for the phenylephrine 
infusions are higher in the cirrhotics than in 
the controls, although this is only significant for log 
PD2 o« Therefore vascular reactivity to an alpha^ 
adrenoceptor agonist is reduced in severe cirrhosis. A 
representative pair of subjects is illustrated in Figure
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6.4. and the mean phenylephrine responses in Figure 6.5.
For alphamethylnoradrenaline, systolic pressure only
has been analysed, since it has no consistent effect on 
diastolic pressure in either group. There is a trend 
towards higher PD-jq values in the cirrhotic group and at the 
P D 2 0 level, this increase in cirrhosis is highly significant 
(p < 0.001). Therefore vascular reactivity to an alpha 
adrenoceptor agonist is also significantly reduced in severe 
cirrhosis. A representative pair of subjects is illustrated in 
Figure 6.6 and the mean values in Figure 6.7.
In contrast, there is no difference between the CD^q or 
C D 2 0 values for isoprenaline in the control and cirrhotic 
groups, nor do the confidence intervals show any trend 
towards a difference. It appears that the chronotropic 
response to beta adrenoceptor stimulation is not reduced (or 
enhanced) in cirrhosis. A representative subject pair is 
illustrated in Figure 6.8 and the mean values are shown in 
F i g u r e  6.9.
6.3.4. Discussion
This study has demonstrated that alpha adrenoceptor- 
mediated pressor responses are impaired in cirrhosis but 
beta adrenoceptor-mediated chronotropic responses are not.
T h i s  is the f i rs t t i m e  that the f u n c t i o n  of s p e c i f i c  
alpha adrenoceptor subtypes has been studied in cirrhosis, 
either in man or in experimental animals. The impairment 
of the pressor response to both phenylephrine (a selective
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alpha-j agonist) and alphamethylnoradrenaline (a preferential 
alpha2 agonist) supports the finding of the previous study 
(Section 6.2.) of impaired pressor response to noradrenaline 
(a mixed alpha^ and alpha2 agonist) in cirrhosis.
Two other groups have recently considered beta- 
adrenoceptor mediated responses (162,164). In contrast to 
the present study, both groups reported a decrease in the 
sensitivity to isoprenaline in cirrhosis. These studies 
differed from the present one in the disease population 
studied, the choice of control group and the methodology 
employed. In both the reported studies, the cirrhotic 
patients appeared to have a more severe degree of liver 
failure. All 11 patients studied by Lenz had ascites and 
hepatic encephalopathy, which proved fatal in 6 of the cases 
(162). All but 3 of the 13 alcholic cirrhotics studied by 
Lebrecfs group (164) had ascites and 7 were in Pugh's grade 
C. In the present study, the degree of jaundice, 
hypoalbuminaemia and coagulopathy placed 4 of the cirrhotics 
in Pugh's grade C and the remaining 6 in Pugh's grade B, 
However, none of these had ascites at the time of study and 
only 2 had encephalopathy, which was mild in both cases. 
Therefore, this study may not have detected a difference if 
this only becomes apparent in the most severely ill 
patients. Nevertheless, the grade of disease in the 
present study was sufficient to detect significant 
differences in alpha adrenoceptor responses, without any 
trend whatsoever to impaired isoprenaline sensitivity.
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This does imply some difference in alpha and beta 
adrenoceptor responses in moderately severe cirrhosis.
The differences in methodology are more difficult to 
compare. In the Lenz study, the heart rate response to a 
single bolus of isoprenaline was assessed. For reasons 
outlined in 6.2.4. this may be a less reliable method than 
constructing dose-response curves from multiple dosing.
The latter method was employed by Lebrec and co-workers, 
using multiple bolus injections of increasing doses of 
isoprenaline, in contrast to the stepwise series of 
infusions to steady state employed in the present study.
Both methods have their advocates (261,253). However, the 
manner in which the dose response was analysed by Lebrec is 
open to criticism. Firstly, the dose response graph was 
constructed by a linear plot of the log dose against heart 
rate. It has been suggested by several workers that a 
quadratic fit of log dose v response is more appropriate 
(253,262). Secondly, the increment in heart rate chosen 
for analysis was 25 min”  ^ (CD2 5 ), but only 4 of their 13 
cirrhotics achieved this increase at the doses used. In 
the other 9 cases the value has been obtained by 
extrapolation. In view of the inevitable degree of error in 
the construction of such graphs, the degree of extrapolation 
raises doubts as to the validity of the interpretation 
(which could have been avoided by adopting a lower response, 
e.g. CD ^ ).
Finally, it has been pointed out previously that the
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choice of control group is critical in catecholamine 
studies (187) and neither of the published papers 
is ideal in this respect. The control group studied by 
Lenz were considerably younger (range 19 to 32 years) than 
the cirrhotics (range 41-65 years). The sensitivity to 
isoprenaline is well known to decrease with age (2 6 3 -2 6 5 ). 
Lebrec studied only 5 control subjects.
Notwithstanding the above criticisms, the reduction in 
isoprenaline sensitivity in these 2 studies was striking and 
they reached the same conclusions by widely differing 
techniques. There is clearly scope for further work on 
beta adrenergic responses in cirrhosis with severe liver 
damage.
In conclusion, the reduced alpha adrenergic pressor 
response, which is a peripheral vascular effect, in 
conjunction with the normal beta adrenergic chronotropic 
response, which is principally a cardiac effect, indicate 
that the reduced vascular reactivity is not part of a 
generalised sympathetic desensitisation.
6.4. BARORECEPTOR FUNCTION
In the previous chapter the blood pressure response to 
reflex sympathetic stimulation in the form of isometric 
exercise was blunted in cirrhosis. This was in keeping 
with the demonstration that the alteration in limb blood 
flow in response to such autonomic stimuli as lower body 
negative pressure and Valsalva manoeuvre is also reduced in
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cirrhosis (151). These particular reflexes 
require an intact baroreceptor response, and it has 
therefore been deemed important to establish whether 
baroreceptor reflexes are normal or not in cirrhosis (162).
The alpha-j agonist used in the previous study, 
phenylephrine, is sufficiently selective to have no direct 
cardiac effects. Therefore the bradycardia which 
accompanies its infusion is a baroreceptor mediated response 
to the rise in blood pressure. The reduction in heart rate 
for a given rise in blood pressure during phenyelphrine 
infusion is therefore a measure of baroreceptor 
responsiveness. This can be calculated as AHR/a BP. The 
values for this ratio in the 10 cirrhotics and 10 controls 
in the previous study are 0.74 ± 0.49 and 0.38 + 0.25 
respectively. It is apparent that the heart rate response in 
cirrhosis is not reduced. Indeed, although the difference 
between cirrhotic and control groups did not achieve 
statistical significance, there is a suggestion that the 
responsiveness is actually increased in cirrhosis (9 5 % 
confidence interval of difference -0.01 to 0.73). If 
subsequent work were to verify this it might indicate a 
disproportionate increase in sympathetic activation in 
response to even a slight drop in blood pressure. This 
could explain the increased sympathetic activity in these 
patients, as judged by plasma noradrenaline concentrations, 
without a significant fall in blood pressure. The lack of 
any impairment of baroreceptor function in cirrhosis is
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supported by the work of Lenz exploring cardiovascular 
responses to sympathetic and non sympathetic 
vasoconstriction (162). Clearly the impaired reflex 
autonomic responses result from defects elsewhere in the 
reflex pathway, as would be anticipated by the similar 
impairment of cardiovascular responses in response to 
exogenous catecholamine infusions (Sections 6.2. and 6.3.).
6.5. GENERAL DISCUSSION AND CONCLUSIONS
The experiments in this chapter have been concerned 
with the cardiovascular responses to a variety of types of 
sympathetic stimulants, or agonists. Appreciation of their 
significance requires some knowledge of selective 
adrenoceptor subtypes and their actions.
The actions of the sympathetic nervous system result 
from the release of 2 catecholamines - adrenaline (from the 
adrenal medulla) and noradrenaline (from post ganglionic 
sympathetic nerve endings). The cardiovascular (and other) 
responses to these catecholamines, whether acting as a 
hormone (adrenaline) or a neurotransmitter (noradrenaline), 
are mediated by highly specific cell surface receptors - 
adrenoceptors. There are different types of adrenoceptors 
which mediate characteristic and different cellular 
responses (266). The two main types of adrenoceptor are 
alpha and beta, which have been subdivided into alpha., and 
alpha2 receptors (267) and beta., and beta2 receptors (268). 
Stimulation of alpha., receptors causes peripheral
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vasoconstriction. Pre-synaptic alpha2 receptors outwith 
the central nervous system provide a negative feedback loop 
by inhibiting noradrenaline release. However, there are 
also post-synaptic alpha2 receptors, which like alpha^, 
cause vasoconstriction. Clasically beta^ receptors are 
predominantly cardiac where they exert both an inotropic and 
a chronotropic effect. Beta2 receptors located on 
peripheral vessels cause vasodilatation when stimulated.
Noradrenaline itself has both alpha and beta effects, 
but is more potent as an alpha agonist. Hence the rise in 
blood pressure seen during the noradrenaline infusion in 
Section 6.2. is predominantly the result of peripheral 
vasoconstriction. However, there is also a beta agonist 
effect. This is demonstrated by the lack of a reflex 
bradycardia in response to the rise in blood pressure, due 
to a positive chronotropic effect on the heart.
These experiments have attempted to explain the anomaly 
of decreased peripheral vascular tone despite increased 
sympathetic activity. The blood pressure response to 
sympathetic stimulation by exogenous noradrenaline infusion 
is impaired in "decompensated" cirrhosis. This is in 
keeping with the blunted response to certain reflex 
sympathetic stimuli, e.g. isometric exercise, as 
demonstrated in the previous chapter. The impaired 
response to exogenous noradrenaline supports the impression 
from that chapter that the reflex sympathetic abnormalities 
are the result of impaired vascular responsiveness rather
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than actual autonomic neuronal damage (see Section 5.4.).
The previous suggestion (151) that these reflex 
abnormalities might be due to baroreceptor dysfunction has 
been disproven; baroreceptor responsiveness, as indicated 
by the reflex bradycardia in response to a rise in blood 
pressure, is normal, or slightly enhanced. The impaired 
vascular responsiveness to angiotensin II as well as 
noradrenaline could indicate a common defect at the site of 
vascular smooth muscle, or parallel separate 
"desensitisation” to both systems, which are both frequently 
over active in cirrhosis. The possibility of generalised 
sympathetic desensitisation seems remote in the light of the 
normal heart rate response to beta-adrenergic stimulation 
with isoprenaline. What the four agents with impaired 
cardiovascular responses - noradrenaline, angiotensin, 
phenylephrine and alphamethylnoradrenaline - have in common 
is a principal or sole action on the peripheral vasculature. 
The evidence is therefore accumulating that the site of the
defect caus ing the impaired neurovascular reactivity is at
the smo oth mus cle of the per ipheral vascular tree. Whether
this is at the cell membrane receptors, or elsewhere , is the
subject of the next chapter.
STUDIES
CHAPTER 2 
ADRENERGIC RECEPTORS IN CIRRHOSIS
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7.1. STUDIES OF PLATELET ALPHAg ADRENOCEPTORS •
7.1.1. Introduction
The studies described in the preceding chapters have 
demonstrated that in cirrhotic patients with severe liver 
damage there is a reduction in perioheral vascular 
responsiveness to sympathetic stimulation. This 
hypothesis could be examined further by direct assessment of 
the adrenoceptors themselves. Clearly the particular 
adrenoceptors of most interest are the alpha-] receptors on 
small peripheral resistance vessels, since these are the 
principal sympathetic mediators of vascular tone. However, 
they are not accessible for study in in vivo experiments on 
human subjects, nor is there an accessible model for human 
alpha-] receptors. Animal studies on isolated vessels would 
be an alternative, but there is no ideal animal model of 
cirrhosis, nor could the behaviour of animal adrenoceptors 
be taken automatically to represent the human situation, 
since there are considerable inter-species variations.
A compromise would be to study the alphap 
adrenoceptors present on circulating platelets. These are 
readily accessible for study in the human subject and may 
give some indication of overall alpha adrenoceptor status. 
This study describes the assessment of the number and 
affinity of platelet alphap adrenoceptors in cirrhosis.
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7.1 . 2. Study 4 ("Unwashed” platelets)
Sub iects and Study Design
Ten patients with cirrhosis and ten control subjects 
were studied. The cirrhotic group comprised 7 males and 3 
females, aged 41-78 years (mean 56.5). The cirrhosis was 
of alcoholic origin in 7 patients, with 2 cases of chronic 
active hepatitis and one cryptogenic cirrhosis. The 
control group consisted of 7 male and 3 female patients with 
non-hepatic disorders, aged 39-77 years (mean 55). None of 
the cirrhotics had taken alcohol within one month of study. 
All medications were omitted on the study day, diuretics 
having been stopped 72 hours previously. The studies were 
performed in pairs matched for sex and age (within 5 years). 
Subjects were studied in the morning, at least one hour 
after a light breakfast. After the insertion of an 
indwelling cannula in a peripheral vein, subjects rested for 
30 minutes. Blood pressure and heart rate were recorded by 
semi automatic sphygmomanometer, and blood was drawn from 
the cannula for liver function tests, plasma catecholamines 
and renin (for details of sampling and analysis, see Chapter 
2). A further 120 ml blood (60 ml for controls) was 
collected and anticoagulated with citrate (1 volume 3.28$ 
citrate to 9 volumes of blood) for platelet analysis.
Preparation of platelets for. binding skud.ig,&
The whole blood was centrifuged at 1 80 g for 15 mins at 
20°C. The platelet-rich plasma was harvested and spun at
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1700 g for 15 mins at 4°C to produce a platelet pellet. 
This was then resuspended in 0.17. FDT A , 150 mM sodium 
chloride (pH 7.4) to give a platelet concentration of 
100,000 platelets/ul as determined by Coulter counting.
13-2 adrenoceptor binding assay on 
intact platelets
Binding studies on intact platelets were performed 
according to the method of Newman (269), as modified by 
Motulsky (270). Aliquots of platelet suspension (0.3 ml) 
were incubated for 20 mins at 25°C with 6 concentrations of 
[^H] yohimbine (Amersham 90 Ci/mmol) 1.2 - 18 nM in 
duplicate. The non specific binding was determined in the 
presence of 1 uM phentolamine. Incubations were terminated 
by filtration with 20 ml of ice cold Tris MCI (50 mM pH 7.4) 
through Whatman GF/C filters, using a millipore multiport 
filtration apparatus set at 30 cn.Hg. The filters were 
dried overnight at room temperature and the [^M] bound 
radioactivity was determined by liquid scintillation 
counting at an efficiency of 36%. Saturation binding 
isotherms were analysed by plotting free/bound radioactivity 
vs free using least squares fitting to obtain values for the 
antagonist dissociation constant, Kp (nM) and the maximum 
number of binding sites, Bmax (fmoles/10^ platelets).
Results
It proved impossible to construct satisfactory
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saturation binding isotherms by least squares fitting in 2 
of the cirrhotics and 4 of the control subjects due to 
variability of their data. The Bmax was increased in the 8 
cirrhotics (48.6 ± 20.9 v 28.4 + 9.1 fmoles/10^ platelets, p 
< 0.05 by unpaired t-test). Kp was similar in cirrhotics 
(10.3 ± 7.2 nmol.l"^) and controls (13.4 + 8.1 nmol.l"^).
Discussion
The apparent increase in alpha2 adrenoceptor number in 
cirrhosis, where sympathetic activity and circulating 
noradrenaline are increased, and where pressor 
responsiveness to alpha adrenoceptor stimulation is reduced, 
is surprising. It was noted that the KD values obtained in 
both groups were considerably higher than those seen in 
previous studies of young, healthy volunteers. It was 
postulated that the reduced affinity that this represents 
might be due to higher concentrations of circulating 
noradrenaline in these patients adhering to binding sites on 
the platelets and thereby interfering with the binding of 
the ligand in vitro. It was therefore decided to repeat 
the above study, with the inclusion of a step to ”wash off” 
any retained noradrenaline prior to incubation with [^H] 
yohimbine.
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7.1.3. Study B ( "Washed11 platelets)
Subjects and Study Design
Eleven cirrhotics were studied, 8 of whom had 
participated in the previous study. On this occasion there 
were 9 males and 2 females, aged 41-65 years (mean 55).
All but one had alcoholic liver disease, the remaining 
diagnosis being chronic active hepatitis. Eleven control 
subjects were studied, with no overlap from the previous 
study. Four were patients with non hepatic disorders, 
the remaining 7 comprising members of staff. There were 6 
males and 5 females, aged 39-62 years (mean 52).
The study design was identical to that described for 
the previous study.
Preparation of platelets and alpha? binding assay
The preparation of platelets was as described in the 
previous experiment with one exception: after resuspension
in the platelet buffer, whose composition was unaltered, the 
suspension was recentrifuged and resusnended twice more to 
remove any retained catecholamines (271). Thereafter the 
pellet was resuspended in the buffer to a final 
concentration of 100,000 platelets/ul as previously.
The binding assay on the intact platelets was performed 
in an identical manner to that described above.
Results
The cirrhotic patients had biochemical evidence of
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severe hepatic impairment indicated by a median bilirubin of 
45 umol.l“1 (range 11-136), a median albumin of 31g.1“  ^
(range 25-40) and a median prolongation of prothrombin time 
of 5 seconds (range 1-15). This placed 2 of the cirrhotics 
in Pugh’s grade A, 5 in grade B and 4 in grade C. However, 
none of the cirrhotics had ascites, and only 1 had mild 
encephalopathy. The results of Kp, Bmax, heart rate, blood 
pressure and catecholamine levels are indicated in Table
7.1. The haemodynamic picture and catecholamine 
concentrations follow a similar pattern to previous studies, 
with lower blood pressure and higher plasma concentrations 
of both noradrenaline and DHPG.
Wide intra subject variability prevented construction 
of satisfactory saturation binding isotherms in 8 of the 22 
subjects (5 cirrhotics and 3 controls). There was no 
difference in either Bmax or KD between the remaining 6 
cirrhotics and 8 controls (Figures 7.1. and 7.2.).
Linear regression analysis of the cirrhotic patients 
only, revealed a significant negative correlation between 
Bmax and plasma bilirubin (r = -0.85, p < 0.05 using log 
bilirubin values), but not other indices of disease 
severity, plasma catecholamine concentrations or 
haemodynamic indices. The affinity appeared to be greater 
in those patients with the most severe liver disease, as 
indicated by correlation coefficients of -0.86 (p < 0.05),
0.92 (p < 0.01) and -0.86 (p < 0.05) between I<D and 
bilirubin, albumin and Pugh’s score, respectively. Again,
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Platelet alpha 2 adrenoceptors
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Bmax
( fm o l/1 0 9 platelets)
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o
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cirrhosis
(n=6)
o 
o
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controls
(n=8)
Bmax for platelet alpha2 receptors (Error bars represent mean and 
standard deviation).
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Platelet alpha2 adrenoceptors
12-,
k d
(nmol/l)
1 0 -
* 4-
2 -
cirrhosis
(n=6)
controls
(n=8)
Eigyrs.
Kp for platelet alpha2 receptors (Error bars represent mean and 
standard deviation).
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Kp was unrelated to plasma catecholamine levels and 
haemodynamic indices.
The differences in and Bmax between Study A 
("unwashed" platelets) and Study B ("washed" platelets) are 
given in Table 7.2. The washing has lowered both and 
Bmax in both groups although this only achieves significance 
in the cirrhotic group.
7.1.4. Discussion
These studies provide no evidence of any reduction in 
the number of platelet alpha2 receptors in cirrhosis, as 
indicated by the values of Bmax. The exclusion of some 
subjects from the analysis due to unsatisfactory saturation 
binding isotherms is unlikely to have biased the result, as 
the degree of hepatic impairment, sympathetic activation and 
haemodynamic disturbance in these individuals was no 
different from the rest of the group. Also, despite the 
reduced numbers remaining for analysis, the chance of the 
study missing a true difference (of one standard deviation 
or more) is less than 20%, and the confidence intervals show 
no trend towards any difference. The negative result is 
therefore likely to be a valid one. The alpha2 receptor on 
platelets is not necessarily representative of the alpha2 
receptor on peripheral vascular smooth muscle. However, if 
so, this study suggests that the decreased cardiovascular 
responsiveness in cirrhosis is not due to down-regulation of 
receptor number, despite the sympathetic over-activity.
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It is tempting to ascribe pathological significance to 
the reduction in Kp by washing the platelets. In 
particular, this might be seen as evidence that the reduced 
cardiovascular responsiveness in cirrhosis was due to some 
interference at the receptor site, e.g. by circulating 
catecholamines or by some catecholamine-like substance which 
the damaged liver has failed to initiate, analagous to the 
’’false neurotransmitter” theory of hepatic encephalopathy 
(148). However, washing the platelets also reduced Kp in 
the control subjects, and the lack of any difference in Kp 
between the cirrhotic and control groups for both ’’washed” 
and ’’unwashed” platelets makes it unlikely that interference 
at the receptor site is the explanation for the decreased 
vascular reactivity in cirrhosis. However, since Kp is a 
measure of the affinity of the receptor for the ligand in 
vitro, this does not absolutely exclude interference at the 
receptor site in vivo.
There are no previous human or animal studies which 
consider alpha adrenoceptor number or affinity in cirrhosis. 
There is however some indirect support for these results 
from work on cirrhotic rats, which suggested that the 
reduced pressor effect of angiotensin II in cirrhosis was 
not due to a defect at the cell membrane receptor (155). 
Previous studies examining the effect of sympathetic 
stimulation on platelet alpha? receptors in situations other 
than cirrhosis have found a similar lack of down-regulation 
as in the present study, both in rabbits (272) and in man
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(271). Although alpha adrenoceptor function (rather than 
number) can be assessed in man by in vitro platelet 
aggregation in response to e.g. adrenaline, this test cannot 
be used in cirrhosis, because the thrombocytopoenia in these 
patients impairs platelet aggregation irrespective of 
adrenoceptor function.
In conclusion, these studies, in conjunction with the 
impaired pressor responses to noradrenaline, phenylephrine, 
alphamethylnoradrenaline and angiotensin II, all of which 
raise blood pressure principally by peripheral 
vasoconstriction (see Chapter 6) provide at least 
circumstantial evidence for a post-receptor defect within 
vascular smooth muscle cells themselves as the explanation 
for the decreased vascular reactivity in cirrhosis.
7.2. STUDY OF LYMPHOCYTE BETA2 ADRENOCEPTORS
7.2.1. Introduction
In addition to studying platelet alpha2 adrenoceptors 
the opportunity was taken to study a beta adrenoceptor in 
cirrhosis, namely the beta2 receptor on circulating 
lymphocytes. This would provide a useful comparison with 
the alpha receptor study, and also provide evidence for or 
against the beta agonist infusion study in Chapter 6. In 
addition it later became of more significance in the light 
of a report claiming that down-regulation of beta receptors 
might explain the decreased efficacy of propranolol in 
preventing oesophageal variceal rebleeding in severe
221
cirrhosis (273).
7.2.2. Methods
Sub iects and study design
The criteria for selection of cirrhotic patients and 
controls, and the conditions under which venous blood was 
collected, were the same as for the platelet adrenoceptor 
studies. Thirteen cirrhotic patients and 13 controls were 
studied, 10 of each group comprising the participants in the 
platelet study. There were 9 males and 4 females in the 
cirrhotic group, aged 41-78 years (mean 57 years). The 
cirrhosis was alcohol-induced in 9 patients, With 2 cases 
each of chronic active hepatitis and cryptogenic cirrhosis. 
The control group also comprised 9 males and 4 females, aged 
41-78 years.
Preparation of lymphocyte membranes
After collection of platelet rich plasma the remaining 
red cells from 120 mis blood were used to isolate 
lymphocytes according to the method of Boyum (274). Blood 
was diluted with Hanks balanced salt solution (Gibco, 
Scotland) and carefully layered onto a Ficoll/Hypaque 
solution (6%10%) (Pharmacia, Uppsala, Sweden) and the 
samples centrifuged at 400 g for 40 mins (20°C). The 
lymphocyte band was harvested by aspiration (consisting of 
at least 85% small lymphocytes) and a broken cell lysate 
prepared according to a modification of the method of Aarons
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(275). The lymphocyte band was resuspended in 30 nM NaCl 
and centrifuged at 180 g for 10 mins at 4°C to remove 
remaining red blood cells, by hypotonic lysis. The pellet 
was resuspended in ice cold distilled water, homogenised for 
5 secs in a Brinkman Polytron at setting 4 (Brinkman 
Instruments Inc. Westbury, N.Y.) and centrifuged at 40,000 g 
for 45 mins at 4°C. The pellet was resuspended in 2 ml of 
ice cold assay buffer (150 mM NaCl with 12.5 mM MgCl£, 1.5 
mM EDTA buffered with 50 mM Tris HC1 pH 7.4) and stored 
frozen at -70°C until assayed. On the day of the assay 
samples were thawed and an additional wash performed by 
resuspending the pellet in 30 ml of ice cold assay buffer 
followed by centrifugation at 40,000 g for 30 mins. The 
pellet was resuspended in 5 ml of ice cold assay buffer, 
homogenised for 5 secs (Brinkman Polytron setting 3) and 
used immediately for binding studies.
Beta adrenoceptor assay on lvmphocvte membranes
Aliquots (100 ul) of membrane preparation were 
incubated with 8 concentrations of [^^1] iodocyanopindolol 
(ICYP) (Amersham UK) 10-150 pM according to the method of 
Brodde (276). Incubations were for 60 mins at 25°C 
and terminated by addition of 10 ml of incubation buffer and 
vacuum filtration over Whatman GFB glass fibre filters.
The radioactivity of the wet filters was determined in a 
gamma counter (Berthold model LB2100) at an efficiency of 
80%. Non specific binding was defined as radioactivity
223
bound to membranes which was not displaced by 1 uM 
propranolol. Specific binding was defined as total 
radioactivity minus non-specific binding. The equilibrium 
binding constant, (pM) and maximum number of binding 
sites, Bmax (fmoles/mg protein) were estimated by Scatchard 
analysis. Protein concentration was measured using the 
method of Lowry (277).
7.2.3. Results
The median bilirubin in the cirrhotic group was 34 
umol.l“1 (range 12-123), albumin 31 g.l“1 (21-41) and 
prothrombin time 4 seconds prolonged (0-11). Most of the 
cirrhotic group had liver disease of moderate severity with 
9 Pugh’s grade B, 3 grade C and 1 grade A. Two had ascites 
and 2 mild encephalopathy.
The Kp, Bmax, heart rate, blood pressure and 
catecholamine values are summarised in Table 7.3. The
haemodynamic picture, as expected, reveals lower blood 
pressure and faster heart rates in the cirrhotic patients. 
The Kp and Bmax values were essentially the same in the 
cirrhotics as the controls, despite significant elevation of 
both noradrenaline and DHPG levels in plasma (Figures 7.3. 
and 7.4. ).
Linear regression analysis of the cirrhotic patients 
revealed no relationship between receptor number (Bmax) and 
severity of liver disease, heart rate, blood pressure and 
plasma catecholamine levels. The only significant
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Lymphocyte beta2 adrenoceptors
6O-1
Bmax
(fmol/mg protein)
5 0 -
4 0 -
10 -
0J
cirrhosis controls
(0=6) (n=8)
Figure 7.3.
Bmax for lymphocyte beta2 receptors (Error bars represent mean and 
standard deviation).
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Figure LA-
Kp for lymphocyte beta2 receptors (Error bars represent mean and 
standard deviation).
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correlation to emerge from the data on receptor affinity was 
a reduction in affinity in patients with the most elevated 
plasma bilirubin levels (r = 0.79* P < 0.02), the opposite 
trend to that seen with the affinity of the platelet alpha 
receptors.
7.2.4. Discussion
The lack of any reduction in Bmax argues against down- 
regulation of the lymphocyte beta2 adrenoeptors in 
moderately severe cirrhosis in this situation. As in the 
platelet studies, a number of subjects could not be included 
as their Scatchard plots were too unreliable to calculate 
or Bmax with confidence. This applied to 4 cirrhotics and 
5 controls, i.e. the receptor analysis was performed on 9 
cirrhotics and 8 controls. Does this alter the validity of 
the data? As in the platelet study, the group of 
cirrhotics with valid results are indistinguishable from 
those excluded in terms of catecholamine levels, heart rate, 
blood pressure and liver function tests. Even with the 
reduced number of results, the power of the study to detect 
a difference of 1 standard deviation exceeds 80%. Finally, 
the confidence intervals of the difference in the mean for 
Kd and Bmax do not indicate any trend. It therefore seems 
likely that the negative conclusion is valid.
During the course of this study Gerbes and co-workers 
in Munich published the results of a similar study (273).
In a similar number of cirrhotics of comparable disease
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severity, they also found no change in density or affinity 
of lymphocyte beta2 adrenoceptors. However they reported 
that in a subgroup of M patients with severe ascites, there 
was a reduction in receptor density. This was interpreted 
as evidence of down-regulation in this group. Since only 2 
of my cirrhotics had ascites, the studies do not necessarily 
contradict each other. However, neither of my ascitic 
patients had low Bmax values. One important difference in 
the two studies is the question of diuretic therapy. None 
of the subjects in the present study had taken diuretics 
within 3 days of the sampling (although 6 had been on 
diuretics prior to this). In contrast, most of the 
cirrhotics in the Munich study were on continuing diuretic 
therapy at the time of study. Since diuretics are known to 
reduce lymphocyte beta adrenoceptor density (278), this 
is a possible confounding factor in the Munich study. 
Although beta adrenoceptor status in severe ascites remains 
a matter of debate, cirrhosis severe enough to significantly 
increase sympathetic activity, lower blood pressure and 
increase heart rate does not cause lymphocyte beta2 
adrenoceptor down-regulation. This supports the normal 
heart rate response to isoprenaline, a beta agonist, in 
cirrhosis (Chapter 6). This is also in keeping with the 
clinical status of cirrhotic patients, where the sympathetic 
over-activity, although unable to correct the reduced blood 
pressure, does result in an appropriate increase in heart 
rate - a beta adrenoceptor-mediated response. The present
229
study is therefore unable to confirm the hypothesis of the 
Munich group, that the reported decreased efficacy of 
propranolol to prevent rebleeding from oesophageal varices 
in severe cirrhosis is due to down-regulation of beta 
adrenoceptors in this group.
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CHAPTER 8 
CONCLUSIONS AND IMPLICATIONS
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CONCLUSIONS AND IMPLICATIONS
The work described in this thesis was inspired by the 
observation that plasma noradrenaline concentrations are 
increased in cirrhosis. The first experiment demonstrated 
that this increase was the result of increased spillover of 
noradrenaline into the circulation from sympathetic nerve 
endings, and hence represents an overall increase in the 
activity of the sympathetic nervous system in cirrhosis. 
Surprisingly, the clearance of noradrenaline from plasma was 
slightly increased in cirrhosis. This observation, which 
has been confirmed by others, remains unexplained. The 
answer lies in regional studies of sympathetic activity 
which are outwith the scope of this thesis.
Having established that plasma noradrenaline is a 
reasonable indicator of the degree of sympathetic activity 
in cirrhosis, plasma noradrenaline was measured in 40 
patients with cirrhosis of varying duration, severity and 
aetiology. The degree of sympathetic activation related to 
the severity of the liver impairment, in agreement with 
other recent work. There has been much enthusiasm in the 
current medical literature regarding the significance of the 
sympathetic nervous system in the pathogenesis of ascites. 
The early studies indicating overactivity of the renin- 
angiotensin-aldosterone system in cirrhosis were greeted 
with similar enthusiasm, only for later work to demonstrate 
that the latter system is only activated in a minority of 
cirrhotics with ascites, and is normal or even suppressed
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earlier in the disease process. The increased sympathetic 
activity which was not due to confounding variables such as 
the ingestion of diuretics or alcohol was present even in 
cirrhotic patients who had never had ascites. Therefore 
the stimulus to sympathetic activity is not simply vascular 
underfilling consequent to the fluid shifts of ascites.
The potential candidates for the stimulus to 
sympathetic activity are increased hepatic sinusoidal 
pressure and systemic vascular underfilling. The former 
could occur as portal hypertension develops and influences 
sympathetic activity by activating hepatic baroreceptors. 
Thus sympathetic activity could increase without reduced 
systemic intravascular volume. If this were the case, 
increased sympathetic activity in cirrhotic patients without 
ascites would not disprove the so called "overflow" theory 
of ascites. However this hepatic baroreceptor reflex has 
only been demonstrated in non cirrhotic dogs, not in 
cirrhotic man, and most authors have taken sympathetic 
overactivity as an indication of reduced effective blood 
volume and therefore supporting the traditional, or 
"underfilling” theory of ascites. The possible reasons for 
reduced effective blood volume include splanchnic pooling of 
blood due to portal hypertension, systemic vasodilatation, 
and arteriovenous shunting.
In addition to providing valuable indirect evidence on 
the state of vascular filling in cirrhosis, this sympathetic 
overactivity may itself be important in the renal sodium
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retention which is critical to the formation of ascites. 
Renal sympathetic stimulation causes sodium reabsorption 
from the proximal tubule. This may be important in the 
early development of ascites and could explain the 
phenomenon of failed mineralocorticoid escape in cirrhosis. 
However in established ascites the success of the 
aldosterone antagonist spironolactone testifies to the 
importance of distal tubular reabsorption of sodium.
This study also demonstrated that high 
concentrations of plasma noradrenaline carry a poor 
prognosis. This is supported by other workers who found 
plasma noradrenaline to be a powerful and independent 
prognostic indicator. Most severely decompensated 
cirrhotic patients also have activation of the renin- 
angiotensin-aldosterone system, which is likewise associated 
with a poor prognosis. These findings might be explained 
by the adverse effects of both these systems on renal blood 
flow. There is some evidence that the functional renal 
failure which can complicate cirrhosis with ascites, and 
which is probably the result of renal cortical 
vasoconstriction, is the result of an imbalance between 
renal vasoconstrictors (e.g. sympathetic nervous system and 
angiotensin II) and renal vasodilators (e.g. renal 
prostaglandins and bradykinin).
The recent identification of atrial natriuretic peptide 
(ANP) led to speculation that deficiency of such a 
natriuretic substance might contribute to the sodium
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retention of ascites. However, in the presence of ascites, 
ANP levels are modestly increased rather than decreased.
This presumably reflects a reflex response (as yet 
undefined) to sodium retention occurring by other 
mechanisms, and suggests that ANP deficiency is not a cause 
of sodium retention in ascites. Although it has potent 
vasodilatory properties, the levels found in cirrhosis do 
not suggest ANP as a major cause of the systemic 
vasodilatation of cirrhosis, although it may be important in 
some individuals.
The second half of this thesis concerns the 
haemodynamic disturbance of cirrhosis. Patients with 
cirrhosis have reduced vascular resistance, indicated by 
systemic hypotension despite increased cardiac output. The 
question of whether autonomic neuropathy, in the 
conventional sense, might contribute to this haemodynamic 
disturbance was considered. Parasympathetic cardiovascular 
responses were impaired in severe cirrhosis, and this did 
not appear to be an alcohol effect, but the changes were 
mild and were not associated with the clinical 
manifestations of neuropathy. Reflex sympathetic response 
to isometric exercise was markedly reduced, but it was not 
clear whether this was due to an abnormality within the 
reflex arc or at the level of the target organ, i.e. 
vascular smooth muscle. Fxperiments infusing exogenous 
sympathetic and non sympathetic vasoactive agents clarified 
the situation. Firstly baroreceptor function was found to
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be normal, or even slightly enhanced. Secondly, the 
pressor response to noradrenaline, the neurotransmitter of 
the sympathetic nervous system was impaired in cirrhosis. 
This confirmed the suspicion that the impairment of reflex 
sympathetic responses was due to a defect beyond the reflex 
arc. It also confirmed that the anomaly of vasodilatation 
despite increased sympathetic activity was due to some form 
of block in the normal sympathetically-induced 
vasoconstriction. The remaining experiments in the thesis 
were designed to try to identify the site of this block.
The reduced pressor response to angiotensin as well as 
to noradrenaline suggested a general reduction in vascular 
reactivity, but could represent parallel desensitisation of 
the vascular tree to the effects of the two vasoconstricting 
systems, both of which are commonly over-active in severe 
cirrhosis. The demonstration of impaired cardiovascular 
responses to two further selective alpha agonists 
(phenylephrine and alphamethylnoradrenaline) but not to a 
beta agonist (isoprenaline) indicated that the reduced 
pressor response to noradrenaline was not part of a 
generalised sympathetic desensitisation. The fact that 
the response to isoprenaline, which is principally a cardiac 
effect, was normal unlike the other four agents, which all 
exert their effect principally on the peripheral 
vasculature, localised the impaired sympathetic response to 
vascular smooth muscle.
The next question to be considered was whether this
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defect involved the adrenergic receptors which mediate the 
vasoconstrictor response. The adrenoceptor status might be 
altered in three ways. Firstly the high concentrations of 
circulating catecholamines might occupy the receptors and 
prevent further activation. Secondly the receptors might 
be occupied by catecholamine-like substances which the 
cirrhotic liver has failed to inactivate (,!false 
neurotransmitters"). Thirdly the increased sympathetic 
activity could lead to a reduction in the number of 
receptors, i.e. "down regulation". Unfortunately the 
receptor most relevant, i.e. the alpha^ receptor on vascular 
smooth muscle, is not accessible to study in man. As a 
compromise an alpha receptor which is accessible, 
namely the alpha2 receptor on platelets, was studied. In 
fact radioligand binding studies revealed that both the 
number of receptors and their affinity for the ligand were 
normal in cirrhosis. Beta adrenoceptor status was also 
studied using circulating lymphocytes and found to be 
normal. This is in keeping with the normal chronotropic 
response to beta stimulation by isoprenaline. Prior 
occupancy of receptor sites by circulating catecholamines or 
false neurotransmitters seems unlikely in view of the normal 
affinity of the alpha receptors. The lack of any down 
regulation of platelet alpha2 receptors does not necessarily 
imply the same for vascular alpha^ receptors. This is a 
problem which cannot be resolved with human studies at 
present and would require work using one of the animal
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models of cirrhosis. If there is indeed no down regulation 
of vascular alpha-j receptors, this would suggest that the 
defect causing impaired sympathetic response lies within the 
smooth muscle cell itself - i.e. a "post-receptor" defect. 
The reduced angiotensin reactivity has also been shown to be 
a post-receptor defect in experimental animals. It seems 
likely that one common defect at the intracellular level is 
responsible for the impaired response to both systems.
What are the implications of the localisation of this 
defect in vascular responsiveness? It suggests that the 
vasodilatation of cirrhosis is due to local effects on 
vascular smooth muscle and that future research should 
concentrate on attempting to identify possible 
pharmacological agents responsible. Candidates include 
substances escaping into the systemic circulation from the 
portal system via shunts or a failing liver. These could 
be physiological e.g. gut peptides, or pathological, e.g. 
endotoxins. Other candidates include enkephalins and 
systemic prostaglandins, e.g. prostacyclin. ANP is 
unlikely to be responsible as it only reached vasodilatory 
concentrations in a few patients. Better understanding of 
the mechanisms of vasodilatation of these various agents may 
allow selection of those likely to cause a defect at the 
site identified. The studies in this thesis indicate that 
certain other potential explanations for the vasodilatation 
must be considered less likely. These include a decrease 
in physiological vasoconstrictors, and interference by false
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neurotransmitters•
Is the cause of the vasodilatation important?
Although this thesis does not specifically consider this 
question, it seems likely that the peripheral vasodilatation 
may be a principal cause for sympathetic overactivity, which 
in turn could initiate sodium retention and ascites.
In summary, the studies described in this thesis have 
examined certain aspects of the sympathetic nervous system 
in cirrhosis of the liver. They have established that 
sympathetic activity is increased in cirrhosis, especially 
where severe liver impairment is present, but also earlier 
in the disease process. They considered the question of 
vasodilatation in cirrhosis despite sympathetic 
overactivity, established that there was impaired 
sympathetic vascular responsiveness both by reflex 
stimulation and exogenous agonist infusions, and accumulated 
indirect evidence suggesting that this is likely to be a 
post-receptor defect in vascular smooth muscle. The cause 
of this defect (and hence the vasodilatation) may hold the 
key to the initiation of ascites, of which the sympathetic 
nervous system appears to be an important mediator.
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